File size: 277,882 Bytes
492eb1e | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310 1311 1312 1313 1314 1315 1316 1317 1318 1319 1320 1321 1322 1323 1324 1325 1326 1327 1328 1329 1330 1331 1332 1333 1334 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 1389 1390 1391 1392 1393 1394 1395 1396 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 1414 1415 1416 1417 1418 1419 1420 1421 1422 1423 1424 1425 1426 1427 1428 1429 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 1534 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 1556 1557 1558 1559 1560 1561 1562 1563 1564 1565 1566 1567 1568 1569 1570 1571 1572 1573 1574 1575 1576 1577 1578 1579 1580 1581 1582 1583 1584 1585 1586 1587 1588 1589 1590 1591 1592 1593 1594 1595 1596 1597 1598 1599 1600 1601 1602 1603 1604 1605 1606 1607 1608 1609 1610 1611 1612 1613 1614 1615 1616 1617 1618 1619 1620 1621 1622 1623 1624 1625 1626 1627 1628 1629 1630 1631 1632 1633 1634 1635 1636 1637 1638 1639 1640 1641 1642 1643 1644 1645 1646 1647 1648 1649 1650 1651 1652 1653 1654 1655 1656 1657 1658 1659 1660 1661 1662 1663 1664 1665 1666 1667 1668 1669 1670 1671 1672 1673 1674 1675 1676 1677 1678 1679 1680 1681 1682 1683 1684 1685 1686 1687 1688 1689 1690 1691 1692 1693 1694 1695 1696 1697 1698 1699 1700 1701 1702 1703 1704 1705 1706 1707 1708 1709 1710 1711 1712 1713 1714 1715 1716 1717 1718 1719 1720 1721 1722 1723 1724 1725 1726 1727 1728 1729 1730 1731 1732 1733 1734 1735 1736 1737 1738 1739 1740 1741 1742 1743 1744 1745 1746 1747 1748 1749 1750 1751 1752 1753 1754 1755 1756 1757 1758 1759 1760 1761 1762 1763 1764 1765 1766 1767 1768 1769 1770 1771 1772 1773 1774 1775 1776 1777 1778 1779 1780 1781 1782 1783 1784 1785 1786 1787 1788 1789 1790 1791 1792 1793 1794 1795 1796 1797 1798 1799 1800 1801 1802 1803 1804 1805 1806 1807 1808 1809 1810 1811 1812 1813 1814 1815 1816 1817 1818 1819 1820 1821 1822 1823 1824 1825 1826 1827 1828 1829 1830 1831 1832 1833 1834 1835 1836 1837 1838 1839 1840 1841 1842 1843 1844 1845 1846 1847 1848 1849 1850 1851 1852 1853 1854 1855 1856 1857 1858 1859 1860 1861 1862 1863 1864 1865 1866 1867 1868 1869 1870 1871 1872 1873 1874 1875 1876 1877 1878 1879 1880 1881 1882 1883 1884 1885 1886 1887 1888 1889 1890 1891 1892 1893 1894 1895 1896 1897 1898 1899 1900 1901 1902 1903 1904 1905 1906 1907 1908 1909 1910 1911 1912 1913 1914 1915 1916 1917 1918 1919 1920 1921 1922 1923 1924 1925 1926 1927 1928 1929 1930 1931 1932 1933 1934 1935 1936 1937 1938 1939 1940 1941 1942 1943 1944 1945 1946 1947 1948 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045 2046 2047 2048 2049 2050 2051 2052 2053 2054 2055 2056 2057 2058 2059 2060 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070 2071 2072 2073 2074 2075 2076 2077 2078 2079 2080 2081 2082 2083 2084 2085 2086 2087 2088 2089 2090 2091 2092 2093 2094 2095 2096 2097 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 2110 2111 2112 2113 2114 2115 2116 2117 2118 2119 2120 2121 2122 2123 2124 2125 2126 2127 2128 2129 2130 2131 2132 2133 2134 2135 2136 2137 2138 2139 2140 2141 2142 2143 2144 2145 2146 2147 2148 2149 2150 2151 2152 2153 2154 2155 2156 2157 2158 2159 2160 2161 2162 2163 2164 2165 2166 2167 2168 2169 2170 2171 2172 2173 2174 2175 2176 2177 2178 2179 2180 2181 2182 2183 2184 2185 2186 2187 2188 2189 2190 2191 2192 2193 2194 2195 2196 2197 2198 2199 2200 2201 2202 2203 2204 2205 2206 2207 2208 2209 2210 2211 2212 2213 2214 2215 2216 2217 2218 2219 2220 2221 2222 2223 2224 2225 2226 2227 2228 2229 2230 2231 2232 2233 2234 2235 2236 2237 2238 2239 2240 2241 2242 2243 2244 2245 2246 2247 2248 2249 2250 2251 2252 2253 2254 2255 2256 2257 2258 2259 2260 2261 2262 2263 2264 2265 2266 2267 2268 2269 2270 2271 2272 2273 2274 2275 2276 2277 2278 2279 2280 2281 2282 2283 2284 2285 2286 2287 2288 2289 2290 2291 2292 2293 2294 2295 2296 2297 2298 2299 2300 2301 2302 2303 2304 2305 2306 2307 2308 2309 2310 2311 2312 2313 2314 2315 2316 2317 2318 2319 2320 2321 2322 2323 2324 2325 2326 2327 2328 2329 2330 2331 2332 2333 2334 2335 2336 2337 2338 2339 2340 2341 2342 2343 2344 2345 2346 2347 2348 2349 2350 2351 2352 2353 2354 2355 2356 2357 2358 2359 2360 2361 2362 2363 2364 2365 2366 2367 2368 2369 2370 2371 2372 2373 2374 2375 2376 2377 2378 2379 2380 2381 2382 2383 2384 2385 2386 2387 2388 2389 2390 2391 2392 2393 2394 2395 2396 2397 2398 2399 2400 2401 2402 2403 2404 2405 2406 2407 2408 2409 2410 2411 2412 2413 2414 2415 2416 2417 2418 2419 2420 2421 2422 2423 2424 2425 2426 2427 2428 2429 2430 2431 2432 2433 2434 2435 2436 2437 2438 2439 2440 2441 2442 2443 2444 2445 2446 2447 2448 2449 2450 2451 2452 2453 2454 2455 2456 2457 2458 2459 2460 2461 2462 2463 2464 2465 2466 2467 2468 2469 2470 2471 2472 2473 2474 2475 2476 2477 2478 2479 2480 2481 2482 2483 2484 2485 2486 2487 2488 2489 2490 2491 2492 2493 2494 2495 2496 2497 2498 2499 2500 2501 2502 2503 2504 2505 2506 2507 2508 2509 2510 2511 2512 2513 2514 2515 2516 2517 2518 2519 2520 2521 2522 2523 2524 2525 2526 2527 2528 2529 2530 2531 2532 2533 2534 2535 2536 2537 2538 2539 2540 2541 2542 2543 2544 2545 2546 2547 2548 2549 2550 2551 2552 2553 2554 2555 2556 2557 2558 2559 2560 2561 2562 2563 2564 2565 2566 2567 2568 2569 2570 2571 2572 2573 2574 2575 2576 2577 2578 2579 2580 2581 2582 2583 2584 2585 2586 2587 2588 2589 2590 2591 2592 2593 2594 2595 2596 2597 2598 2599 2600 2601 2602 2603 2604 2605 2606 2607 2608 2609 2610 2611 2612 2613 2614 2615 2616 2617 2618 2619 2620 2621 2622 2623 2624 2625 2626 2627 2628 2629 2630 2631 2632 2633 2634 2635 2636 2637 2638 2639 2640 2641 2642 2643 2644 2645 2646 2647 2648 2649 2650 2651 2652 2653 2654 2655 2656 2657 2658 2659 2660 2661 2662 2663 2664 2665 2666 2667 2668 2669 2670 2671 2672 2673 2674 2675 2676 2677 2678 2679 2680 2681 2682 2683 2684 2685 2686 2687 2688 2689 2690 2691 2692 2693 2694 2695 2696 2697 2698 2699 2700 2701 2702 2703 2704 2705 2706 2707 2708 2709 2710 2711 2712 2713 2714 2715 2716 2717 2718 2719 2720 2721 2722 2723 2724 2725 2726 2727 2728 2729 2730 2731 2732 2733 2734 2735 2736 2737 2738 2739 2740 2741 2742 2743 2744 2745 2746 2747 2748 2749 2750 2751 2752 2753 2754 2755 2756 2757 2758 2759 2760 2761 2762 2763 2764 2765 2766 2767 2768 2769 2770 2771 2772 2773 2774 2775 2776 2777 2778 2779 2780 2781 2782 2783 2784 2785 2786 2787 2788 2789 2790 2791 2792 2793 2794 2795 2796 2797 2798 2799 2800 2801 2802 2803 2804 2805 2806 2807 2808 2809 2810 2811 2812 2813 2814 2815 2816 2817 2818 2819 2820 2821 2822 2823 2824 2825 2826 2827 2828 2829 2830 2831 2832 2833 2834 2835 2836 2837 2838 2839 2840 2841 2842 2843 2844 2845 2846 2847 2848 2849 2850 2851 2852 2853 2854 2855 2856 2857 2858 2859 2860 2861 2862 2863 2864 2865 2866 2867 2868 2869 2870 2871 2872 2873 2874 2875 2876 2877 2878 2879 2880 2881 2882 2883 2884 2885 2886 2887 2888 2889 2890 2891 2892 2893 2894 2895 2896 2897 2898 2899 2900 2901 2902 2903 2904 2905 2906 2907 2908 2909 2910 2911 2912 2913 2914 2915 2916 2917 2918 2919 2920 2921 2922 2923 2924 2925 2926 2927 2928 2929 2930 2931 2932 2933 2934 2935 2936 2937 2938 2939 2940 2941 2942 2943 2944 2945 2946 2947 2948 2949 2950 2951 2952 2953 2954 2955 2956 2957 2958 2959 2960 2961 2962 2963 2964 2965 2966 2967 2968 2969 2970 2971 2972 2973 2974 2975 2976 2977 2978 2979 2980 2981 2982 2983 2984 2985 2986 2987 2988 2989 2990 2991 2992 2993 2994 2995 2996 2997 2998 2999 3000 3001 3002 3003 3004 3005 3006 3007 3008 3009 3010 3011 3012 3013 3014 3015 3016 3017 3018 3019 3020 3021 3022 3023 3024 3025 3026 3027 3028 3029 3030 3031 3032 3033 3034 3035 3036 3037 3038 3039 3040 3041 3042 3043 3044 3045 3046 3047 3048 3049 3050 3051 3052 3053 3054 3055 3056 3057 3058 3059 3060 3061 3062 3063 3064 3065 3066 3067 3068 3069 3070 3071 3072 3073 3074 3075 3076 3077 3078 3079 3080 3081 3082 3083 3084 3085 3086 3087 3088 3089 3090 3091 3092 3093 3094 3095 3096 3097 3098 3099 3100 3101 3102 3103 3104 3105 3106 3107 3108 3109 3110 3111 3112 3113 3114 3115 3116 3117 3118 3119 3120 3121 3122 3123 3124 3125 3126 3127 3128 3129 3130 3131 3132 3133 3134 3135 3136 3137 3138 3139 3140 3141 3142 3143 3144 3145 3146 3147 3148 3149 3150 3151 3152 3153 3154 3155 3156 3157 3158 3159 3160 3161 3162 3163 3164 3165 3166 3167 3168 3169 3170 3171 3172 3173 3174 3175 3176 3177 3178 3179 3180 3181 3182 3183 3184 3185 3186 3187 3188 3189 3190 3191 3192 3193 3194 3195 3196 3197 3198 3199 3200 3201 3202 3203 3204 3205 3206 3207 3208 3209 3210 3211 3212 3213 3214 3215 3216 3217 3218 3219 3220 3221 3222 3223 3224 3225 3226 3227 3228 3229 3230 3231 3232 3233 3234 3235 3236 3237 3238 3239 3240 3241 3242 3243 3244 3245 3246 3247 3248 3249 3250 3251 3252 3253 3254 3255 3256 3257 3258 3259 3260 3261 3262 3263 3264 3265 3266 3267 3268 3269 3270 3271 3272 3273 3274 3275 3276 3277 3278 3279 3280 3281 3282 3283 3284 3285 3286 3287 3288 3289 3290 3291 3292 3293 3294 3295 3296 3297 3298 3299 3300 3301 3302 3303 3304 3305 3306 3307 3308 3309 3310 3311 3312 3313 3314 3315 3316 3317 3318 3319 3320 3321 3322 3323 3324 3325 3326 3327 3328 3329 3330 3331 3332 3333 3334 3335 3336 3337 3338 3339 3340 3341 3342 3343 3344 3345 3346 3347 3348 3349 3350 3351 3352 3353 3354 3355 3356 3357 3358 3359 3360 3361 3362 3363 3364 3365 3366 3367 3368 3369 3370 3371 3372 3373 3374 3375 3376 3377 3378 3379 3380 3381 3382 3383 3384 3385 3386 3387 3388 3389 3390 3391 3392 3393 3394 3395 3396 3397 3398 3399 3400 3401 3402 3403 3404 3405 3406 3407 3408 3409 3410 3411 3412 3413 3414 3415 3416 3417 3418 3419 3420 3421 3422 3423 3424 3425 3426 3427 3428 3429 3430 3431 3432 3433 3434 3435 3436 3437 3438 3439 3440 3441 3442 3443 3444 3445 3446 3447 3448 3449 3450 3451 3452 3453 3454 3455 3456 3457 3458 3459 3460 3461 3462 3463 3464 3465 3466 3467 3468 3469 3470 3471 3472 3473 3474 3475 3476 3477 3478 3479 3480 3481 3482 3483 3484 3485 3486 3487 3488 3489 3490 3491 3492 3493 3494 3495 3496 3497 3498 3499 3500 3501 3502 3503 3504 3505 3506 3507 3508 3509 3510 3511 3512 3513 3514 3515 3516 3517 3518 3519 3520 3521 3522 3523 3524 3525 3526 3527 3528 3529 3530 3531 3532 3533 3534 3535 3536 3537 3538 3539 3540 3541 3542 3543 3544 3545 3546 3547 3548 3549 3550 3551 3552 3553 3554 3555 3556 3557 3558 3559 3560 3561 3562 3563 3564 3565 3566 3567 3568 3569 3570 3571 3572 3573 3574 3575 3576 3577 3578 3579 3580 3581 3582 3583 3584 3585 3586 3587 3588 3589 3590 3591 3592 3593 3594 3595 3596 3597 3598 3599 3600 3601 3602 3603 3604 3605 3606 3607 3608 3609 3610 3611 3612 3613 3614 3615 3616 3617 3618 3619 3620 3621 3622 3623 3624 3625 3626 3627 3628 3629 3630 3631 3632 3633 3634 3635 3636 3637 3638 3639 3640 3641 3642 3643 3644 3645 3646 3647 3648 3649 3650 3651 3652 3653 3654 3655 3656 3657 3658 3659 3660 3661 3662 3663 3664 3665 3666 3667 3668 3669 3670 3671 3672 3673 3674 3675 3676 3677 3678 3679 3680 3681 3682 3683 3684 3685 3686 3687 3688 3689 3690 3691 3692 3693 3694 3695 3696 3697 3698 3699 3700 3701 3702 3703 3704 3705 3706 3707 3708 3709 3710 3711 3712 3713 3714 3715 3716 3717 3718 3719 3720 3721 3722 3723 3724 3725 3726 3727 3728 3729 3730 3731 3732 3733 3734 3735 3736 3737 3738 3739 3740 3741 3742 3743 3744 3745 3746 3747 3748 3749 3750 3751 3752 3753 3754 3755 3756 3757 3758 3759 3760 3761 3762 3763 3764 3765 3766 3767 3768 3769 3770 3771 3772 3773 3774 3775 3776 3777 3778 3779 3780 3781 3782 3783 3784 3785 3786 3787 3788 3789 3790 3791 3792 3793 3794 3795 3796 3797 3798 3799 3800 3801 3802 3803 3804 3805 3806 3807 3808 3809 3810 3811 3812 3813 3814 3815 3816 3817 3818 3819 3820 3821 3822 3823 3824 3825 3826 3827 3828 3829 3830 3831 3832 3833 3834 3835 3836 3837 3838 3839 3840 3841 3842 3843 3844 3845 3846 3847 3848 3849 3850 3851 3852 3853 3854 3855 3856 3857 3858 3859 3860 3861 3862 3863 3864 3865 3866 3867 3868 3869 3870 3871 3872 3873 3874 3875 3876 3877 3878 3879 3880 3881 3882 3883 3884 3885 3886 3887 3888 3889 3890 3891 3892 3893 3894 3895 3896 3897 3898 3899 3900 3901 3902 3903 3904 3905 3906 3907 3908 3909 3910 3911 3912 3913 3914 3915 3916 3917 3918 3919 3920 3921 3922 3923 3924 3925 3926 3927 3928 3929 3930 3931 3932 3933 3934 3935 3936 3937 3938 3939 3940 3941 3942 3943 3944 3945 3946 3947 3948 3949 3950 3951 3952 3953 3954 3955 3956 3957 3958 3959 3960 3961 3962 3963 3964 3965 3966 3967 3968 3969 3970 3971 3972 3973 3974 3975 3976 3977 3978 3979 3980 3981 3982 3983 3984 3985 3986 3987 3988 3989 3990 3991 3992 3993 3994 3995 3996 3997 3998 3999 4000 4001 4002 4003 4004 4005 4006 4007 4008 4009 4010 4011 4012 4013 4014 4015 4016 4017 4018 4019 4020 4021 4022 4023 4024 4025 4026 4027 4028 4029 4030 4031 4032 4033 4034 4035 4036 4037 4038 4039 4040 4041 4042 4043 4044 4045 4046 4047 4048 4049 4050 4051 4052 4053 4054 4055 4056 4057 4058 4059 4060 4061 4062 4063 4064 4065 4066 4067 4068 4069 4070 4071 4072 4073 4074 4075 4076 4077 4078 4079 4080 4081 4082 4083 4084 4085 4086 4087 4088 4089 4090 4091 4092 4093 4094 4095 4096 4097 4098 4099 4100 4101 4102 4103 4104 4105 4106 4107 4108 4109 4110 4111 4112 4113 4114 4115 4116 4117 4118 4119 4120 4121 4122 4123 4124 4125 4126 4127 4128 4129 4130 4131 4132 4133 4134 4135 4136 4137 4138 4139 4140 4141 4142 4143 4144 4145 4146 4147 4148 4149 4150 4151 4152 4153 4154 4155 4156 4157 4158 4159 4160 4161 4162 4163 4164 4165 4166 4167 4168 4169 4170 4171 4172 4173 4174 4175 4176 4177 4178 4179 4180 4181 4182 4183 4184 4185 4186 4187 4188 4189 4190 4191 4192 4193 4194 4195 4196 4197 4198 4199 4200 4201 4202 4203 4204 4205 4206 4207 4208 4209 4210 4211 4212 4213 4214 4215 4216 4217 4218 4219 4220 4221 4222 4223 4224 4225 4226 4227 4228 4229 4230 4231 4232 4233 4234 4235 4236 4237 4238 4239 4240 4241 4242 4243 4244 4245 4246 4247 4248 4249 4250 4251 4252 4253 4254 4255 4256 4257 4258 4259 4260 4261 4262 4263 4264 4265 4266 4267 4268 4269 4270 4271 4272 4273 4274 4275 4276 4277 4278 4279 4280 4281 4282 4283 4284 4285 4286 4287 4288 4289 4290 4291 4292 4293 4294 4295 4296 4297 4298 4299 4300 4301 4302 4303 4304 4305 4306 4307 4308 4309 4310 4311 4312 4313 4314 4315 4316 4317 4318 4319 4320 4321 4322 4323 4324 4325 4326 4327 4328 4329 4330 4331 4332 4333 4334 4335 4336 4337 4338 4339 4340 4341 4342 4343 4344 4345 4346 4347 4348 4349 4350 4351 4352 4353 4354 4355 4356 4357 4358 4359 4360 4361 4362 4363 4364 4365 4366 4367 4368 4369 4370 4371 4372 4373 4374 4375 4376 4377 4378 4379 4380 4381 4382 4383 4384 4385 4386 4387 4388 4389 4390 4391 4392 4393 4394 4395 4396 4397 4398 4399 4400 4401 4402 4403 4404 4405 4406 4407 4408 4409 4410 4411 4412 4413 4414 4415 4416 4417 4418 4419 4420 4421 4422 4423 4424 4425 4426 4427 4428 4429 4430 4431 4432 4433 4434 4435 4436 4437 4438 4439 4440 4441 4442 4443 4444 4445 4446 4447 4448 4449 4450 4451 4452 4453 4454 4455 4456 4457 4458 4459 4460 4461 4462 4463 4464 4465 4466 4467 4468 4469 4470 4471 4472 4473 4474 4475 4476 4477 4478 4479 4480 4481 4482 4483 4484 4485 4486 4487 4488 4489 4490 4491 4492 4493 4494 4495 4496 4497 4498 4499 4500 4501 4502 4503 4504 4505 4506 4507 4508 4509 4510 4511 4512 4513 4514 4515 4516 4517 4518 4519 4520 4521 4522 4523 4524 4525 4526 4527 4528 4529 4530 4531 4532 4533 4534 4535 4536 4537 4538 4539 4540 4541 4542 4543 4544 4545 4546 4547 4548 4549 4550 4551 4552 4553 4554 4555 4556 4557 4558 4559 4560 4561 4562 4563 4564 4565 4566 4567 4568 4569 4570 4571 4572 4573 4574 4575 4576 4577 4578 4579 4580 4581 4582 4583 4584 4585 4586 4587 4588 4589 4590 4591 4592 4593 4594 4595 4596 4597 4598 4599 4600 4601 4602 4603 4604 4605 4606 4607 4608 4609 4610 4611 4612 4613 4614 4615 4616 4617 4618 4619 4620 4621 4622 4623 4624 4625 4626 4627 4628 4629 4630 4631 4632 4633 4634 4635 4636 4637 4638 4639 4640 4641 4642 4643 4644 4645 4646 4647 4648 4649 4650 4651 4652 4653 4654 4655 4656 4657 4658 4659 4660 4661 4662 4663 4664 4665 4666 4667 4668 4669 4670 4671 4672 4673 4674 4675 4676 4677 4678 4679 4680 4681 4682 4683 4684 4685 4686 4687 4688 4689 4690 4691 4692 4693 4694 4695 4696 4697 4698 4699 4700 4701 4702 4703 4704 4705 4706 4707 4708 4709 4710 4711 4712 4713 4714 4715 4716 4717 4718 4719 4720 4721 4722 4723 4724 4725 4726 4727 4728 4729 4730 4731 4732 4733 4734 4735 4736 4737 4738 4739 4740 4741 4742 4743 4744 4745 4746 4747 4748 4749 4750 4751 4752 4753 4754 4755 4756 4757 4758 4759 4760 4761 4762 4763 4764 4765 4766 4767 4768 4769 4770 4771 4772 4773 4774 4775 4776 4777 4778 4779 4780 4781 4782 4783 4784 4785 4786 4787 4788 4789 4790 4791 4792 4793 4794 4795 4796 4797 4798 4799 4800 4801 4802 4803 4804 4805 4806 4807 4808 4809 4810 4811 4812 4813 4814 4815 4816 4817 4818 4819 4820 4821 4822 4823 4824 4825 4826 4827 4828 4829 4830 4831 4832 4833 4834 4835 4836 4837 4838 4839 4840 4841 4842 4843 4844 4845 4846 4847 4848 4849 4850 4851 4852 4853 4854 4855 4856 4857 4858 4859 4860 4861 4862 4863 4864 4865 4866 4867 4868 4869 4870 4871 4872 4873 4874 4875 4876 4877 4878 4879 4880 4881 4882 4883 4884 4885 4886 4887 4888 4889 4890 4891 4892 4893 4894 4895 4896 4897 4898 4899 4900 4901 4902 4903 4904 4905 4906 4907 4908 4909 4910 4911 4912 4913 4914 4915 4916 4917 4918 4919 4920 4921 4922 4923 4924 4925 4926 4927 4928 4929 4930 4931 4932 4933 4934 4935 4936 4937 4938 4939 4940 4941 4942 4943 4944 4945 4946 4947 4948 4949 4950 4951 4952 4953 4954 4955 4956 4957 4958 4959 4960 4961 4962 4963 4964 4965 4966 4967 4968 4969 4970 4971 4972 4973 4974 4975 4976 4977 4978 4979 4980 4981 4982 4983 4984 4985 4986 4987 4988 4989 4990 4991 4992 4993 4994 4995 4996 4997 4998 4999 5000 5001 5002 5003 5004 5005 5006 5007 5008 5009 5010 5011 5012 5013 5014 5015 5016 5017 5018 5019 5020 5021 5022 5023 5024 5025 5026 5027 5028 5029 5030 5031 5032 5033 5034 5035 5036 5037 5038 5039 5040 5041 5042 5043 5044 5045 5046 5047 5048 5049 5050 5051 5052 5053 5054 5055 5056 5057 5058 5059 5060 5061 5062 5063 5064 5065 5066 5067 5068 5069 5070 5071 5072 5073 5074 5075 5076 5077 5078 5079 5080 5081 5082 5083 5084 5085 5086 5087 5088 5089 5090 5091 5092 5093 5094 5095 5096 5097 5098 5099 5100 5101 5102 5103 5104 5105 5106 5107 5108 5109 5110 5111 5112 5113 5114 5115 5116 5117 5118 5119 5120 5121 5122 5123 5124 5125 5126 5127 5128 5129 5130 5131 5132 5133 5134 5135 5136 5137 5138 5139 5140 5141 5142 5143 5144 5145 5146 5147 5148 5149 5150 5151 5152 5153 5154 5155 5156 5157 5158 5159 5160 5161 5162 5163 5164 5165 5166 5167 5168 5169 5170 5171 5172 5173 5174 5175 5176 5177 5178 5179 5180 5181 5182 5183 5184 5185 5186 5187 5188 5189 5190 5191 5192 5193 5194 5195 5196 5197 5198 5199 5200 5201 5202 5203 5204 5205 5206 5207 5208 5209 5210 5211 5212 5213 5214 5215 5216 5217 5218 5219 5220 5221 5222 5223 5224 5225 5226 5227 5228 5229 5230 5231 5232 5233 5234 5235 5236 5237 5238 5239 5240 5241 5242 5243 5244 5245 5246 5247 5248 5249 5250 5251 5252 5253 5254 5255 5256 5257 5258 5259 5260 5261 5262 5263 5264 5265 5266 5267 5268 5269 5270 5271 5272 5273 5274 5275 5276 5277 5278 5279 5280 5281 5282 5283 5284 5285 5286 5287 5288 5289 5290 5291 5292 5293 5294 5295 5296 5297 5298 5299 5300 5301 5302 5303 5304 5305 5306 5307 5308 5309 5310 5311 5312 5313 5314 5315 5316 5317 5318 5319 5320 5321 5322 5323 5324 5325 5326 5327 5328 5329 5330 5331 5332 5333 5334 5335 5336 5337 5338 5339 5340 5341 5342 5343 5344 5345 5346 5347 5348 5349 5350 5351 5352 5353 5354 5355 5356 5357 5358 5359 5360 5361 5362 5363 5364 5365 5366 5367 5368 5369 5370 5371 5372 5373 5374 5375 5376 5377 5378 5379 5380 5381 5382 5383 5384 5385 5386 5387 5388 5389 5390 5391 5392 5393 5394 5395 5396 5397 5398 5399 5400 5401 5402 5403 5404 5405 5406 5407 5408 5409 5410 5411 5412 5413 5414 5415 5416 5417 5418 5419 5420 5421 5422 5423 5424 5425 5426 5427 5428 5429 5430 5431 5432 5433 5434 5435 5436 5437 5438 5439 5440 5441 5442 5443 5444 5445 5446 5447 5448 5449 5450 5451 5452 5453 5454 5455 5456 5457 5458 5459 5460 5461 5462 5463 5464 5465 5466 5467 5468 5469 5470 5471 5472 5473 5474 5475 5476 5477 5478 5479 5480 5481 5482 5483 5484 5485 5486 5487 5488 5489 5490 5491 5492 5493 5494 5495 5496 5497 5498 5499 5500 5501 5502 5503 5504 5505 5506 5507 5508 5509 5510 5511 5512 5513 5514 5515 5516 5517 5518 5519 5520 5521 5522 5523 5524 5525 5526 5527 5528 5529 5530 5531 5532 5533 5534 5535 5536 5537 5538 5539 5540 5541 5542 5543 5544 5545 5546 5547 5548 5549 5550 5551 5552 5553 5554 5555 5556 5557 5558 5559 5560 5561 5562 5563 5564 5565 5566 5567 5568 5569 5570 5571 5572 5573 5574 5575 5576 5577 5578 5579 5580 5581 5582 5583 5584 5585 5586 5587 5588 5589 5590 5591 5592 5593 5594 5595 5596 5597 5598 5599 5600 5601 5602 5603 5604 5605 5606 5607 5608 5609 5610 5611 5612 5613 5614 5615 5616 5617 5618 5619 5620 5621 5622 5623 5624 5625 5626 5627 5628 5629 5630 5631 5632 5633 5634 5635 5636 5637 5638 5639 5640 5641 5642 5643 5644 5645 5646 5647 5648 5649 5650 5651 5652 5653 5654 5655 5656 5657 5658 5659 5660 5661 5662 5663 5664 5665 5666 5667 5668 5669 5670 5671 5672 5673 5674 5675 5676 5677 5678 5679 5680 5681 5682 5683 5684 5685 5686 5687 5688 5689 5690 5691 5692 5693 5694 5695 5696 5697 5698 5699 5700 5701 5702 5703 5704 5705 5706 5707 5708 5709 5710 5711 5712 5713 5714 5715 5716 5717 5718 5719 5720 5721 5722 5723 5724 5725 5726 5727 5728 5729 5730 5731 5732 5733 5734 5735 5736 5737 5738 5739 5740 5741 5742 5743 5744 5745 5746 5747 5748 5749 5750 5751 5752 5753 5754 5755 5756 5757 5758 5759 5760 5761 5762 5763 5764 5765 5766 5767 5768 5769 5770 5771 5772 5773 5774 5775 5776 5777 5778 5779 5780 5781 5782 5783 5784 5785 5786 5787 5788 5789 5790 5791 5792 5793 5794 5795 5796 5797 5798 5799 5800 5801 5802 5803 5804 5805 5806 5807 5808 5809 5810 5811 5812 5813 5814 5815 5816 5817 5818 5819 5820 5821 5822 5823 5824 5825 5826 5827 5828 5829 5830 5831 5832 5833 5834 5835 5836 5837 5838 5839 5840 5841 5842 5843 5844 5845 5846 5847 5848 5849 5850 5851 5852 5853 5854 5855 5856 5857 5858 5859 5860 5861 5862 5863 5864 5865 5866 5867 5868 5869 5870 5871 5872 5873 5874 5875 5876 5877 5878 5879 5880 5881 5882 5883 5884 5885 5886 5887 5888 5889 5890 5891 5892 5893 5894 5895 5896 5897 5898 5899 5900 5901 5902 5903 5904 5905 5906 5907 5908 5909 5910 5911 5912 5913 5914 5915 5916 5917 5918 5919 5920 5921 5922 5923 5924 5925 5926 5927 5928 5929 5930 5931 5932 5933 5934 5935 5936 5937 5938 5939 5940 5941 5942 5943 5944 5945 5946 5947 5948 5949 5950 5951 5952 5953 5954 5955 5956 5957 5958 5959 5960 5961 5962 5963 5964 5965 5966 5967 5968 5969 5970 5971 5972 5973 5974 5975 5976 5977 5978 5979 5980 5981 5982 5983 5984 5985 5986 5987 5988 5989 5990 5991 5992 5993 5994 5995 5996 5997 5998 5999 6000 6001 6002 6003 6004 6005 6006 6007 6008 6009 6010 6011 6012 6013 6014 6015 6016 6017 6018 6019 6020 6021 6022 6023 6024 6025 6026 6027 6028 6029 6030 6031 6032 6033 6034 6035 6036 6037 6038 6039 6040 6041 6042 6043 6044 6045 6046 6047 6048 6049 6050 6051 6052 6053 6054 6055 6056 6057 6058 6059 6060 6061 6062 6063 6064 6065 6066 6067 6068 6069 6070 6071 6072 6073 6074 6075 6076 6077 6078 6079 6080 6081 6082 6083 6084 6085 6086 6087 6088 6089 6090 6091 6092 6093 6094 6095 6096 6097 6098 6099 6100 6101 6102 6103 6104 6105 6106 6107 6108 6109 6110 6111 6112 6113 6114 6115 6116 6117 6118 6119 6120 6121 6122 6123 6124 6125 6126 6127 6128 6129 6130 6131 6132 6133 6134 6135 6136 6137 6138 6139 6140 6141 6142 6143 6144 6145 6146 6147 6148 6149 6150 6151 6152 6153 6154 6155 6156 6157 6158 6159 6160 6161 6162 6163 6164 6165 6166 6167 6168 6169 6170 6171 6172 6173 6174 6175 6176 6177 6178 6179 6180 6181 6182 6183 6184 6185 6186 6187 6188 6189 6190 6191 6192 6193 6194 6195 6196 6197 6198 6199 6200 6201 6202 6203 6204 6205 6206 6207 6208 6209 6210 6211 6212 6213 6214 6215 6216 6217 6218 6219 6220 6221 6222 6223 6224 6225 6226 6227 6228 6229 6230 6231 6232 6233 6234 6235 6236 6237 6238 6239 6240 6241 6242 6243 6244 6245 6246 6247 6248 6249 6250 6251 6252 6253 6254 6255 6256 6257 6258 6259 6260 6261 6262 6263 6264 6265 6266 6267 6268 6269 6270 6271 6272 6273 6274 6275 6276 6277 6278 6279 6280 6281 6282 6283 6284 6285 6286 6287 6288 6289 6290 6291 6292 6293 6294 6295 6296 6297 6298 6299 6300 6301 6302 6303 6304 6305 6306 6307 6308 6309 6310 6311 6312 6313 6314 6315 6316 6317 6318 6319 6320 6321 6322 6323 6324 6325 6326 6327 6328 6329 6330 6331 6332 6333 6334 6335 6336 6337 6338 6339 6340 6341 6342 6343 6344 6345 6346 6347 6348 6349 6350 6351 6352 6353 6354 6355 6356 6357 6358 6359 6360 6361 6362 6363 6364 6365 6366 6367 6368 6369 6370 6371 6372 6373 6374 6375 6376 6377 6378 6379 6380 6381 6382 6383 6384 6385 6386 6387 6388 6389 6390 6391 6392 6393 6394 6395 6396 6397 6398 6399 6400 6401 6402 6403 6404 6405 6406 6407 6408 6409 6410 6411 6412 6413 6414 6415 6416 6417 6418 6419 6420 6421 6422 6423 6424 6425 6426 6427 6428 6429 6430 6431 6432 6433 6434 6435 6436 6437 6438 6439 6440 6441 6442 6443 6444 6445 6446 6447 6448 6449 6450 6451 6452 6453 6454 6455 6456 6457 6458 6459 6460 6461 6462 6463 6464 6465 6466 6467 6468 6469 6470 6471 6472 6473 6474 6475 6476 6477 6478 6479 6480 6481 6482 6483 6484 6485 6486 6487 6488 6489 6490 6491 6492 6493 6494 6495 6496 6497 6498 6499 6500 6501 6502 6503 6504 6505 6506 6507 6508 6509 6510 6511 6512 6513 6514 6515 6516 6517 6518 6519 6520 6521 6522 6523 6524 6525 6526 6527 6528 6529 6530 6531 6532 6533 6534 6535 6536 6537 6538 6539 6540 6541 6542 6543 6544 6545 6546 6547 6548 6549 6550 6551 6552 6553 6554 6555 6556 6557 6558 6559 6560 6561 6562 6563 6564 6565 6566 6567 6568 6569 6570 6571 6572 6573 6574 6575 6576 6577 6578 6579 6580 6581 6582 6583 6584 6585 6586 6587 6588 6589 6590 6591 6592 6593 6594 6595 6596 6597 6598 6599 6600 6601 6602 6603 6604 6605 6606 6607 6608 6609 6610 6611 6612 6613 6614 6615 6616 6617 6618 6619 6620 6621 6622 6623 6624 6625 6626 6627 6628 6629 6630 6631 6632 6633 6634 6635 6636 6637 6638 6639 6640 6641 6642 6643 6644 6645 6646 6647 6648 6649 6650 6651 6652 6653 6654 6655 6656 6657 6658 6659 6660 6661 6662 6663 6664 6665 6666 6667 6668 6669 6670 6671 6672 6673 6674 6675 6676 6677 6678 6679 6680 6681 6682 6683 6684 6685 6686 6687 6688 6689 6690 6691 6692 6693 6694 6695 6696 6697 6698 6699 6700 6701 6702 6703 6704 6705 6706 6707 6708 6709 6710 6711 6712 6713 6714 6715 6716 6717 6718 6719 6720 6721 6722 6723 6724 6725 6726 6727 6728 6729 6730 6731 6732 6733 6734 6735 6736 6737 6738 6739 6740 6741 6742 6743 6744 6745 6746 6747 6748 6749 6750 6751 6752 6753 6754 6755 6756 6757 6758 6759 6760 6761 6762 6763 6764 6765 6766 6767 6768 6769 6770 6771 6772 6773 6774 6775 6776 6777 6778 6779 6780 6781 6782 6783 6784 6785 6786 6787 6788 6789 6790 6791 6792 6793 6794 6795 6796 6797 6798 6799 6800 6801 6802 6803 6804 6805 6806 6807 6808 6809 6810 6811 6812 6813 6814 6815 6816 6817 6818 6819 6820 6821 6822 6823 6824 6825 6826 6827 6828 6829 6830 6831 6832 6833 6834 6835 6836 6837 6838 6839 6840 6841 6842 6843 6844 6845 6846 6847 6848 6849 6850 6851 6852 6853 6854 6855 6856 6857 6858 6859 6860 6861 6862 6863 6864 6865 6866 6867 6868 6869 6870 6871 6872 6873 6874 6875 6876 6877 6878 6879 6880 6881 6882 6883 6884 6885 | [
{
"nctId": "NCT01213784",
"briefTitle": "Optimized Glycemic Control in Heart Failure Patients With DM2:\"Effect on Left Ventricular Function and Skeletal Muscle\"",
"officialTitle": "Optimized Glycemic Control in Type 2 Diabetics With Heart Failure:\"Effect on Left Ventricular Function and Skeletal Muscle\"",
"acronym": "HFDM",
"organization": "University of Aarhus",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE2"
],
"enrollmentCount": 40,
"leadSponsor": "University of Aarhus",
"sponsorClass": "OTHER",
"collaborators": [
"The Danish Diabetes Association"
],
"conditions": [
"Type 2 Diabetes",
"Heart Failure"
],
"interventions": [
"OTHER: all antidiabetic drugs will be appliable"
],
"briefSummary": "The investigators wish to investigate wether a more strict diabetic control improves cardiac function, muscle strength, exercise capacity and decreases symptoms.\n\nThe investigators hypothesis is that improving the glycemic control in suboptimized diabetics with heart failure will improve cardiac performance, muscle strength, exercise capacity and decrease symptoms.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": "90 Years",
"healthyVolunteers": false,
"startDate": "2010-09",
"completionDate": "2012-11",
"primaryCompletionDate": "2012-11",
"firstPostedDate": "2010-10-04",
"lastUpdatePostedDate": "2015-03-06",
"locations": [
{
"facility": "Dept. of cardiology, Aarhus university hospital Skejby",
"city": "Aarhus",
"state": "Central Jutland",
"country": "Denmark"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT01213784",
"scrapedAt": "2026-05-14T17:51:03.369Z"
},
{
"nctId": "NCT03060538",
"briefTitle": "A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease",
"officialTitle": "A Phase Ib, Randomized, Blinded, Placebo-Controlled, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous BFKB8488A in Patients With Type 2 Diabetes Mellitus and Patients With Non-Alcoholic Fatty Liver Disease",
"acronym": null,
"organization": "Genentech, Inc.",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE1"
],
"enrollmentCount": 154,
"leadSponsor": "Genentech, Inc.",
"sponsorClass": "INDUSTRY",
"collaborators": [],
"conditions": [
"Diabetes Mellitus, Type 2",
"Non-Alcoholic Fatty Liver Disease"
],
"interventions": [
"DRUG: BFKB8488A",
"OTHER: Placebo"
],
"briefSummary": "This is a Phase Ib, randomized, blinded, placebo-controlled, multiple ascending-dose study of the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of BFKB8488A in participants with Type 2 diabetes mellitus (T2DM) and participants with non-alcoholic fatty liver disease(NAFLD). A maximum of approximately 160 participants will be enrolled across multiple sites in the United States. Participants will be randomly assigned to receive study drug (active BFKB8488A or placebo). The study will consist of a screening period (up to 8 weeks), a 12-week treatment period, and a 6-week follow-up period. Participants may come to clinic for an optional pre-screening visit.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": "75 Years",
"healthyVolunteers": false,
"startDate": "2017-03-05",
"completionDate": "2019-12-13",
"primaryCompletionDate": "2019-12-13",
"firstPostedDate": "2017-02-23",
"lastUpdatePostedDate": "2020-03-27",
"locations": [
{
"facility": "Pinnacle Research Group Cullman",
"city": "Anniston",
"state": "Alabama",
"country": "United States"
},
{
"facility": "Pinnacle Research Group; Llc, Central",
"city": "Anniston",
"state": "Alabama",
"country": "United States"
},
{
"facility": "Southern California Research Center, Inc.",
"city": "Coronado",
"state": "California",
"country": "United States"
},
{
"facility": "Stanford Health Care",
"city": "Stanford",
"state": "California",
"country": "United States"
},
{
"facility": "Diabetes Research Center",
"city": "Tustin",
"state": "California",
"country": "United States"
},
{
"facility": "MD Clinical",
"city": "Hallandale",
"state": "Florida",
"country": "United States"
},
{
"facility": "Premier Research Associate, Inc",
"city": "Miami",
"state": "Florida",
"country": "United States"
},
{
"facility": "Agile Clinical Research Trials",
"city": "Atlanta",
"state": "Georgia",
"country": "United States"
},
{
"facility": "MidWest Clinical Research",
"city": "Overland Park",
"state": "Kansas",
"country": "United States"
},
{
"facility": "Hassman Research Institute",
"city": "Berlin",
"state": "New Jersey",
"country": "United States"
},
{
"facility": "Carolina Research Center at Jones Family Practice",
"city": "Shelby",
"state": "North Carolina",
"country": "United States"
},
{
"facility": "New Orleans Center for Clinical Research",
"city": "Knoxville",
"state": "Tennessee",
"country": "United States"
},
{
"facility": "Texas Clinical Research Institute, LLC",
"city": "Arlington",
"state": "Texas",
"country": "United States"
},
{
"facility": "Dallas Diabetes & Endocrine Center",
"city": "Dallas",
"state": "Texas",
"country": "United States"
},
{
"facility": "Clinical Trials of Texas Incorporated",
"city": "San Antonio",
"state": "Texas",
"country": "United States"
},
{
"facility": "Northeast Clinical Research of San Antonio LLC",
"city": "San Antonio",
"state": "Texas",
"country": "United States"
},
{
"facility": "Consano Clinical Research",
"city": "Shavano Park",
"state": "Texas",
"country": "United States"
},
{
"facility": "inVentiv Health Clinical",
"city": "Montreal",
"state": "Quebec",
"country": "Canada"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT03060538",
"scrapedAt": "2026-05-14T17:51:03.463Z"
},
{
"nctId": "NCT02675855",
"briefTitle": "GrafixPRIME® for the Treatment of Chronic Diabetic Foot Ulcers",
"officialTitle": "A Multicenter, Randomized, Single-Blind Study Comparing the Efficacy of GrafixPRIME® to Active Comparator for the Treatment of Chronic Diabetic Foot Ulcers",
"acronym": null,
"organization": "Osiris Therapeutics",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE4"
],
"enrollmentCount": 75,
"leadSponsor": "Osiris Therapeutics",
"sponsorClass": "INDUSTRY",
"collaborators": [],
"conditions": [
"Foot Ulcer, Diabetic"
],
"interventions": [
"OTHER: GrafixPRIME®",
"PROCEDURE: Dressing Application",
"DEVICE: Off-loading (walking boot)"
],
"briefSummary": "The objective of the study is to compare the efficacy of weekly GrafixPRIME® administration to an Active Comparator in patients with chronic DFUs in a randomized, single-blind study.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": "80 Years",
"healthyVolunteers": false,
"startDate": "2016-01",
"completionDate": "2017-07",
"primaryCompletionDate": "2017-07",
"firstPostedDate": "2016-02-05",
"lastUpdatePostedDate": "2017-07-17",
"locations": [
{
"facility": null,
"city": "Arizona City",
"state": "Arizona",
"country": "United States"
},
{
"facility": null,
"city": "California City",
"state": "California",
"country": "United States"
},
{
"facility": null,
"city": "New Mexico",
"state": "New Mexico",
"country": "United States"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT02675855",
"scrapedAt": "2026-05-14T17:51:03.504Z"
},
{
"nctId": "NCT01185743",
"briefTitle": "Antipsychotics and Gene Expression in Soft Tissues",
"officialTitle": "Effect of Atypical Antipsychotics on Gene Expression in Soft Tissues of Healthy Subjects - A Placebo Controlled Randomised Pilot Study",
"acronym": null,
"organization": "Medical University of Vienna",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE4"
],
"enrollmentCount": 16,
"leadSponsor": "Medical University of Vienna",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Schizophrenia",
"Diabetes"
],
"interventions": [
"DRUG: olanzapine",
"DRUG: ziprasidone",
"DRUG: placebo"
],
"briefSummary": "Schizophrenia is a severe chronic and disabling mental disorder and is associated with a significant reduction in life expectancy. Atypical antipsychotic treatment compliance may be jeopardized because of drug induced weight gain and abnormalities in carbohydrate and lipid metabolism.\n\nAim: to gain data on drug related effects on gene expression and regulation with special regard to glucose metabolism.",
"sex": "MALE",
"minimumAge": "18 Years",
"maximumAge": "45 Years",
"healthyVolunteers": true,
"startDate": "2010-07",
"completionDate": "2017-01-01",
"primaryCompletionDate": "2017-01-01",
"firstPostedDate": "2010-08-20",
"lastUpdatePostedDate": "2017-03-23",
"locations": [
{
"facility": "Medical University of Vienna",
"city": "Vienna",
"state": "State of Vienna",
"country": "Austria"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT01185743",
"scrapedAt": "2026-05-14T17:51:03.591Z"
},
{
"nctId": "NCT01827735",
"briefTitle": "Regulatory T Cells in Type 1 Diabetes Patients Treated With IL-2",
"officialTitle": "Adaptive Study of IL-2 Dose on Regulatory T Cells in Type 1 Diabetes (DILT1D)",
"acronym": "DILT1D",
"organization": "Cambridge University Hospitals NHS Foundation Trust",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE1",
"PHASE2"
],
"enrollmentCount": 40,
"leadSponsor": "Cambridge University Hospitals NHS Foundation Trust",
"sponsorClass": "OTHER",
"collaborators": [
"University of Cambridge",
"Juvenile Diabetes Research Foundation",
"National Institute for Health Research, United Kingdom",
"Wellcome Trust"
],
"conditions": [
"Type 1 Diabetes"
],
"interventions": [
"DRUG: Aldesleukin (Proleukin)"
],
"briefSummary": "Type 1 diabetes is the most common severe chronic autoimmune disease worldwide and is caused by the autoimmune (loss of self tolerance) mediated destruction of the insulin producing pancreatic beta cells thus leading to insulin deficiency and development of hyperglycaemia. Currently, medical management of type 1 diabetes focuses on intensive insulin replacement therapy to limit complications (retinopathy, nephropathy, neuropathy); nevertheless clinical outcomes remain sub optimal. There are intensive efforts to design novel immunotherapies that can arrest the autoimmune process and thereby preserve residual insulin production leading to fewer complications and better clinical outcomes.\n\nThe vast majority of genes that contribute to susceptibility to type 1 diabetes have been found to encode proteins involved in immune regulation and function. In particular, several susceptibility proteins are involved in the interleukin 2 (IL-2) pathway that regulates T cell activation and tolerance to self antigens. Aldesleukin is a human recombinant IL-2 product produced by recombinant DNA technology using genetically engineered E. coli stain containing an analog of the human interleukin-2 gene. There is substantial nonclinical, preclinical and clinical data that ultra low dose IL-2 (aldesleukin) therapy can arrest the autoimmune mediated destruction of pancreatic beta cells by induction of functional T regulatory cells. However, prior to embarking on large proof of concept trials in type 1 diabetes it is essential that the optimum dose of IL-2 (aldesleukin) is determined. The objective of this study is to establish in patients with type 1 diabetes the optimal dose of IL-2 (aldesleukin) to administer in order to increase T regulatory cell response.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": "50 Years",
"healthyVolunteers": false,
"startDate": "2013-03",
"completionDate": "2014-05",
"primaryCompletionDate": "2014-05",
"firstPostedDate": "2013-04-10",
"lastUpdatePostedDate": "2015-06-23",
"locations": [
{
"facility": "Wellcome Trust Clinical Research Facility, Addenbrooke's Hospital",
"city": "Cambridge",
"state": null,
"country": "United Kingdom"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT01827735",
"scrapedAt": "2026-05-14T17:51:03.641Z"
},
{
"nctId": "NCT00437008",
"briefTitle": "Effects of Benfotiamine and AGE on Endothelial Function in People With Diabetes",
"officialTitle": "Acute Effects of a Low-AGE vs. High-AGE Meal on Postprandial Endothelial Function in People With Type 2 Diabetes Mellitus. Protective Effects of Benfotiamine",
"acronym": "AGE-Benfo",
"organization": "Ruhr University of Bochum",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE4"
],
"enrollmentCount": 21,
"leadSponsor": "Ruhr University of Bochum",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Endothelial Dysfunction",
"Type 2 Diabetes Mellitus"
],
"interventions": [
"DRUG: Benfotiamine 1050mg, 3 days",
"BEHAVIORAL: high-AGE vs. low-AGE meal"
],
"briefSummary": "The purpose of the study is to determine whether there are differences in postprandial endothelial function following a high-AGE(Advanced Glycation End-products) meal vs. a low-AGE meal. We also intend to investigate if the therapy with 1050mg Benfotiamine for 3 days protects against the postulated deterioration of endothelial function after a high-AGE meal in people with type 2 diabetes mellitus.",
"sex": "ALL",
"minimumAge": "35 Years",
"maximumAge": "70 Years",
"healthyVolunteers": false,
"startDate": "2004-11",
"completionDate": "2006-01",
"primaryCompletionDate": null,
"firstPostedDate": "2007-02-19",
"lastUpdatePostedDate": "2007-02-19",
"locations": [
{
"facility": "Heart and Diabetes Center NRW",
"city": "Bad Oeynhausen",
"state": null,
"country": "Germany"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT00437008",
"scrapedAt": "2026-05-14T17:51:03.685Z"
},
{
"nctId": "NCT05452525",
"briefTitle": "Pharmacokinetics and Safety/Tolerability Profile of CKD-379",
"officialTitle": "A Randomized, Open-label, Single Dose, 3-period, 6-treatment, Crossover Study to Compare the Pharmacokinetics and Safety/Tolerability of CKD-379 and Coadministration of D759, D745 and D150 in Healthy Subjects",
"acronym": null,
"organization": "Chong Kun Dang Pharmaceutical",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE1"
],
"enrollmentCount": 24,
"leadSponsor": "Chong Kun Dang Pharmaceutical",
"sponsorClass": "INDUSTRY",
"collaborators": [],
"conditions": [
"Type II Diabetes Mellitus"
],
"interventions": [
"DRUG: CKD-379 I",
"DRUG: CKD-379 II",
"DRUG: D759+D745+D150"
],
"briefSummary": "A study to compare the pharmacokinetics and safety/tolerability between CKD-379 tablet and D759, D745, D150 combination",
"sex": "ALL",
"minimumAge": "19 Years",
"maximumAge": "50 Years",
"healthyVolunteers": true,
"startDate": "2022-07-26",
"completionDate": "2022-09-21",
"primaryCompletionDate": "2022-08-27",
"firstPostedDate": "2022-07-11",
"lastUpdatePostedDate": "2022-10-18",
"locations": [
{
"facility": "Seoul National University Hospital",
"city": "Seoul",
"state": "Jongno-gu",
"country": "South Korea"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT05452525",
"scrapedAt": "2026-05-14T17:51:03.718Z"
},
{
"nctId": "NCT01387425",
"briefTitle": "Efficacy And Safety Of Smoking Cessation With Varenicline Tartrate In Diabetic Smokers: (DIASMOKE)",
"officialTitle": "Efficacy And Safety Of Smoking Cessation With Varenicline Tartrate In Diabetic Smokers: A Double-Blind, Placebo-Controlled, Randomized, Trial",
"acronym": "DIASMOKE",
"organization": "Universita degli Studi di Catania",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 300,
"leadSponsor": "Universita degli Studi di Catania",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Smoking Cessation",
"Diabetes"
],
"interventions": [
"DRUG: varenicline",
"DRUG: placebo tablet is made of lactose"
],
"briefSummary": "Objectives\n\nThis protocol is intended to provide information regarding the efficacy and safety of the nicotine partial agonist varenicline tartrate, at a dose of 1 mg twice daily, for smoking cessation in diabetic subjects who smoke. Given that a better understanding of predictors of smoking cessation can be useful in identifying potential quitters and likely relapsers and that little is known about these predictors in diabetics, the role of different predictors of abstinence at the end of the study will also be examined Study Population The study will enroll 150 type 2 diabetic patients (≤ 75 years) who are regular smokers (≥10 cigs/day) and motivated to stop smoking in each of 2 treatment arms (active drug and placebo) Study Design The study is a double-blind, placebo-controlled, randomized clinical trial designed to assess the efficacy and safety of varenicline 1 mg BID in comparison to placebo for smoking cessation. The duration of active treatment will be 12 weeks and subjects will be followed in the nontreatment phase for an additional 12 weeks. This clinical study has an optional research component to prolong the follow up in the nontreatment phase for a full year. Predictors of abstinence at the end of the study will also be examined Study Endpoints Primary Endpoint: Success rates at week 24 in the varenicline vs placebo group. Success rates will be defined as the Continuous Quit Rate since last visit. Subjects will be classified as responders if they are able to maintain abstinence from cigarette smoking during this period of time with end-expiratory exhaled CO measurements ≤ 10 ppm. This measure will be obtained through reports of cigarette use by means of the Nicotine Use Inventory confirmed by a measurement of an end-expiratory exhaled carbon monoxide concentration that is ≤ 10 ppm on the study visit at week 24 Co-primary endpoint: Success rates at week 12 in the varenicline vs placebo group. Success rates will be defined as Continuous Quit Rate for Weeks 8 to 12 of treatment. Subjects will be classified as responders if they are able to maintain complete abstinence from cigarette smoking in each of the last four study visits (week 9, week 10, week 11, and week 12) with end-expiratory exhaled CO measurements ≤ 10 ppm. This measure will be obtained through reports of cigarette use by means of the Nicotine Use Inventory during the last four study visits (week 9, week 10, week 11, and week 12) confirmed by a measurement of an end-expiratory exhaled carbon monoxide concentration that is ≤ 10 ppm on each study visit Secondary Endpoint: Success rates at week 52 in the varenicline vs placebo group. Success rates will be defined as the Continuous Quit Rate throughout the last three visits (week 24, week 36, and week 44). Subjects will be classified as responders if they are able to maintain abstinence from cigarette smoking during this period of time with end-expiratory exhaled CO measurements ≤ 10 ppm. This measure will be obtained through reports of cigarette use by means of the Nicotine Use Inventory during the last three study visits (week 24, week 36 and week 44) confirmed by a measurement of an end-expiratory exhaled carbon monoxide concentration that is ≤ 10 ppm on each study visit Additional Measures: Given that a better understanding of predictors of smoking cessation can be useful in identifying potential quitters and likely relapsers and that little is known about these predictors in diabetics, the role of different predictors of abstinence at week 24 and at week 52 will also be examined",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": "75 Years",
"healthyVolunteers": false,
"startDate": "2011-06",
"completionDate": null,
"primaryCompletionDate": "2015-12",
"firstPostedDate": "2011-07-04",
"lastUpdatePostedDate": "2015-12-02",
"locations": [
{
"facility": "Centro per la Prevenzione e Cura del Tabagimso",
"city": "Catania",
"state": "Italy",
"country": "Italy"
},
{
"facility": "Centro per la Prevenzione eCura del Tabagimso",
"city": "Catania",
"state": "Italy",
"country": "Italy"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT01387425",
"scrapedAt": "2026-05-14T17:51:03.761Z"
},
{
"nctId": "NCT06069076",
"briefTitle": "Diagnostic Value of Serum Cathepsin S and Chromogranin A in DKD",
"officialTitle": "Diagnostic Value of Serum Cathepsin S and Chromogranin A in Diabetic Kidney Disease",
"acronym": null,
"organization": "Assiut University",
"overallStatus": "NOT_YET_RECRUITING",
"studyType": "OBSERVATIONAL",
"phases": [],
"enrollmentCount": 92,
"leadSponsor": "Assiut University",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Diabetic Kidney Disease"
],
"interventions": [
"DIAGNOSTIC_TEST: cathepsin S and chromogranin A"
],
"briefSummary": "1. Evulate the diagnostic value of serum cathepsin S and chromogranin A for Diabetic kidney disease.\n2. To correlate the levels of serum Cathepsin S and chromogranin A with HbA1c and eGFR in type 2 diabetic patients based on urinary Albumin- Creatinine Ratio.",
"sex": "ALL",
"minimumAge": "20 Years",
"maximumAge": "80 Years",
"healthyVolunteers": true,
"startDate": "2023-11-01",
"completionDate": "2026-10-01",
"primaryCompletionDate": "2025-10-01",
"firstPostedDate": "2023-10-05",
"lastUpdatePostedDate": "2023-10-13",
"locations": [],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT06069076",
"scrapedAt": "2026-05-14T17:51:03.813Z"
},
{
"nctId": "NCT04841668",
"briefTitle": "Gut-Brain-axis: Targets for Improvement of Cognition in the Elderly",
"officialTitle": "Gut-Brain-axis: Targets for Improvement of Cognition in the Elderly",
"acronym": "SmartAge",
"organization": "Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta",
"overallStatus": "COMPLETED",
"studyType": "OBSERVATIONAL",
"phases": [],
"enrollmentCount": 50,
"leadSponsor": "Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Type 2 Diabetes Mellitus"
],
"interventions": [
"DRUG: Metformin"
],
"briefSummary": "Cognitive disorders increase with age and in the presence of metabolic diseases such as Type 2 Diabetes Mellitus (T2DM). In addition, digestive disorders, changes in dietary pattern and decreased activity negatively influence the microbiome.\n\nThe hypothesis is that pharmacological intervention with metformin will modify the composition of the gut microbiota and cognition.\n\nThe study has a pilot longitudinal design, where each patient with T2DM will be followed for one year. Two groups will be recruited:\n\n1. Group A: The aim will be to evaluate the associations between glucose (measured by continuous glucose monitoring (CGM)), cognitive function (by means of cognitive tests and magnetic resonance imaging (MRI)), physical activity (recorded by activity and sleep tracker devicer), metformin, diet (evaluated by nutritional survey) and composition of the microbiota (evaluated by metagenomics), during 12 months (6 months without metformin and 6 months with metformin treatment).\n2. Group B: The aim will be to evaluate the associations between glucose, diet (evaluated by nutritional survey), cognitive function (by means of cognitive tests), physical activity (measured by activity and sleep tracker device), the treatment and composition of the microbiota (evaluated by metagenomics), during 12 months.",
"sex": "ALL",
"minimumAge": "65 Years",
"maximumAge": "80 Years",
"healthyVolunteers": false,
"startDate": "2021-04-10",
"completionDate": "2024-12-03",
"primaryCompletionDate": "2024-12-03",
"firstPostedDate": "2021-04-12",
"lastUpdatePostedDate": "2026-03-31",
"locations": [
{
"facility": "Institut d'Investigació Biomèdica de Girona (IDIBGI)",
"city": "Girona",
"state": "Girona",
"country": "Spain"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT04841668",
"scrapedAt": "2026-05-14T17:51:03.861Z"
},
{
"nctId": "NCT03353376",
"briefTitle": "Group Versus Individual Care in Diabetes Clinic",
"officialTitle": "Group Versus Individual Care in Patients With Long Standing Type 1 and Type 2 Diabetes: Non Inferiority in a One Year Prospective Study in a Tertiary Diabetes Clinic",
"acronym": null,
"organization": "Rabin Medical Center",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 60,
"leadSponsor": "Rabin Medical Center",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Diabetes Mellitus",
"Group Meetings"
],
"interventions": [
"BEHAVIORAL: group care with Empowerment model"
],
"briefSummary": "In this prospective, randomized, non blinded, one center (University hospital) trial, 60 patients (28 with type 1 and 32 with type 2 diabetes) with a mean duration of diabetes of 22.5 ± 11.7 years were randomly assigned to group (6 patients per group) or individual usual care for one year. Primary end-point included change in Hba1c and visits to out-patients clinics, secondary endpoint included change in body mass index, blood pressure levels, waist circumference, non HDL Cholesterol, diabetes related and quality of life questionnaires and hospitalizations.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2010-09-13",
"completionDate": "2014-01-02",
"primaryCompletionDate": "2014-01-02",
"firstPostedDate": "2017-11-27",
"lastUpdatePostedDate": "2017-11-27",
"locations": [],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT03353376",
"scrapedAt": "2026-05-14T17:51:03.905Z"
},
{
"nctId": "NCT04978974",
"briefTitle": "Implications of Stress Management Program",
"officialTitle": "Stress, Coping Strategies and Quality of Life Among Patients With Chronic Conditions: Implications of Stress Management Program",
"acronym": null,
"organization": "University of Gujrat",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 110,
"leadSponsor": "University of Gujrat",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Chronic Conditions, Multiple"
],
"interventions": [
"BEHAVIORAL: Stress Management Program"
],
"briefSummary": "Previous studies indicated that patients with diabetes mellitus and hypertension had higher level of perceived stress, used maladaptive coping strategies and poor health-related quality of life. Therefore, stress management program was applied to reduce their perceived stress, improve their coping strategies, improve their health-related quality of life and psychological health of the patients with type 2 diabetes mellitus and hypertension in current study. The main objectives of the current study were to observe the effects of stress management program on perceived stress, coping strategies and health-related quality of life using pre-experimental research design. Patients with diabetes mellitus type 2 and hypertension were selected through purposive sampling technique to apply the eclectic approach of the stress management program. Total 110 patients with type 2 diabetes and hypertension completed the program from 114 patients who gave inform consent for participation in the first session. Perceived stress scale, WHOQOL and Coping strategies questionnaire were administered at the pre and post-levels of the program. Further, base line of targeted domains variables was also filled from the participants at pre, mid and post-levels to access the efficacy of the program which was formulated according to previous research data by the researcher. The stress Management program consisted of 10 session which were delivered to eight groups (diabetic and Hypertensive) in five weeks. Each session had the duration 90 minutes and two sessions were conducted in one week.",
"sex": "ALL",
"minimumAge": "31 Years",
"maximumAge": "60 Years",
"healthyVolunteers": false,
"startDate": "2019-05-03",
"completionDate": "2020-12-29",
"primaryCompletionDate": "2020-01-03",
"firstPostedDate": "2021-07-27",
"lastUpdatePostedDate": "2021-07-27",
"locations": [
{
"facility": "Jhelum Poly Clinic",
"city": "Jhelum",
"state": "Punjab Province",
"country": "Pakistan"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT04978974",
"scrapedAt": "2026-05-14T17:51:03.953Z"
},
{
"nctId": "NCT00283218",
"briefTitle": "A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, Biphasic Insulin Aspart 30, 50 and 70.",
"officialTitle": "A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, Biphasic Insulin Aspart 30, 50 and 70. - A Randomised, Quadruple Cross-Over Trial",
"acronym": null,
"organization": "University of Aarhus",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 24,
"leadSponsor": "University of Aarhus",
"sponsorClass": "OTHER",
"collaborators": [
"Novo Nordisk A/S"
],
"conditions": [
"Type 1 Diabetes"
],
"interventions": [
"DRUG: NovoRapid, NovoMix 30, Bifasisk Insulin Aspart 50, BIAsp70"
],
"briefSummary": "The hypothesis is that an optimal formulation of fast acting and intermediary acting insulin analogues will improve post prandial glycaemic control in patients with type 1 diabetes.\n\nOBJECTIVE:\n\nThe objective is to describe pharmacodynamic (PD) and pharmacokinetic (PK) profiles of Insulin Aspart (IAsp), Biphasic Insulin Aspart (BIAsp) 30, 50 and 70 for a period of 12 hours following a standard test meal on four days respectively in subjects with type 1 diabetes.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2006-01",
"completionDate": "2006-08",
"primaryCompletionDate": null,
"firstPostedDate": "2006-01-27",
"lastUpdatePostedDate": "2006-08-08",
"locations": [
{
"facility": "Dept of Medicine M, Aarhus University Hospital, Nørrebrogade 44",
"city": "Aarhus",
"state": "C",
"country": "Denmark"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT00283218",
"scrapedAt": "2026-05-14T17:51:04.004Z"
},
{
"nctId": "NCT03819790",
"briefTitle": "The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians",
"officialTitle": "Variability of Glucose Assessed in a Randomized Trial Comparing the Initiation of A Treatment Approach With Biosimilar Basal Insulin Analog Or a Titratable iGlarLixi combinatioN in Type 2 Diabetes Among South Asian Subjects (VARIATION 2 SA Trial)",
"acronym": "VARIATION 2 SA",
"organization": "LMC Diabetes & Endocrinology Ltd.",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE4"
],
"enrollmentCount": 119,
"leadSponsor": "LMC Diabetes & Endocrinology Ltd.",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Diabetes Mellitus, Type 2"
],
"interventions": [
"DRUG: Basal insulin glargine and lixisenatide",
"DRUG: Basal insulin Basaglar/Lantus + gliclazide MR",
"DRUG: Metformin"
],
"briefSummary": "The overall objective of this study is to compare the effects of Soliqua, a titratable combination of insulin and GLP-1 receptor agonist in a single pen versus Glargine U100 insulin (Basaglar or Lantus) and gliclazide MR, both added to metformin, on measures of glucose variability using masked CGM data among people of South Asian origin living in Canada with type 2 diabetes (T2DM).",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": "80 Years",
"healthyVolunteers": false,
"startDate": "2018-10-02",
"completionDate": "2019-11-19",
"primaryCompletionDate": "2019-11-19",
"firstPostedDate": "2019-01-29",
"lastUpdatePostedDate": "2021-02-25",
"locations": [
{
"facility": "LMC Brampton",
"city": "Brampton",
"state": "Ontario",
"country": "Canada"
},
{
"facility": "LMC Etobicoke",
"city": "Etobicoke",
"state": "Ontario",
"country": "Canada"
},
{
"facility": "LMC Scarborough",
"city": "Toronto",
"state": "Ontario",
"country": "Canada"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT03819790",
"scrapedAt": "2026-05-14T17:51:04.056Z"
},
{
"nctId": "NCT07442110",
"briefTitle": "This Observational Study Evaluates the Clinical Outcomes of Patients With Diabetes Who Utilize a Specialized Dietary Supplements for Foot Ulcer Healing. The Study Documents the Rate of Complete Wound Closure and the Prevention of Lower Extremity Amputations in a Real-world, At-home Setting.",
"officialTitle": "Observational Study of a Specialized Dietary Supplements on the Healing of Diabetic Foot Ulcers and Prevention of Amputations",
"acronym": null,
"organization": "Amar Zireg",
"overallStatus": "COMPLETED",
"studyType": "OBSERVATIONAL",
"phases": [],
"enrollmentCount": 35,
"leadSponsor": "Amar h Zireg",
"sponsorClass": "OTHER",
"collaborators": [
"Self funded"
],
"conditions": [
"Limb Salvage",
"Diabetes Complication",
"Dietary Supplements",
"Healed Ulcer",
"Wound Closure",
"At Home Setting",
"Diabetes Mellitus, Type 1, Type 2",
"Wound Healing",
"Diabetic Foot Ulcer"
],
"interventions": [
"DIETARY_SUPPLEMENT: Diabetic foot ulcer treatment by dietary supplements"
],
"briefSummary": "This observational study evaluates the clinical outcomes of patients with diabetes who utilize a specialized dietary supplements for foot ulcer healing. The study documents the rate of complete wound closure and the prevention of lower extremity amputations in a real-world, at-home setting.",
"sex": "ALL",
"minimumAge": "25 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2025-07-05",
"completionDate": "2025-09-30",
"primaryCompletionDate": "2025-09-02",
"firstPostedDate": "2026-03-02",
"lastUpdatePostedDate": "2026-03-04",
"locations": [
{
"facility": "Amar hocine Zireg",
"city": "Bordj Bou Arreridj",
"state": "Wilaya de Bordj Bou Arréridj",
"country": "Algeria"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT07442110",
"scrapedAt": "2026-05-14T17:51:04.097Z"
},
{
"nctId": "NCT00643110",
"briefTitle": "Milk as Treatment for Hypoglycemia",
"officialTitle": "Milk as Treatment for Hypoglycemia",
"acronym": null,
"organization": "Creighton University",
"overallStatus": "WITHDRAWN",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 0,
"leadSponsor": "Creighton University",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Type 1 Diabetes"
],
"interventions": [
"DRUG: D50 glucose"
],
"briefSummary": "Test hypothesis that milk can raise blood sugars as well as orange juice or glucose tablets without raising blood sugars too much the way that orange juice or glucose tablets sometimes do.",
"sex": "ALL",
"minimumAge": "19 Years",
"maximumAge": null,
"healthyVolunteers": true,
"startDate": "2008-04",
"completionDate": "2009-01",
"primaryCompletionDate": "2009-01",
"firstPostedDate": "2008-03-26",
"lastUpdatePostedDate": "2015-03-25",
"locations": [
{
"facility": "Creighton Diabetes Center",
"city": "Omaha",
"state": "Nebraska",
"country": "United States"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT00643110",
"scrapedAt": "2026-05-14T17:51:04.139Z"
},
{
"nctId": "NCT05626413",
"briefTitle": "Cardiovascular Disease in Patients With Diabetes: The Silesia Diabetes-Heart Project",
"officialTitle": "Cardiovascular Disease and Diabetes in Silesian Patients",
"acronym": null,
"organization": "Medical University of Silesia",
"overallStatus": "UNKNOWN",
"studyType": "OBSERVATIONAL",
"phases": [],
"enrollmentCount": 4000,
"leadSponsor": "Medical University of Silesia",
"sponsorClass": "OTHER",
"collaborators": [
"Silesian University of Technology",
"Liverpool Heart and Chest Hospital NHS Foundation Trust"
],
"conditions": [
"Diabetes Mellitus"
],
"interventions": [],
"briefSummary": "The project is an observational one which undertakes different, easy to obtain in everyday clinical practice, demographical, laboratory and clinical parameters of patients with diabetes in Silesian Region in Poland to predict cardiovascular disease, cardiovascular events and neuropathy using machine learning approach.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2015-01-01",
"completionDate": "2026-01-31",
"primaryCompletionDate": "2025-12-31",
"firstPostedDate": "2022-11-23",
"lastUpdatePostedDate": "2024-04-10",
"locations": [
{
"facility": "Department of Internal Diseases, Diabetology and Nephrology",
"city": "Zabrze",
"state": null,
"country": "Poland"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT05626413",
"scrapedAt": "2026-05-14T17:51:04.171Z"
},
{
"nctId": "NCT04583813",
"briefTitle": "Empagliflozin and Atrial Fibrillation Treatment",
"officialTitle": "Efficacy of Empagliflozin in Patients With Heart Failure and Atrial Fibrillation",
"acronym": "EMPA-AF",
"organization": "Miulli General Hospital",
"overallStatus": "UNKNOWN",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE4"
],
"enrollmentCount": 400,
"leadSponsor": "Miulli General Hospital",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Atrial Fibrillation",
"Heart Failure",
"Obesity",
"Diabetes Mellitus"
],
"interventions": [
"DRUG: Empagliflozin",
"OTHER: Placebo"
],
"briefSummary": "The primary purpose of this trial is to evaluate the impact of empagliflozin, as compared with placebo, in patients with diabetes mellitus or overweight, heart failure and atrial fibrillation.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": "80 Years",
"healthyVolunteers": false,
"startDate": "2021-09",
"completionDate": "2024-04",
"primaryCompletionDate": "2024-01",
"firstPostedDate": "2020-10-12",
"lastUpdatePostedDate": "2021-04-02",
"locations": [
{
"facility": "Miulli General Hospital",
"city": "Acquaviva delle Fonti",
"state": "Bari",
"country": "Italy"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT04583813",
"scrapedAt": "2026-05-14T17:51:04.208Z"
},
{
"nctId": "NCT03825926",
"briefTitle": "Early Screening of Gestational Diabetes Mellitus and Prospective Cohort Study of Postpartum Follow-up",
"officialTitle": "Early Screening of Gestational Diabetes Mellitus and Prospective Cohort Study of Postpartum Follow-up",
"acronym": null,
"organization": "Fifth Affiliated Hospital, Sun Yat-Sen University",
"overallStatus": "UNKNOWN",
"studyType": "OBSERVATIONAL",
"phases": [],
"enrollmentCount": 600,
"leadSponsor": "Fifth Affiliated Hospital, Sun Yat-Sen University",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Gestational Diabetes Mellitus"
],
"interventions": [],
"briefSummary": "Extraction of whole blood from 10 to 15ml at 24 weeks before pregnancy test, with a view to early detection of GDM, provides evidence for early intervention to improve maternal pregnancy outcomes and metabolic abnormalities.",
"sex": "FEMALE",
"minimumAge": "18 Years",
"maximumAge": "50 Years",
"healthyVolunteers": true,
"startDate": "2019-06-01",
"completionDate": "2025-12-01",
"primaryCompletionDate": "2025-06-01",
"firstPostedDate": "2019-02-01",
"lastUpdatePostedDate": "2020-03-31",
"locations": [
{
"facility": "the Fifth Affiliated Hospital of Sun Yat-sen University of Gynaecology and Obstetrics",
"city": "Zhuhai",
"state": "Guangdong",
"country": "China"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT03825926",
"scrapedAt": "2026-05-14T17:51:04.248Z"
},
{
"nctId": "NCT01426685",
"briefTitle": "Prognosis of Type 2 Diabetic Patients",
"officialTitle": "Prediction of Cardiovascular Events in Type 2 Diabetic Patients With Coronary Artery Disease- Application of Novel Risk Markers and Technology",
"acronym": "ARTEMIS",
"organization": "University of Oulu",
"overallStatus": "UNKNOWN",
"studyType": "OBSERVATIONAL",
"phases": [],
"enrollmentCount": 1880,
"leadSponsor": "University of Oulu",
"sponsorClass": "OTHER",
"collaborators": [
"The Finnish Funding Agency for Technology and Innovation"
],
"conditions": [
"Cardiovascular Risk Assessment"
],
"interventions": [],
"briefSummary": "The study will include 1200 patients with type 2 diabetes and angiographically documented coronary artery disease and 600 matched non-diabetic patients without type 2 diabetes. Extensive traditional and novel risk marker tests are performed for the patients and they will be followed-up for 5 years. Sudden cardiac death is the main outcome measure and various other endpoints are secondary endpoints. As a substudy, 120 diabetic patients and 120 non-diabetic patients will undergo exercise training with home monitoring to assess the effects of exercise training on risk profiles.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": "75 Years",
"healthyVolunteers": false,
"startDate": "2007-08",
"completionDate": "2019-06",
"primaryCompletionDate": "2019-06",
"firstPostedDate": "2011-08-31",
"lastUpdatePostedDate": "2019-04-19",
"locations": [
{
"facility": "University of Oulu",
"city": "Oulu",
"state": null,
"country": "Finland"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT01426685",
"scrapedAt": "2026-05-14T17:51:04.291Z"
},
{
"nctId": "NCT07395050",
"briefTitle": "Autologous CD6-CAR Treg Cells for Patients With Stage 3 Type 1 Diabetes",
"officialTitle": "A Pilot Study to Evaluate the Safety, Tolerability, and Feasibility of Autologous Anti-CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) in Patients With Stage 3 Type 1 Diabetes",
"acronym": null,
"organization": "City of Hope Medical Center",
"overallStatus": "NOT_YET_RECRUITING",
"studyType": "INTERVENTIONAL",
"phases": [
"EARLY_PHASE1"
],
"enrollmentCount": 6,
"leadSponsor": "City of Hope Medical Center",
"sponsorClass": "OTHER",
"collaborators": [
"National Cancer Institute (NCI)"
],
"conditions": [
"Stage 3 Type 1 Diabetes"
],
"interventions": [
"DRUG: AutoCD6-CAR Treg cells"
],
"briefSummary": "Type 1 diabetes (T1D) is a persistent and gradually increasing genetic autoimmune disease requiring life-long management. The disease commonly impacts children. However, a quarter of cases are diagnosed in adults. The pancreatic islet beta-cells are responsible for producing insulin, a peptide hormone that is involved in the tight regulation of blood glucose levels. In T1D, the beta-cells are mistakenly destroyed by autoreactive T cells resulting in insulin deficiency and an inability to regulate blood glucose levels. The cause for such an autoimmune reaction to beta-cells is under active investigation. T regulatory cells (Tregs), are specialized immune cells that typically act to control your immune system. Tregs can be modified in the laboratory to recognize and deactivate T1D-causing cells. This process is done by inserting a piece of DNA (the molecules inside cells that carry genetic information and pass it from one generation to the next) into the Tregs. A non-infectious virus called a lentivirus will carry the piece of DNA into the cells that were collected from a donor. Tregs are then grown to large numbers in the laboratory and stored for treatment of T1D. It is not known whether these Tregs cells will treat T1D.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": "35 Years",
"healthyVolunteers": false,
"startDate": "2026-06-01",
"completionDate": "2026-09-14",
"primaryCompletionDate": "2026-09-14",
"firstPostedDate": "2026-02-09",
"lastUpdatePostedDate": "2026-05-13",
"locations": [
{
"facility": "City of Hope Medical Center",
"city": "Duarte",
"state": "California",
"country": "United States"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT07395050",
"scrapedAt": "2026-05-14T17:51:04.321Z"
},
{
"nctId": "NCT03457168",
"briefTitle": "Treatment of Hypertension During Sleep",
"officialTitle": "A Prospective, Randomized, Open-label Clinical Trial on the Effects of Intensive Versus Conventional Control of Ambulatory-determined Asleep Systolic Blood Pressure Mean on Cardiovascular, Metabolic, and Renal Disease Risks",
"acronym": "THADEUS",
"organization": "University of Vigo",
"overallStatus": "RECRUITING",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 5320,
"leadSponsor": "University of Vigo",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Hypertension",
"Hypertension, Systolic"
],
"interventions": [
"PROCEDURE: Treatment of elevated asleep SBP mean"
],
"briefSummary": "On the basis of new evidence on the relationship between achieved office blood pressure (BP) measurements (OBPM) and the risk of cardiovascular disease (CVD) morbidity and mortality documented in the SPRINT trial, the recent 2017 guidelines of the American College of Cardiology (ACC) and the American Heart Association (AHA) have established lower values of 130/80 mmHg for clinic systolic BP (SBP)/diastolic BP (DBP) as new diagnostic thresholds for hypertension and therapeutic targets for treatment of all individuals aged ≥18 years regardless of age, sex, or concomitant complications including presence of diabetes, chronic kidney disease (CKD), or history of past CVD event. According to these guidelines, the new proposed ambulatory BP measurment (ABPM) thresholds for diagnosis of hypertension in adults are 130/80 and 110/65 mmHg for the awake and asleep SBP/DBP means, respectively. However, the ACC/AHA guidelines do not provide any scientific evidence documenting neither the equivalence between these ABPM thresholds and the 130/80 mmHg cut-off values for OBPM nor the potential improved CVD event-free survival time of the proposed more intensive control of ambulatory BP.\n\nResults derived from observational prospective studies consistently document that therapeutic BP targets in hypertensive individuals, i.e., persons at increased CVD risk, should be established in terms of proper control of asleep BP. To date, no prospective randomized study has ever before evaluated which should be the adequate therapeutic ABPM target for most effective reduction of CVD risk. Accordingly, the Tratamiento de Hipertensión Arterial Durante el Sueño study (THADEUS, i.e., Treatment of Hypertension During Sleep) has been designed to prospectively evaluate if \"intensive control\" of asleep SBP mean proposed by the new ACC/AHA guidelines (\\<110 mmHg) in more effective than the so far its \"conventional control\" (\\<120 mmHg) to reduce CVD morbidity and mortality in hypertensive individuals.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2019-02-01",
"completionDate": "2032-12-31",
"primaryCompletionDate": "2031-12-31",
"firstPostedDate": "2018-03-07",
"lastUpdatePostedDate": "2024-12-06",
"locations": [
{
"facility": "Complexo Hospitalario Universitario de Ourense",
"city": "Ourense",
"state": "Orense",
"country": "Spain"
},
{
"facility": "CS A Estrada",
"city": "A Estrada",
"state": "Pontevedra",
"country": "Spain"
},
{
"facility": "CS Panxón",
"city": "Nigrán",
"state": "Pontevedra",
"country": "Spain"
},
{
"facility": "Centro de Salud de A Doblada",
"city": "Vigo",
"state": "Pontevedra",
"country": "Spain"
},
{
"facility": "Centro de Salud de Bembrive",
"city": "Vigo",
"state": "Pontevedra",
"country": "Spain"
},
{
"facility": "Centro de Salud de Sardoma",
"city": "Vigo",
"state": "Pontevedra",
"country": "Spain"
},
{
"facility": "CS Teis",
"city": "Vigo",
"state": "Pontevedra",
"country": "Spain"
},
{
"facility": "Bioengineering & Chronobilogy Labs., University of Vigo",
"city": "Vigo",
"state": "Pontevedra",
"country": "Spain"
},
{
"facility": "CS San Roque",
"city": "Vilagarcía de Arousa",
"state": "Pontevedra",
"country": "Spain"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT03457168",
"scrapedAt": "2026-05-14T17:51:04.353Z"
},
{
"nctId": "NCT06683391",
"briefTitle": "Updating Preventive and Treatment Guidelines for Hypoglycemia in Individuals Living With Type 1 Diabetes",
"officialTitle": "Updating pReventive and Treatment guidelinEs for Mild hypOglycemia in Individuals Living With Type 1 Diabetes During the erA of Continuous gLucose Monitoring: The REMODAL Trial",
"acronym": "REMODAL",
"organization": "Institut de Recherches Cliniques de Montreal",
"overallStatus": "RECRUITING",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 32,
"leadSponsor": "Institut de Recherches Cliniques de Montreal",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Type 1 Diabetes"
],
"interventions": [
"BEHAVIORAL: Oral Carbohydrate (CHO) Administration for Hypoglycemia Prevention and Treatment"
],
"briefSummary": "The REMODAL trial is a randomized crossover study aiming to update treatment guidelines for mild hypoglycemia in people with Type 1 diabetes using continuous glucose monitoring (CGM) technology. The study will assess whether treating mild hypoglycemia proactively (at a glucose threshold of 5.0 mmol/L) with lower doses of carbohydrate (CHO) is more effective than the traditional reactive approach (treatment at \\< 4.0 mmol/L). The goal is to reduce hypoglycemia frequency and improve quality of life, while minimizing caloric intake and rebound hyperglycemia.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2025-02-06",
"completionDate": "2027-12-31",
"primaryCompletionDate": "2026-12-31",
"firstPostedDate": "2024-11-12",
"lastUpdatePostedDate": "2025-02-25",
"locations": [
{
"facility": "Institut de recherches cliniques de Montréal",
"city": "Montreal",
"state": "Quebec",
"country": "Canada"
},
{
"facility": "Montreal Clinical Research Institute",
"city": "Montreal",
"state": "Quebec",
"country": "Canada"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT06683391",
"scrapedAt": "2026-05-14T17:51:04.389Z"
},
{
"nctId": "NCT03915990",
"briefTitle": "Middle Cerebral and Umbilical Arteries Doppler Indices in the Prediction of Adverse Neonatal Outcome Among Diabetic Pregnant Women",
"officialTitle": "Middle Cerebral and Umbilical Arteries Doppler Indices in Pregestational Diabetic Versus Normal Pregnancies and Their Values in Predicting Adverse Neonatal Outcome",
"acronym": null,
"organization": "Cairo University",
"overallStatus": "UNKNOWN",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 120,
"leadSponsor": "Cairo University",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Diabetes Mellitus, Type 1"
],
"interventions": [
"DIAGNOSTIC_TEST: umbilical and middle cerebral artery Doppler"
],
"briefSummary": "120 patients will be included and divided into two groups; Control group that will include 60 healthy pregnant women and Study group that will include 60 pregestational diabetic pregnant patients which furtherly will be subdivided into two groups according to HbA1C levels namely; controlled diabetics ( will include 30 diabetic pregnant women with controlled DM - HbA1C \\< 6.5 %) and uncontrolled diabetics (will include 30 diabetic pregnant women with uncontrolled DM - HbA1C ≥ 6.5 %). Umbilical and middle cerebral arteries Doppler indices (resistance index and pulsatility index) and Cerebroplacental Doppler ratio will be measured for every patient. The recorded neonatal outcomes will include neonatal birth weight, neonatal blood sugar, Apgar score at 1 \\& 5 min and neonatal intensive care unit admission.",
"sex": "FEMALE",
"minimumAge": "18 Years",
"maximumAge": "40 Years",
"healthyVolunteers": false,
"startDate": "2019-07-01",
"completionDate": "2020-12",
"primaryCompletionDate": "2020-12",
"firstPostedDate": "2019-04-16",
"lastUpdatePostedDate": "2020-11-10",
"locations": [
{
"facility": "kasr elainy hospital (Faculty of Medicine - Cairo University)",
"city": "Cairo",
"state": null,
"country": "Egypt"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT03915990",
"scrapedAt": "2026-05-14T17:51:04.424Z"
},
{
"nctId": "NCT00476710",
"briefTitle": "Effects of Colesevelam HCl On Bile Acid Kinetics",
"officialTitle": "Effects of Colesevelam HCl On Bile Acid Pools And Kinetic Parameters in Normal Subjects, Subjects With Impaired Glucose Tolerance, And Subjects With Type 2 Diabetes Mellitus",
"acronym": null,
"organization": "KineMed",
"overallStatus": "COMPLETED",
"studyType": "OBSERVATIONAL",
"phases": [],
"enrollmentCount": 36,
"leadSponsor": "KineMed",
"sponsorClass": "INDUSTRY",
"collaborators": [
"Daiichi Sankyo",
"University Medical Center Groningen",
"Diabetes & Glandular Disease Research Associates"
],
"conditions": [
"Type 2 Diabetes Mellitus",
"Impaired Glucose Tolerance"
],
"interventions": [
"DRUG: Colesevelam HCl"
],
"briefSummary": "This project will compare the amount of bile acids and their kinetics in overweight and obese people with normal glucose metabolism, impaired glucose tolerance and frank type 2 diabetes. We hypothesize that bile acids will behave differently in these groups. We will also explore the effects of Colesevelam HCl, a medicine that lowers LDL cholesterol by binding bile acids, on bile acids in those groups. We hypothesize the drug may have different actions on bile acids in subjects with different degrees of abnormal glucose metabolism.",
"sex": "ALL",
"minimumAge": "40 Years",
"maximumAge": "60 Years",
"healthyVolunteers": true,
"startDate": "2007-05",
"completionDate": "2009-04",
"primaryCompletionDate": "2009-04",
"firstPostedDate": "2007-05-22",
"lastUpdatePostedDate": "2015-04-01",
"locations": [
{
"facility": "Diabetes & Glandular Disease Research Associates, Inc.",
"city": "San Antonio",
"state": "Texas",
"country": "United States"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT00476710",
"scrapedAt": "2026-05-14T17:51:04.462Z"
},
{
"nctId": "NCT01659697",
"briefTitle": "Diabetes Prevention in Prediabetic Patients",
"officialTitle": "Diabetes Prevention in Patients Aged 25-55 From Ethiopian Origin With Prediabetes: Evaluation of Feasibility and Efficacy of Intensive or Less Intensive Lifestyle Intervention",
"acronym": "DPEP",
"organization": "Meir Medical Center",
"overallStatus": "UNKNOWN",
"studyType": "OBSERVATIONAL",
"phases": [],
"enrollmentCount": 200,
"leadSponsor": "Meir Medical Center",
"sponsorClass": "OTHER",
"collaborators": [
"Clalit Health Services"
],
"conditions": [
"Ethnic Group",
"Young Adults",
"Prediabetes",
"Community Health Services"
],
"interventions": [
"BEHAVIORAL: intensive lifestyle counseling"
],
"briefSummary": "This study will evaluate the feasibility and efficacy of two interventions of lifestyle ( intensive and less intensive) to prevent diabetes in patients from Ethiopian origin, aged 25 to 55 years old with prediabetes living in Israel and insured by Clalit Health Services in the Central district, using resources existing in this Health Care system (HMO).",
"sex": "ALL",
"minimumAge": "25 Years",
"maximumAge": "55 Years",
"healthyVolunteers": false,
"startDate": "2012-08",
"completionDate": "2015-07",
"primaryCompletionDate": "2014-12",
"firstPostedDate": "2012-08-08",
"lastUpdatePostedDate": "2012-08-08",
"locations": [
{
"facility": "Central district Clalit Health Services",
"city": "Rishon LeZiyyon",
"state": null,
"country": "Israel"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT01659697",
"scrapedAt": "2026-05-14T17:51:04.605Z"
},
{
"nctId": "NCT00974090",
"briefTitle": "Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes",
"officialTitle": "A Phase III Study of MP-513 in Combination With Sulfonylurea in Japanese Patients With Type 2 Diabetes Mellitus",
"acronym": null,
"organization": "Tanabe Pharma Corporation",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE3"
],
"enrollmentCount": 194,
"leadSponsor": "Tanabe Pharma Corporation",
"sponsorClass": "INDUSTRY",
"collaborators": [],
"conditions": [
"Type 2 Diabetes Mellitus"
],
"interventions": [
"DRUG: Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea)",
"DRUG: Teneli / Teneli + SU"
],
"briefSummary": "The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) in combination with Sulfonylurea in patients with type 2 Diabetes for 12 weeks administration and to evaluate the safety and efficacy of MP-513 in combination with Sulfonylurea with an extension treatment for up to 52 weeks.",
"sex": "ALL",
"minimumAge": "20 Years",
"maximumAge": "75 Years",
"healthyVolunteers": false,
"startDate": "2009-09",
"completionDate": "2011-03",
"primaryCompletionDate": "2011-03",
"firstPostedDate": "2009-09-10",
"lastUpdatePostedDate": "2026-01-05",
"locations": [
{
"facility": null,
"city": "Sapporo",
"state": "Hokkaido",
"country": "Japan"
}
],
"hasResults": true,
"url": "https://clinicaltrials.gov/study/NCT00974090",
"scrapedAt": "2026-05-14T17:51:04.688Z"
},
{
"nctId": "NCT01583790",
"briefTitle": "Factors Influencing the Positive Outcome of Bariatric Surgery for Morbidly Obese Patients",
"officialTitle": "A Prospective Trial for Laparoscopic Adjustable Gastric Banding in Morbidly Obese Patients: Report on Weight Loss, Metabolic Changes and Quality of Life",
"acronym": null,
"organization": "Assuta Hospital Systems",
"overallStatus": "UNKNOWN",
"studyType": "OBSERVATIONAL",
"phases": [],
"enrollmentCount": 2000,
"leadSponsor": "Assuta Hospital Systems",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Morbid Obesity",
"Diabetes",
"Hypertension"
],
"interventions": [],
"briefSummary": "The purpose of this study is to report data with patients after bariatric surgery.",
"sex": "ALL",
"minimumAge": "14 Years",
"maximumAge": "65 Years",
"healthyVolunteers": false,
"startDate": "2012-01",
"completionDate": "2020-01",
"primaryCompletionDate": "2019-01",
"firstPostedDate": "2012-04-24",
"lastUpdatePostedDate": "2018-01-25",
"locations": [
{
"facility": "Assuta Medical Center",
"city": "Tel Aviv",
"state": null,
"country": "Israel"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT01583790",
"scrapedAt": "2026-05-14T17:51:04.712Z"
},
{
"nctId": "NCT00746460",
"briefTitle": "The Healthy Options Feasibility Study",
"officialTitle": "The Effectiveness of CVD Risk Profiles When Used by Allied Health Care Providers (HCP) Within a \"Groupe de Médecine de Famille\": The Healthy Options Feasibility Study.",
"acronym": null,
"organization": "McGill University",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 50,
"leadSponsor": "McGill University",
"sponsorClass": "OTHER",
"collaborators": [
"Pfizer"
],
"conditions": [
"Obesity",
"Sedentary Lifestyle",
"Dyslipidemia",
"Hypertension",
"Cigarette Smoking",
"Diabetes"
],
"interventions": [
"BEHAVIORAL: CVD risk profile"
],
"briefSummary": "The investigators hypothesize that having health care providers other than physicians within a \"Groupe de Médecine de Famille\" conduct cardiovascular risk assessments and teach lifestyle interventions to primary prevention patients will increase the likelihood that patients will adopt and maintain healthy lifestyles. These objectives will be supported by providing subjects with a cardiovascular risk profile estimating the subject's risk of cardiovascular disease and teaching them how to use the resources related to lifestyle changes available on the www.myhealthcheckup.com Web site.",
"sex": "ALL",
"minimumAge": "30 Years",
"maximumAge": "79 Years",
"healthyVolunteers": false,
"startDate": "2008-06",
"completionDate": "2009-10",
"primaryCompletionDate": "2009-04",
"firstPostedDate": "2008-09-04",
"lastUpdatePostedDate": "2014-01-14",
"locations": [
{
"facility": "McGill Cardiovascular Health Improvement Program",
"city": "Montreal",
"state": "Quebec",
"country": "Canada"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT00746460",
"scrapedAt": "2026-05-14T17:51:04.762Z"
},
{
"nctId": "NCT05463744",
"briefTitle": "A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy",
"officialTitle": "A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy",
"acronym": "QWINT-5",
"organization": "Eli Lilly and Company",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE3"
],
"enrollmentCount": 692,
"leadSponsor": "Eli Lilly and Company",
"sponsorClass": "INDUSTRY",
"collaborators": [],
"conditions": [
"Type 1 Diabetes",
"Diabetes"
],
"interventions": [
"DRUG: Insulin Efsitora Alfa",
"DRUG: Insulin Degludec"
],
"briefSummary": "The main purpose of this study is to measure the safety and efficacy of insulin efsitora alfa (LY3209590) compared with insulin degludec in participants with type 1 diabetes treated with multiple daily injection therapy.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2022-08-12",
"completionDate": "2024-05-07",
"primaryCompletionDate": "2024-05-07",
"firstPostedDate": "2022-07-19",
"lastUpdatePostedDate": "2025-06-24",
"locations": [
{
"facility": "John Muir Physician Network Research Center",
"city": "Concord",
"state": "California",
"country": "United States"
},
{
"facility": "Valley Research",
"city": "Fresno",
"state": "California",
"country": "United States"
},
{
"facility": "Catalina Research Institute, LLC",
"city": "Montclair",
"state": "California",
"country": "United States"
},
{
"facility": "Sansum Diabetes Research Institute",
"city": "Santa Barbara",
"state": "California",
"country": "United States"
},
{
"facility": "University Clinical Investigators, Inc.",
"city": "Tustin",
"state": "California",
"country": "United States"
},
{
"facility": "University of Colorado Anschutz Medical Campus",
"city": "Aurora",
"state": "Colorado",
"country": "United States"
},
{
"facility": "Northeast Research Institute (NERI)",
"city": "Fleming Island",
"state": "Florida",
"country": "United States"
},
{
"facility": "Jellinger and Lerman, MD PA dba The Center for Diabetes and Endocrine Care",
"city": "Fort Lauderdale",
"state": "Florida",
"country": "United States"
},
{
"facility": "Suncoast Clinical Research, Inc.",
"city": "New Port Richey",
"state": "Florida",
"country": "United States"
},
{
"facility": "Hanson Clinical Research Center",
"city": "Port Charlotte",
"state": "Florida",
"country": "United States"
},
{
"facility": "East Coast Institute for Research at The Jones Center",
"city": "Macon",
"state": "Georgia",
"country": "United States"
},
{
"facility": "East-West Medical Research Institute",
"city": "Honolulu",
"state": "Hawaii",
"country": "United States"
},
{
"facility": "Rocky Mountain Clinical Research",
"city": "Idaho Falls",
"state": "Idaho",
"country": "United States"
},
{
"facility": "Iowa Diabetes and Endocrinology Research Center",
"city": "West Des Moines",
"state": "Iowa",
"country": "United States"
},
{
"facility": "Cotton O'Neil Clinical Research Center",
"city": "Topeka",
"state": "Kansas",
"country": "United States"
},
{
"facility": "MedStar Health Research Institute (MedStar Physician Based Research Network)",
"city": "Hyattsville",
"state": "Maryland",
"country": "United States"
},
{
"facility": "Endocrine and Metabolic Consultants",
"city": "Rockville",
"state": "Maryland",
"country": "United States"
},
{
"facility": "Clinvest Research LLC",
"city": "Springfield",
"state": "Missouri",
"country": "United States"
},
{
"facility": "Palm Research Center Tenaya",
"city": "Las Vegas",
"state": "Nevada",
"country": "United States"
},
{
"facility": "Palm Research Center Sunset",
"city": "Las Vegas",
"state": "Nevada",
"country": "United States"
},
{
"facility": "Research Foundation of SUNY - University of Buffalo",
"city": "Buffalo",
"state": "New York",
"country": "United States"
},
{
"facility": "NYU Langone Hospital - Long Island",
"city": "Mineola",
"state": "New York",
"country": "United States"
},
{
"facility": "NYC Research",
"city": "New York",
"state": "New York",
"country": "United States"
},
{
"facility": "SUNY Upstate Medical University",
"city": "Syracuse",
"state": "New York",
"country": "United States"
},
{
"facility": "Thomas Jefferson University Hospital",
"city": "Philadelphia",
"state": "Pennsylvania",
"country": "United States"
},
{
"facility": "Texas Diabetes & Endocrinology, P.A.",
"city": "Austin",
"state": "Texas",
"country": "United States"
},
{
"facility": "Dallas Diabetes Research Center",
"city": "Dallas",
"state": "Texas",
"country": "United States"
},
{
"facility": "North Texas Endocrine Center",
"city": "Dallas",
"state": "Texas",
"country": "United States"
},
{
"facility": "Research Institute of Dallas",
"city": "Dallas",
"state": "Texas",
"country": "United States"
},
{
"facility": "Biopharma Informatic, LLC",
"city": "Houston",
"state": "Texas",
"country": "United States"
},
{
"facility": "Amir A Hassan, MD, PA",
"city": "Houston",
"state": "Texas",
"country": "United States"
},
{
"facility": "Southern Endocrinology Associates",
"city": "Mesquite",
"state": "Texas",
"country": "United States"
},
{
"facility": "Texas Diabetes & Endocrinology, P.A.",
"city": "Round Rock",
"state": "Texas",
"country": "United States"
},
{
"facility": "Rainier Clinical Research Center",
"city": "Renton",
"state": "Washington",
"country": "United States"
},
{
"facility": "CEDIC",
"city": "CABA",
"state": "Buenos Aires",
"country": "Argentina"
},
{
"facility": "Centro de Investigaciones Metabólicas (CINME)",
"city": "Ciudad Autónoma de Buenos Aire",
"state": "Buenos Aires",
"country": "Argentina"
},
{
"facility": "Consultorio de Investigación Clínica EMO SRL",
"city": "Ciudad Autonoma de Buenos Aire",
"state": "Buenos Air",
"country": "Argentina"
},
{
"facility": "CIAD Moron",
"city": "Morón",
"state": "Buenos Air",
"country": "Argentina"
},
{
"facility": "Investigaciones Medicas Imoba Srl",
"city": "Balvanera",
"state": "Ciudad Autónoma de Buenos Aire",
"country": "Argentina"
},
{
"facility": "Mautalen Salud e Investigación",
"city": "Buenos Aires",
"state": "Ciudad Autónoma de Buenos Aire",
"country": "Argentina"
},
{
"facility": "Centro Medico Privado CEMAIC",
"city": "Capital",
"state": "Córdoba Province",
"country": "Argentina"
},
{
"facility": "Centro Medico Privado San Vicente Diabetes",
"city": "Córdoba",
"state": "Córdoba Province",
"country": "Argentina"
},
{
"facility": "Centro de Salud e Investigaciones Médicas",
"city": "Santa Rosa",
"state": "La Pampa Province",
"country": "Argentina"
},
{
"facility": "CIPADI - Centro Integral de Prevencion y Atencion en Diabetes",
"city": "Godoy Cruz",
"state": "Mendoza Province",
"country": "Argentina"
},
{
"facility": "Clínica Mayo de Urgencias Médicas Cruz Blanca S.R.L",
"city": "San Miguel de Tucumán",
"state": "Tucumán Province",
"country": "Argentina"
},
{
"facility": "Centro Medico Privado de Reumatologia",
"city": "San Miguel de Tucumán",
"state": "Tucumán Province",
"country": "Argentina"
},
{
"facility": "Instituto Médico Especializado (IME)",
"city": "Buenos Aires",
"state": null,
"country": "Argentina"
},
{
"facility": "Centro Diabetológico Dr. Waitman",
"city": "Córdoba",
"state": null,
"country": "Argentina"
},
{
"facility": "Tosaki Clinic for Diabetes and Endocrinology",
"city": "Nagoya",
"state": "Aichi-ken",
"country": "Japan"
},
{
"facility": "Manda Memorial Hospital",
"city": "Sapporo",
"state": "Hokkaido",
"country": "Japan"
},
{
"facility": "MinamiAkatsukaClinic",
"city": "Mito",
"state": "Ibaraki",
"country": "Japan"
},
{
"facility": "Nakakinen clinic",
"city": "Naka",
"state": "Ibaraki",
"country": "Japan"
},
{
"facility": "Noritake Clinic",
"city": "Ushiku",
"state": "Ibaraki",
"country": "Japan"
},
{
"facility": "Takai Internal Medicine Clinic",
"city": "Kamakura-shi",
"state": "Kanagawa",
"country": "Japan"
},
{
"facility": "Takatsuki Red Cross Hospital",
"city": "Takatsuki",
"state": "Osaka",
"country": "Japan"
},
{
"facility": "Shimizu Clinic Fusa",
"city": "Saitama-shi",
"state": "Saitama",
"country": "Japan"
},
{
"facility": "The Institute for Adult Disease, Asahi Life Foundation",
"city": "Chuo-ku",
"state": "Tokyo",
"country": "Japan"
},
{
"facility": "Hachioji Diabetes Clinic",
"city": "Hachioji-shi",
"state": "Tokyo",
"country": "Japan"
},
{
"facility": "Clinic Masae Minami",
"city": "Fukuoka",
"state": null,
"country": "Japan"
},
{
"facility": "Jinnouchi Hospital",
"city": "Kumamoto",
"state": null,
"country": "Japan"
},
{
"facility": "Heiwadai Hospital",
"city": "Miyazaki",
"state": null,
"country": "Japan"
},
{
"facility": "Abe Clinic",
"city": "Ōita",
"state": null,
"country": "Japan"
},
{
"facility": "Medyczne Centrum Diabetologiczno Endokrynologiczno Metaboliczne DIAB-ENDO-MET",
"city": "Krakow",
"state": "Lesser Poland Voivodeship",
"country": "Poland"
},
{
"facility": "Gabinety TERPA",
"city": "Lublin",
"state": "Lublin Voivodeship",
"country": "Poland"
},
{
"facility": "NZOZ Medica",
"city": "Lublin",
"state": "Lublin Voivodeship",
"country": "Poland"
},
{
"facility": "Centrum Medyczne \"Diabetika\"",
"city": "Radom",
"state": "Masovian Voivodeship",
"country": "Poland"
},
{
"facility": "Centralny Szpital Kliniczny MSWiA w Warszawie",
"city": "Warsaw",
"state": "Masovian Voivodeship",
"country": "Poland"
},
{
"facility": "NBR Polska",
"city": "Warsaw",
"state": "Mazowiecki",
"country": "Poland"
},
{
"facility": "SN ZOZ Lege Artis Poradnia Diabetologiczna",
"city": "Bialystok",
"state": "Podlaskie Voivodeship",
"country": "Poland"
},
{
"facility": "NZOZ Specjalistyczny Ośrodek Internistyczno-Diabetologiczny",
"city": "Bialystok",
"state": "Podlaskie Voivodeship",
"country": "Poland"
},
{
"facility": "Centrum Badan Klinicznych PI-House sp. z o.o.",
"city": "Gdansk",
"state": "Pomeranian Voivodeship",
"country": "Poland"
},
{
"facility": "Private Practice - Dr. Janusz Gumprecht",
"city": "Zabrze",
"state": "Silesian Voivodeship",
"country": "Poland"
},
{
"facility": "Advanced Clinical Research, LLC",
"city": "Bayamón",
"state": null,
"country": "Puerto Rico"
},
{
"facility": "Endocrinologist Metabolic Clinic & Research Institute",
"city": "San Juan",
"state": null,
"country": "Puerto Rico"
},
{
"facility": "Tatratrial s.r.o.",
"city": "Rožňava",
"state": "Košice Region",
"country": "Slovakia"
},
{
"facility": "Funkystuff",
"city": "Nové Zámky",
"state": "Nitra Region",
"country": "Slovakia"
},
{
"facility": "ENDIAMED s.r.o",
"city": "Dolný Kubín",
"state": "Žilina Region",
"country": "Slovakia"
},
{
"facility": "Chung Shan Medical University Hospital",
"city": "Taichung",
"state": "Taichung",
"country": "Taiwan"
},
{
"facility": "Taichung Veterans General Hospital",
"city": "Taichung",
"state": "Taichung",
"country": "Taiwan"
},
{
"facility": "Chi Mei Medical Center",
"city": "Tainan",
"state": "Tainan",
"country": "Taiwan"
},
{
"facility": "Taipei Veterans General Hospital",
"city": "Taipei City",
"state": "Taipei",
"country": "Taiwan"
},
{
"facility": "Changhua Christian Hospital",
"city": "Changhua",
"state": null,
"country": "Taiwan"
},
{
"facility": "National Cheng Kung University Hospital",
"city": "Tainan",
"state": null,
"country": "Taiwan"
}
],
"hasResults": true,
"url": "https://clinicaltrials.gov/study/NCT05463744",
"scrapedAt": "2026-05-14T17:51:04.834Z"
},
{
"nctId": "NCT03331432",
"briefTitle": "Effects of Dietary Supplement Tauroursodeoxycholic Acid on Vascular Function",
"officialTitle": "Targeting Endoplasmic Reticulum Stress to Correct Vascular Insulin Resistance and Glycemic Dysregulation",
"acronym": null,
"organization": "University of Missouri-Columbia",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 8,
"leadSponsor": "University of Missouri-Columbia",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Type 2 Diabetes Mellitus"
],
"interventions": [
"DIETARY_SUPPLEMENT: Tauroursodeoxycholic acid",
"DIETARY_SUPPLEMENT: Placebo"
],
"briefSummary": "The purpose of the present study is to determine if use of dietary supplement tauroursodeoxycholic acid enhances insulin-stimulated leg blood flow and glucose disposal.",
"sex": "ALL",
"minimumAge": "20 Years",
"maximumAge": "65 Years",
"healthyVolunteers": false,
"startDate": "2015-10-28",
"completionDate": "2018-02-14",
"primaryCompletionDate": "2017-08-15",
"firstPostedDate": "2017-11-06",
"lastUpdatePostedDate": "2018-02-19",
"locations": [
{
"facility": "University of Missouri",
"city": "Columbia",
"state": "Missouri",
"country": "United States"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT03331432",
"scrapedAt": "2026-05-14T17:51:04.875Z"
},
{
"nctId": "NCT05785832",
"briefTitle": "A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes",
"officialTitle": "A Randomized Trial Evaluating the Efficacy and Safety of Control-IQ+ Technology in Adults With Type 2 Diabetes Using Basal-Bolus Insulin Therapy (2IQP)",
"acronym": "2IQP",
"organization": "Tandem Diabetes Care, Inc.",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 319,
"leadSponsor": "Tandem Diabetes Care, Inc.",
"sponsorClass": "INDUSTRY",
"collaborators": [
"Jaeb Center for Health Research"
],
"conditions": [
"Type 2 Diabetes Treated With Insulin"
],
"interventions": [
"DEVICE: t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM",
"DEVICE: Standard Therapy plus continuous glucose monitoring (CGM)"
],
"briefSummary": "A randomized controlled trial (RCT) to assess the safety and efficacy of use of Control-IQ+ technology in adults with type 2 diabetes using basal-bolus insulin therapy.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2023-06-01",
"completionDate": "2024-09-24",
"primaryCompletionDate": "2024-09-24",
"firstPostedDate": "2023-03-27",
"lastUpdatePostedDate": "2026-02-19",
"locations": [
{
"facility": "Hoag Memorial Hospital Presbyterian",
"city": "Newport Beach",
"state": "California",
"country": "United States"
},
{
"facility": "Emory University School of Medicine",
"city": "Atlanta",
"state": "Georgia",
"country": "United States"
},
{
"facility": "Rocky Mountain Clinical Research",
"city": "Idaho Falls",
"state": "Idaho",
"country": "United States"
},
{
"facility": "Northwestern University",
"city": "Chicago",
"state": "Illinois",
"country": "United States"
},
{
"facility": "Baltimore VA Medical Center",
"city": "Baltimore",
"state": "Maryland",
"country": "United States"
},
{
"facility": "Boston Medical Center Corporation",
"city": "Boston",
"state": "Massachusetts",
"country": "United States"
},
{
"facility": "Henry Ford Health System",
"city": "Detroit",
"state": "Michigan",
"country": "United States"
},
{
"facility": "Mayo Clinic",
"city": "Rochester",
"state": "Minnesota",
"country": "United States"
},
{
"facility": "Icahn School of Medicine at Mt. Sinai",
"city": "New York",
"state": "New York",
"country": "United States"
},
{
"facility": "SUNY Upstate Medical University",
"city": "Syracuse",
"state": "New York",
"country": "United States"
},
{
"facility": "UHH Cleveland Medical Center",
"city": "Cleveland",
"state": "Ohio",
"country": "United States"
},
{
"facility": "Oregon Health & Science University",
"city": "Portland",
"state": "Oregon",
"country": "United States"
},
{
"facility": "University of Pennsylvania",
"city": "Philadelphia",
"state": "Pennsylvania",
"country": "United States"
},
{
"facility": "Texas Diabetes and Endocrinology, P.A.",
"city": "Austin",
"state": "Texas",
"country": "United States"
},
{
"facility": "University of Texas Southwestern",
"city": "Dallas",
"state": "Texas",
"country": "United States"
},
{
"facility": "Diabetes & Endocrine Treatment Specialists",
"city": "Sandy City",
"state": "Utah",
"country": "United States"
},
{
"facility": "University of Virginia",
"city": "Charlottesville",
"state": "Virginia",
"country": "United States"
},
{
"facility": "Rainier Clinical Research Center",
"city": "Renton",
"state": "Washington",
"country": "United States"
},
{
"facility": "University of Washington",
"city": "Seattle",
"state": "Washington",
"country": "United States"
},
{
"facility": "Lawson Health Research Institute",
"city": "London",
"state": "Ontario",
"country": "Canada"
},
{
"facility": "McGill University",
"city": "Montreal",
"state": "Quebec",
"country": "Canada"
}
],
"hasResults": true,
"url": "https://clinicaltrials.gov/study/NCT05785832",
"scrapedAt": "2026-05-14T17:51:04.914Z"
},
{
"nctId": "NCT03314714",
"briefTitle": "Duality of Lipids: the Athlete's Paradox",
"officialTitle": "The Dual Role of Intramyocellular Lipids in Mediating Insulin Resistance: Assessing the Mechanisms of the Athlete's Paradox",
"acronym": "LIDDIA",
"organization": "German Diabetes Center",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 100,
"leadSponsor": "German Diabetes Center",
"sponsorClass": "OTHER",
"collaborators": [
"Maastricht University"
],
"conditions": [
"Insulin Resistance, Diabetes",
"Lipid Metabolism Disorders"
],
"interventions": [
"PROCEDURE: Acute bout of endurance exercise"
],
"briefSummary": "Accumulation of intramyocellular lipids (IMCLs) due to increased supply of fatty acids can induce defects in the insulin signaling cascade, causing skeletal muscle insulin resistance. However, the causes for muscle insulin resistance are not well understood. The association of elevated IMCLs and insulin resistance has been shown in obese humans and individuals with type 2 diabetes as well as several animal models of insulin resistance. Despite the strong relationship between IMCLs and insulin resistance, this suggested relationship disappears when well-trained endurance athletes are included into this consideration as this group is highly insulin sensitive. This metabolic enigma has been termed the 'athlete's paradox'. The aim of this project is to resolve the mechanisms contributing to the athlete's paradox.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": "69 Years",
"healthyVolunteers": true,
"startDate": "2017-04-03",
"completionDate": "2023-06-01",
"primaryCompletionDate": "2023-06-01",
"firstPostedDate": "2017-10-19",
"lastUpdatePostedDate": "2023-06-13",
"locations": [
{
"facility": "German Diabetes Center",
"city": "Düsseldorf",
"state": "North Rhine-Westphalia",
"country": "Germany"
},
{
"facility": "Maastricht University",
"city": "Maastricht",
"state": null,
"country": "Netherlands"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT03314714",
"scrapedAt": "2026-05-14T17:51:04.940Z"
},
{
"nctId": "NCT06760416",
"briefTitle": "Online Diabetic Foot Support Program- Care Kit",
"officialTitle": "Effect of Online Diabetic Foot Support Program (DiaFootSuP) and Care Kit on Diabetic Foot Care Outcomes: Randomized Controlled Trial",
"acronym": "DiaFootSuP",
"organization": "Dokuz Eylul University",
"overallStatus": "ACTIVE_NOT_RECRUITING",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 62,
"leadSponsor": "Merve GÃnbaAY",
"sponsorClass": "OTHER",
"collaborators": [
"The Scientific and Technological Research Council of Turkey"
],
"conditions": [
"Diabetes Mellitus",
"Diabetic Foot Ulcer",
"Diabetic Foot"
],
"interventions": [
"OTHER: Nursing Education"
],
"briefSummary": "The aim of this project is to examine the effects of the online diabetic foot support program (DiaFootSuP) and care kit applied to type 2 diabetic individuals who have previously had a diabetic foot ulcer on diabetic foot outcomes (diabetic foot knowledge level, foot care behavior level, foot care self-efficacy level, HbA1c, etc.).",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2024-11-01",
"completionDate": "2025-03-31",
"primaryCompletionDate": "2024-12-27",
"firstPostedDate": "2025-01-06",
"lastUpdatePostedDate": "2025-01-06",
"locations": [
{
"facility": "Dokuz Eylül University",
"city": "Izmir",
"state": "Buca",
"country": "Turkey (Türkiye)"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT06760416",
"scrapedAt": "2026-05-14T17:51:04.983Z"
},
{
"nctId": "NCT04024306",
"briefTitle": "Steroid-induced Diabetes Mellitus in Systemic Lupus Erythematosus (SLE) Patients",
"officialTitle": "Steroid-induced Diabetes Mellitus in Systemic Lupus Erythematosus (SLE) Patients",
"acronym": null,
"organization": "Assiut University",
"overallStatus": "UNKNOWN",
"studyType": "OBSERVATIONAL",
"phases": [],
"enrollmentCount": 120,
"leadSponsor": "Assiut University",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"System; Lupus Erythematosus"
],
"interventions": [],
"briefSummary": "The aim of the study is to determine the prevalence of steroid-induced diabetes mellitus (SDM) among systemic lupus erythematosus (SLE) patients and identify and assess the associated risk factors .",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": "75 Years",
"healthyVolunteers": false,
"startDate": "2022-09-01",
"completionDate": "2024-04-20",
"primaryCompletionDate": "2024-04-01",
"firstPostedDate": "2019-07-18",
"lastUpdatePostedDate": "2023-07-19",
"locations": [
{
"facility": "Assiut university hospital",
"city": "Asyut",
"state": null,
"country": "Egypt"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT04024306",
"scrapedAt": "2026-05-14T17:51:04.999Z"
},
{
"nctId": "NCT00607906",
"briefTitle": "First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050",
"officialTitle": "A Single-blinded, Randomized, Placebo-controlled, Staggered-parallel, Escalating Single Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered SB756050 in Healthy Volunteers and in Subjects With Type 2 Diabetes Mellitus",
"acronym": null,
"organization": "GlaxoSmithKline",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE1"
],
"enrollmentCount": 36,
"leadSponsor": "GlaxoSmithKline",
"sponsorClass": "INDUSTRY",
"collaborators": [],
"conditions": [
"Diabetes Mellitus, Type 2"
],
"interventions": [
"DRUG: SB-756050 immediate release capsule",
"DRUG: SB-756050 modified release capsule",
"DRUG: Placebo"
],
"briefSummary": "This study will use single escalating doses of SB756050 to assess safety, pharmacokinetics, and pharmacodynamics in healthy volunteers and in subjects with Type 2 Diabetes Mellitus.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": "60 Years",
"healthyVolunteers": true,
"startDate": "2007-11-16",
"completionDate": "2008-03-10",
"primaryCompletionDate": "2008-03-10",
"firstPostedDate": "2008-02-06",
"lastUpdatePostedDate": "2017-09-06",
"locations": [
{
"facility": "GSK Investigational Site",
"city": "Minneapolis",
"state": "Minnesota",
"country": "United States"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT00607906",
"scrapedAt": "2026-05-14T17:51:05.053Z"
},
{
"nctId": "NCT05251506",
"briefTitle": "The Evaluation of Laser Lancing Devices in Adult Type 2 Diabetes Patients",
"officialTitle": "The Evaluation of Laser Lancing Devices in Constructing Self-management Systems for Chronic Diseases in Adult Diabetes Patients",
"acronym": null,
"organization": "Korea University Guro Hospital",
"overallStatus": "UNKNOWN",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 80,
"leadSponsor": "Korea University Guro Hospital",
"sponsorClass": "OTHER",
"collaborators": [
"Korea Medical Device Development Fund"
],
"conditions": [
"Type 2 Diabetes"
],
"interventions": [
"DEVICE: laser lancing device or lancet for blood glucose level measurement"
],
"briefSummary": "Self monitoring of blood glucose level is crucial in diabetes management, but currently available methods, lancet, have shown low compliance of self monitoring of blood glucose because of pain, keratinization of finger tip, secondary infection. The purpose of this study is evaluating laser lancing device which cause much less pain than lancet to increase compliance of blood sugar checking, and to establish self monitoring system for patients of chronic diseases.\n\nThe investigators recruit total of 80 type 2 diabetes patients who visit Korea University Medical center Guro and Ansan hospital. HbA1c level of subject is more than 6.5% and less than 8.5%, and their age is above 20 years and under 80 years. Subjects are randomly distributed in group A or B. Group A subjects use laser device to check blood glucose for 2 months, then take a month for wash out period. After wash out period, participants use lancet for following 2 months. Group B perform the process vice versa. The investigators evaluate the number of blood glucose measurement, HbA1c, diabetes distress scale, average pain score, average satisfaction score from each group.",
"sex": "ALL",
"minimumAge": "20 Years",
"maximumAge": "79 Years",
"healthyVolunteers": false,
"startDate": "2021-08-10",
"completionDate": "2022-12-31",
"primaryCompletionDate": "2022-03-31",
"firstPostedDate": "2022-02-22",
"lastUpdatePostedDate": "2022-02-22",
"locations": [
{
"facility": "Korea University medical center",
"city": "Seoul",
"state": null,
"country": "South Korea"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT05251506",
"scrapedAt": "2026-05-14T17:51:05.121Z"
},
{
"nctId": "NCT02898506",
"briefTitle": "Incretin-based Therapy in Late Preclinical Type 1 Diabetes",
"officialTitle": "Incretin-based Therapy in Late Preclinical Type 1 Diabetes",
"acronym": null,
"organization": "University of Oulu",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE2"
],
"enrollmentCount": 13,
"leadSponsor": "University of Oulu",
"sponsorClass": "OTHER",
"collaborators": [
"Oulu University Hospital",
"Tampere University Hospital",
"Turku University Hospital",
"Skane University Hospital"
],
"conditions": [
"Type 1 Diabetes"
],
"interventions": [
"DRUG: Victoza®",
"DRUG: Placebo"
],
"briefSummary": "The objective of the trial is to study whether daily treatment with liraglutide improves endogenous insulin secretion, postpones progression to overt Type 1 diabetes, and is tolerable and safe in subjects aged 10-30 years, who are positive for multiple islet autoantibodies and have dysglycemia.",
"sex": "ALL",
"minimumAge": "10 Years",
"maximumAge": "30 Years",
"healthyVolunteers": false,
"startDate": "2016-03",
"completionDate": "2021-06",
"primaryCompletionDate": "2021-06",
"firstPostedDate": "2016-09-13",
"lastUpdatePostedDate": "2022-01-25",
"locations": [
{
"facility": "University of Oulu and Oulu University Hospital, Dept of Children and Adolescents",
"city": "Oulu",
"state": null,
"country": "Finland"
},
{
"facility": "University of Tampere and Tampere University Hospital",
"city": "Tampere",
"state": null,
"country": "Finland"
},
{
"facility": "University of Turku and Turku University Hospital",
"city": "Turku",
"state": null,
"country": "Finland"
},
{
"facility": "Lund University and Skåne University Hospital",
"city": "Malmö",
"state": null,
"country": "Sweden"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT02898506",
"scrapedAt": "2026-05-14T17:51:05.147Z"
},
{
"nctId": "NCT04361552",
"briefTitle": "Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)",
"officialTitle": "Tociluzumab for Cytokine Release Syndrome With SARS-CoV-2: An Open-Labeled, Randomized Phase 3 Trial",
"acronym": null,
"organization": "Emory University",
"overallStatus": "WITHDRAWN",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE3"
],
"enrollmentCount": 0,
"leadSponsor": "Emory University",
"sponsorClass": "OTHER",
"collaborators": [
"National Cancer Institute (NCI)"
],
"conditions": [
"Cerebrovascular Accident",
"Chronic Obstructive Pulmonary Disease",
"Chronic Renal Failure",
"Coronary Artery Disease",
"Diabetes Mellitus",
"Malignant Neoplasm",
"SARS Coronavirus 2 Infection"
],
"interventions": [
"OTHER: Best Practice",
"BIOLOGICAL: Tocilizumab"
],
"briefSummary": "This phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substance that is made by cells of the immune system (cytokines) as a response to viral infection. Tocilizumab is used to decrease the body's immune response. Adding tocilizumab to standard of care may work better in treating CRS in patients with SARS-CoV-2 infection compared to standard of care alone.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2020-04-07",
"completionDate": "2020-06-02",
"primaryCompletionDate": "2020-06-02",
"firstPostedDate": "2020-04-24",
"lastUpdatePostedDate": "2020-06-18",
"locations": [
{
"facility": "Emory University Hospital/Winship Cancer Institute",
"city": "Atlanta",
"state": "Georgia",
"country": "United States"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT04361552",
"scrapedAt": "2026-05-14T17:51:05.194Z"
},
{
"nctId": "NCT05184049",
"briefTitle": "Effects of Epalrestat on Peripheral Neuropathy and Central Nervous System in Diabetic Patients",
"officialTitle": "Effects of Epalrestat on Peripheral Neuropathy and Central Nervous System in Diabetic Patient",
"acronym": null,
"organization": "Xiangya Hospital of Central South University",
"overallStatus": "UNKNOWN",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE4"
],
"enrollmentCount": 72,
"leadSponsor": "Xiangya Hospital of Central South University",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Diabetes"
],
"interventions": [
"DRUG: Epalrestat,Mecobalamin",
"DRUG: Mecobalamin"
],
"briefSummary": "This study evaluated the efficacy of epalrestat in diabetic peripheral neuropathy and its effects on the central nervous system in diabetic peripheral neuropathy subjects.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": "65 Years",
"healthyVolunteers": false,
"startDate": "2022-01",
"completionDate": "2023-10",
"primaryCompletionDate": "2023-10",
"firstPostedDate": "2022-01-11",
"lastUpdatePostedDate": "2022-01-11",
"locations": [
{
"facility": "Xiangya Hospital of Central South University",
"city": "Changsha",
"state": "Hunan",
"country": "China"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT05184049",
"scrapedAt": "2026-05-14T17:51:05.210Z"
},
{
"nctId": "NCT00806338",
"briefTitle": "An Ascending Multi-Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers",
"officialTitle": "A Phase I, Double-Blind, Randomized, Placebo-Controlled Ascending IV Multiple Dose Tolerance and Pharmacokinetic Study of Trodusquemine (MSI-1436) in Obese or Overweight Type 2 Diabetic Volunteers",
"acronym": null,
"organization": "Genaera Corporation",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE1"
],
"enrollmentCount": 22,
"leadSponsor": "Genaera Corporation",
"sponsorClass": "INDUSTRY",
"collaborators": [],
"conditions": [
"Diabetes Mellitus",
"Obesity"
],
"interventions": [
"DRUG: Trodusquemine (MSI-1436)",
"DRUG: Placebo"
],
"briefSummary": "The purpose of this study is to evaluate the safety and tolerance of multiple intravenous (through a vein) doses of trodusquemine (MSI-1436) in obese or overweight, type 2 diabetics.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": "65 Years",
"healthyVolunteers": false,
"startDate": "2008-11",
"completionDate": "2009-04",
"primaryCompletionDate": "2009-04",
"firstPostedDate": "2008-12-10",
"lastUpdatePostedDate": "2009-04-15",
"locations": [
{
"facility": "Cetero Research",
"city": "Miami Gardens",
"state": "Florida",
"country": "United States"
},
{
"facility": "dgd Research",
"city": "San Antonio",
"state": "Texas",
"country": "United States"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT00806338",
"scrapedAt": "2026-05-14T17:51:05.234Z"
},
{
"nctId": "NCT07258758",
"briefTitle": "Diabetes Intervention Involving Person-centred Nutritional Education",
"officialTitle": "Diabetes Intervention Involving Person-centred Nutritional Education (DINE) - Exploring the Benefits and Challenges of a Person-centred Education on the Nordic Diet for Adults With Type 1 Diabetes.",
"acronym": "DINE",
"organization": "Umeå University",
"overallStatus": "RECRUITING",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 54,
"leadSponsor": "Umeå University",
"sponsorClass": "OTHER",
"collaborators": [
"Lasarettet i Enköping"
],
"conditions": [
"Diabetes Type 1"
],
"interventions": [
"BEHAVIORAL: Dietary intervention"
],
"briefSummary": "The overall objective for this project is to evaluate the effects of a person-centred education intervention to promote a healthy, sustainable Nordic diet compared with the current practice of providing short dietary information on health outcomes of adults with Type 1 diabetes. The study will measure the intervention's impact on blood glucose levels, blood lipids, blood pressure, and adherence to a sustainable and healthy Nordic diet.\n\nThe main question the trial aims to answer is:\n\nDoes a person-centred nutritional education have an impact on glucose time in range for adults with Type 1 diabetes, compared with short dietary information?\n\nThe participants will:\n\n* Attend either a person-centred nutrition education (intervention) or receive short dietary information (control group).\n* Wear their sensor for continuous glucose monitoring (CGM) throughout the trial.\n* Visit the clinic for data collection (blood samples and clinical checks) at the start and end of the trial.\n* Keep a four-day food diary, fill out a food frequency questionnaire (FFQ) and estimate their food enjoyment at the start and end of the trial.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2025-09-01",
"completionDate": "2027-06",
"primaryCompletionDate": "2027-06",
"firstPostedDate": "2025-12-02",
"lastUpdatePostedDate": "2025-12-12",
"locations": [
{
"facility": "Hospital of Enköping",
"city": "Enköping",
"state": "Uppland",
"country": "Sweden"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT07258758",
"scrapedAt": "2026-05-14T17:51:05.277Z"
},
{
"nctId": "NCT03574558",
"briefTitle": "Personalized Automated Determination of Insulin Pump Setting for Subjects With Type 1 Diabetes Switching From MDI to Pump Therapy and Vice Versa- Safety and Efficacy Feasibility Study",
"officialTitle": "Personalized Automated Determination of Insulin Pump Setting for Subjects With Type 1 Diabetes Switching From MDI to Pump Therapy and Vice Versa- Safety and Efficacy Feasibility Study",
"acronym": null,
"organization": "Rabin Medical Center",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 28,
"leadSponsor": "Rabin Medical Center",
"sponsorClass": "OTHER",
"collaborators": [
"Juvenile Diabetes Research Foundation",
"Jaeb Center for Health Research",
"DreaMed",
"University of Padova"
],
"conditions": [
"Type1diabetes"
],
"interventions": [
"DEVICE: MD-Logic Switch Advisor"
],
"briefSummary": "The \"MD-Logic Switch Advisor\" is a software product that is designed to assist in insulin dosage decision making and has two components:\n\nA. MD-Logic Switch Advisor for initiation of pump therapy - this product is designed to assist physicians in decision making when initiating insulin pump therapy.\n\nB. MD-Logic Switch Advisor for patients who use insulin pump therapy and need to switch to MDI (Multiple Daily Injections).\n\nThis feasibility study will be divided to two parts:\n\npart A - will include up to 20 patients to evaluate in a feasibility study the switch Advisor from MDI to pump therapy part B - will include up to 20 patients to evaluate in a feasibility study the switch Advisor from pump therapy to MDI The main objective is to evaluate the safety and efficacy of using the MD-Logic Switch Advisor to determine insulin dosing for subjects with type 1 diabetes using pump therapy who wish to switch to from pump to MDI therapy and vice versa.",
"sex": "ALL",
"minimumAge": "6 Years",
"maximumAge": "30 Years",
"healthyVolunteers": false,
"startDate": "2018-08-01",
"completionDate": "2019-11-25",
"primaryCompletionDate": "2019-11-25",
"firstPostedDate": "2018-07-02",
"lastUpdatePostedDate": "2019-12-27",
"locations": [
{
"facility": "Schnider children's medical center",
"city": "Petah Tikva",
"state": null,
"country": "Israel"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT03574558",
"scrapedAt": "2026-05-14T17:51:05.316Z"
},
{
"nctId": "NCT00516958",
"briefTitle": "Pilot Study of the Safety and Clinical Efficacy of Topical Dermacyn™ Wound Care to Treat Mild Diabetic Foot Infections",
"officialTitle": "An Open Label, Three Arm, Pilot Study of the Safety and Clinical Efficacy of Topical Dermacyn™ Wound Care vs. Oral Levofloxacin vs. Combined Therapy for Mild Diabetic Foot Infections",
"acronym": null,
"organization": "Oculus Innovative Sciences, Inc.",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE2"
],
"enrollmentCount": 65,
"leadSponsor": "Oculus Innovative Sciences, Inc.",
"sponsorClass": "INDUSTRY",
"collaborators": [],
"conditions": [
"Foot Ulcer, Diabetic"
],
"interventions": [
"DRUG: Topical Dermacyn",
"DRUG: Topical Dermacyn and Levofloxacin",
"DRUG: Topical Saline and Levofloxacin"
],
"briefSummary": "To compare the rates of clinical success of Topical Dermacyn™ vs. Oral Levofloxacin vs. Combined therapy, in subjects with mild diabetic foot infections in non-ischemic ulcers.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2007-05",
"completionDate": "2007-12",
"primaryCompletionDate": "2007-12",
"firstPostedDate": "2007-08-16",
"lastUpdatePostedDate": "2008-01-14",
"locations": [
{
"facility": null,
"city": "Tucson",
"state": "Arizona",
"country": "United States"
},
{
"facility": null,
"city": "La Jolla",
"state": "California",
"country": "United States"
},
{
"facility": null,
"city": "Los Angeles",
"state": "California",
"country": "United States"
},
{
"facility": null,
"city": "San Diego",
"state": "California",
"country": "United States"
},
{
"facility": null,
"city": "Santa Rosa",
"state": "California",
"country": "United States"
},
{
"facility": null,
"city": "Denver",
"state": "Colorado",
"country": "United States"
},
{
"facility": null,
"city": "New Haven",
"state": "Connecticut",
"country": "United States"
},
{
"facility": null,
"city": "Boca Raton",
"state": "Florida",
"country": "United States"
},
{
"facility": null,
"city": "Spring Hill",
"state": "Florida",
"country": "United States"
},
{
"facility": null,
"city": "Evansville",
"state": "Indiana",
"country": "United States"
},
{
"facility": null,
"city": "Louisville",
"state": "Kentucky",
"country": "United States"
},
{
"facility": null,
"city": "Boston",
"state": "Massachusetts",
"country": "United States"
},
{
"facility": null,
"city": "Harrisburgh",
"state": "Pennsylvania",
"country": "United States"
},
{
"facility": null,
"city": "Hazleton",
"state": "Pennsylvania",
"country": "United States"
},
{
"facility": null,
"city": "Pittsburgh",
"state": "Pennsylvania",
"country": "United States"
},
{
"facility": null,
"city": "Salt Lake City",
"state": "Utah",
"country": "United States"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT00516958",
"scrapedAt": "2026-05-14T17:51:05.347Z"
},
{
"nctId": "NCT03510078",
"briefTitle": "Intensive Versus Conventional Hyperglycemic Control in Hospitalized Non-critically Ill Patients",
"officialTitle": "Intensive Versus Conventional Hyperglycemic Control in Hospitalized Non-critically Ill Patients",
"acronym": null,
"organization": "Rabin Medical Center",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 600,
"leadSponsor": "Rabin Medical Center",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Diabetes Mellitus",
"Non-critically Ill Patients"
],
"interventions": [
"DRUG: Insulin"
],
"briefSummary": "Hyperglycemia is a common condition among hospitalized patients. The occurrence of severe hyperglycemia is associated with increased morbidity and mortality in several populations. Several trials assessed the benefits of aggressive versus conventional glucose control. These studies evaluated different patient populations, glucose targets and treatment protocols and as a result reported conflicting results. To date there are no clear guidelines regarding to the preferred glucose target range in hospitalized non-critically ill patients. The common practice is to maintain glucose level lower than 180 mg/dl however there are no evidence based regarding to the outcomes of hospitalized patients treated with intensive compared to conventional glycemic control. This prospective randomized controlled study will compare intensive vs. standard glycemic control in hospitalized non-critically ill patients.\n\nWithin 24 hours of hospitalization in the internal medical or geriatric departments, patients who are expected to require hospitalization for at least three consecutive days will be randomly assigned into one of the two study groups - intensive with a target blood glucose range of 130 mg per deciliter or less, or conventional glucose control, with a target of 130-180 mg per deciliter. The investigators defined the primary end point as a composite outcome of mortality in 30 days, severe hypoglycemia, severe infections within 30 days, CVA and cardiac ischemic events within 30 days.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": "120 Years",
"healthyVolunteers": false,
"startDate": "2018-04-17",
"completionDate": "2025-12-10",
"primaryCompletionDate": "2025-07-01",
"firstPostedDate": "2018-04-27",
"lastUpdatePostedDate": "2026-04-30",
"locations": [
{
"facility": "Rabin Medical Center",
"city": "Petah Tikva",
"state": "Israel",
"country": "Israel"
},
{
"facility": "Soroka University Medical Center",
"city": "Beersheba",
"state": null,
"country": "Israel"
},
{
"facility": "Rambam Medical Center",
"city": "Haifa",
"state": null,
"country": "Israel"
},
{
"facility": "Shamir Medical Center",
"city": "Ẕerifin",
"state": null,
"country": "Israel"
},
{
"facility": "Unit of Geriatric Medicine University of Modena and Reggio Emilia, University Hospital of Baggiovara",
"city": "Modena",
"state": null,
"country": "Italy"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT03510078",
"scrapedAt": "2026-05-14T17:51:05.400Z"
},
{
"nctId": "NCT01293578",
"briefTitle": "Study to Test Use of a Decision Aid in a Clinical Visit to Help Patients Choose a Diabetes Medication",
"officialTitle": "Translating Information on Comparative Effectiveness Into Practice (TRICEP)",
"acronym": "TRICEP",
"organization": "Mayo Clinic",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 550,
"leadSponsor": "Mayo Clinic",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Type 2 Diabetes Mellitus"
],
"interventions": [
"OTHER: Diabetes Medication Choice Cards"
],
"briefSummary": "The goal of this study is to test the relative merits of a decision aid for diabetes medications that we have developed - Diabetes Medication Choice Cards- versus usual care in translating comparative effectiveness research (CER) into real world clinics. This study will involve about 20 primary care practice sites affiliated with Mayo Health System, Park Nicollet, or Hennepin County Medical Center. There will be no recruiting done at the Mayo Clinic.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": true,
"startDate": "2011-01",
"completionDate": "2015-06",
"primaryCompletionDate": "2015-06",
"firstPostedDate": "2011-02-10",
"lastUpdatePostedDate": "2022-09-28",
"locations": [
{
"facility": "Albert Lea Medical Center",
"city": "Albert Lea",
"state": "Minnesota",
"country": "United States"
},
{
"facility": "Mayo Clinic Kasson",
"city": "Kasson",
"state": "Minnesota",
"country": "United States"
},
{
"facility": "Mayo Clinic Health System- Immanual St. Joseph's",
"city": "Mankato",
"state": "Minnesota",
"country": "United States"
},
{
"facility": "Hennepin County Medical Center",
"city": "Minneapolis",
"state": "Minnesota",
"country": "United States"
},
{
"facility": "Park Nicollet Institute",
"city": "Saint Louis Park",
"state": "Minnesota",
"country": "United States"
},
{
"facility": "Mayo Clinic Health System-Franciscan Healthcare",
"city": "La Crosse",
"state": "Wisconsin",
"country": "United States"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT01293578",
"scrapedAt": "2026-05-14T17:51:05.417Z"
},
{
"nctId": "NCT05659043",
"briefTitle": "Glycation of apoA-I and Diabetic Atherogenesis",
"officialTitle": "The Impact of Glycation Modification of apoA-I on HDL Function and Atherogenesis in Type Diabetes Mellitus",
"acronym": null,
"organization": "Ruijin Hospital",
"overallStatus": "UNKNOWN",
"studyType": "OBSERVATIONAL",
"phases": [],
"enrollmentCount": 2000,
"leadSponsor": "Ruijin Hospital",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Diabetes Mellitus, Type 2"
],
"interventions": [
"OTHER: overnight fasting"
],
"briefSummary": "The goal of this study is to determine the relationship of apoprotein A-1 (apoA-I) glycation and development of diabetic atherosclerosis.\n\nApoA-I is crucial for reverse cholesterol transport and anti-inflammation/anti-atherosclersis functions of HDL. However, apoA-I is easily subjected to non-enzymatic glycation modification in diabetic milleu. Our preliminary study has shown that apoA-I in HDL from type 2 diabetes mellitus (T2DM) patients with coronary artery disease (CAD) is significantly glycated, and site specific glycation of apoA-I impairs HDL function and is related to the development of atherosclerosis. To the best of our knowledge, less clinical information regarding apoA-I glycation and CAD has been reported. In this cross-sectional study, by consecutively enrolling diabetic patients with (two to three hundred) or without CAD (controls, six to eight hundred) in our hospital, we will isolate their serum HDL and perform a qualitative and quantitative proteomic analysis of apoA-I glycation. The relation of apoA-I glycation and HDL function and angiography-determined severity of CAD will be evaluated. Later, we will follow these diabetic patients to analyze the influence of apoA-I glycation on the outcome including plaque progression.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": "90 Years",
"healthyVolunteers": false,
"startDate": "2017-01",
"completionDate": "2023-12",
"primaryCompletionDate": "2021-12",
"firstPostedDate": "2022-12-21",
"lastUpdatePostedDate": "2022-12-21",
"locations": [
{
"facility": "Ruijin Hospital, Shanghai Jiaotong University School of Medicine",
"city": "Shanghai",
"state": "Shanghai Municipality",
"country": "China"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT05659043",
"scrapedAt": "2026-05-14T17:51:05.501Z"
},
{
"nctId": "NCT05767255",
"briefTitle": "Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue",
"officialTitle": "Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue",
"acronym": null,
"organization": "Hospital Universitario San Ignacio",
"overallStatus": "UNKNOWN",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE3"
],
"enrollmentCount": 66,
"leadSponsor": "Hospital Universitario San Ignacio",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Diabetes Mellitus, Type 2 Treated With Insulin"
],
"interventions": [
"DRUG: insulin degludec + liraglutide",
"DRUG: Insulin Glargine - Insulin Aspart"
],
"briefSummary": "The association of insulin degludec with liraglutide in the same device (IDegLira) is a potent but at the same time safe drug that reduces the risk of hypoglycemia when compared to a basal or basal-bolus insulin schedule.\n\nThe DUAL (Dual Action of Liraglutide and Insulin Degludec) studies are the pivotal studies of this combination. Specifically, the DUAL VII study has demonstrated that ideglira is a non-inferior drug in terms of glycemic control versus a basal-bolus schedule in patients in the outpatient setting who have failed basal insulin.\n\nAlthough the basal-bolus insulin plus correction schedule is frequently used in hospitalized patients with hyperglycemia, outpatient management with a complex insulin schedule creates challenges that are difficult to mitigate due to limited time for patient education during an acute illness and limited access to the physician responsible for post-discharge diabetes management.\n\nThe use of IDegLira has not been evaluated in clinical studies in the hospital discharge setting where the authors believe it has great potential because it offers similar potency to the basal-bolus scheme but with greater safety with respect to hypoglycemia and less complexity for the patient because it is associated with fewer applications and less need for capillary self-monitoring.\n\nFor this reason, in the hospital-home transition scenario, ideglira therapy in patients with poor metabolic control and requiring intensification therapy is proposed as an alternative to the basal-bolus scheme.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2022-12-01",
"completionDate": "2023-08-30",
"primaryCompletionDate": "2023-08-30",
"firstPostedDate": "2023-03-14",
"lastUpdatePostedDate": "2023-03-14",
"locations": [
{
"facility": "Hospital Universitario San Ignacio",
"city": "Bogotá",
"state": null,
"country": "Colombia"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT05767255",
"scrapedAt": "2026-05-14T17:51:05.540Z"
},
{
"nctId": "NCT05959135",
"briefTitle": "Gastric Ultrasound in Diabetic and Non-Diabetic Pregnant Women",
"officialTitle": "Ultrasound Evaluation of Gastric Content in Diabetic and Non-Diabetic Term Pregnant Women: An Observational Study",
"acronym": null,
"organization": "Sisli Hamidiye Etfal Training and Research Hospital",
"overallStatus": "COMPLETED",
"studyType": "OBSERVATIONAL",
"phases": [],
"enrollmentCount": 80,
"leadSponsor": "Sisli Hamidiye Etfal Training and Research Hospital",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Gastric Ultrasonography",
"Gastric Volume",
"Pulmonary Aspiration",
"Diabetic Pregnancy",
"Fasting"
],
"interventions": [
"DEVICE: Gastric ultrasonography"
],
"briefSummary": "Perioperative aspiration is particularly concerning in pregnant women due to anatomical changes. To mitigate this risk, pre-anesthetic fasting is recommended, with varying guidelines. Gastric ultrasound can non-invasively assess stomach contents, and mathematical models help estimate stomach volumes using the gastric antral cross-sectional area (CSA).\n\nThis study aims to compare CSA and estimated gastric volumes through ultrasound in fasting diabetic and non-diabetic pregnant women scheduled for cesarean section, as diabetes may affect stomach fullness. Additionally, it will investigate the relation between demographic and clinical variables and CSA values.\n\nThis research can shed light on diabetes' influence on aspiration risk in pregnancy and evaluate fasting guidelines, underscoring the significance of gastric ultrasound.",
"sex": "FEMALE",
"minimumAge": "18 Years",
"maximumAge": "40 Years",
"healthyVolunteers": true,
"startDate": "2023-07-26",
"completionDate": "2023-12-25",
"primaryCompletionDate": "2023-12-10",
"firstPostedDate": "2023-07-25",
"lastUpdatePostedDate": "2023-12-29",
"locations": [
{
"facility": "Sisli Hamidiye Etfal Training and Research Hospital",
"city": "Sarıyer",
"state": "Istanbul",
"country": "Turkey (Türkiye)"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT05959135",
"scrapedAt": "2026-05-14T17:51:05.560Z"
},
{
"nctId": "NCT06912035",
"briefTitle": "Efficacy of Diacerein Supplementation on Interleukin-1β, Hs-CRP, TNF-α Levels and Glycemic Control in Uncontrolled Type 2 Diabetes Mellitus Patients at Dr. Mohammad Hoesin General Hospital Palembang",
"officialTitle": "EFFICACY OF DIACEREIN ADDITION ON INTERLEUKIN-1Β, HS-CRP, TNF-Α LEVELS AND GLYCEMIC CONTROL IN UNCONTROLLED TYPE 2 DIABETES MELLITUS PATIENTS AT DR. MOHAMMAD HOESIN GENERAL HOSPITAL PALEMBANG",
"acronym": null,
"organization": "Universitas Sriwijaya",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE2",
"PHASE3"
],
"enrollmentCount": 34,
"leadSponsor": "Universitas Sriwijaya",
"sponsorClass": "OTHER",
"collaborators": [
"Indonesia Endowment Fund for Education (LPDP), Ministry of Finance Republik of Indonesia"
],
"conditions": [
"Uncontrolled Diabetes",
"Diabetes Mellitus Type 2"
],
"interventions": [
"DRUG: Diacerein 50 mg Capsule",
"DRUG: Placebo"
],
"briefSummary": "The goal of this clinical trial is to learn if diacerein supplementation can help improve inflammation and glycemic control in adults with uncontrolled type 2 diabetes. It will also study the safety and tolerability of diacerein. The main questions it aims to answer are:\n\n* Does diacerein lower levels of inflammatory markers like interleukin-1β, hs-CRP, and TNF-α?\n* Does diacerein improve blood sugar control?\n* What side effects or problems do participants have when taking diacerein?\n\nResearchers will compare diacerein to a placebo (a look-alike substance with no active drug) to see if it works better for managing type 2 diabetes.\n\nParticipants will:\n\n* Be adults aged 40-60 with uncontrolled type 2 diabetes\n* Take either diacerein or a placebo every day for 12 weeks\n* Visit the clinic for blood tests and monitoring at the beginning and end of the trial\n* Be evaluated for side effects and medication adherence\\]",
"sex": "ALL",
"minimumAge": "60 Years",
"maximumAge": "60 Years",
"healthyVolunteers": false,
"startDate": "2024-06-21",
"completionDate": "2024-11-08",
"primaryCompletionDate": "2024-11-08",
"firstPostedDate": "2025-04-04",
"lastUpdatePostedDate": "2025-04-04",
"locations": [
{
"facility": "Universitas Sriwijaya",
"city": "Palembang",
"state": "South Sumatera",
"country": "Indonesia"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT06912035",
"scrapedAt": "2026-05-14T17:51:05.603Z"
},
{
"nctId": "NCT01973374",
"briefTitle": "Sugar Text: A Randomized Controlled Trial of a Text Message Intervention for Women With Diabetes in Pregnancy",
"officialTitle": "Sugar Text: A Randomized Controlled Trial of a Text Message Intervention for Women With Diabetes in Pregnancy",
"acronym": "Sugar Text",
"organization": "University of Pennsylvania",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 30,
"leadSponsor": "University of Pennsylvania",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Diabetes in Pregnancy",
"Gestational Diabetes",
"Texting Interventions"
],
"interventions": [
"BEHAVIORAL: Text Message Intervention"
],
"briefSummary": "Maternal diabetes in pregnancy can negatively impact fetal well-being and contribute to adverse pregnancy outcomes. Much of the morbidity associated with diabetes in pregnancy can be minimized with tight glucose control. A number of studies in non-pregnant populations have highlighted the feasibility, acceptability and efficacy of text messaging interventions for improving diabetic compliance and control. This study will investigate whether a text messaging intervention is feasible and effective in an urban, diabetic, obstetric clinic and whether this intervention can improve compliance with diabetes care, glucose control and pregnancy outcomes. The study will also assess satisfaction with the intervention itself.",
"sex": "FEMALE",
"minimumAge": "18 Years",
"maximumAge": "50 Years",
"healthyVolunteers": false,
"startDate": "2013-01",
"completionDate": "2014-04",
"primaryCompletionDate": "2014-04",
"firstPostedDate": "2013-10-31",
"lastUpdatePostedDate": "2015-02-20",
"locations": [
{
"facility": "Hospital of the University of Pennsylvania",
"city": "Philadelphia",
"state": "Pennsylvania",
"country": "United States"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT01973374",
"scrapedAt": "2026-05-14T17:51:05.645Z"
},
{
"nctId": "NCT02607410",
"briefTitle": "Sitagliptin (DPP-4 Inhibitor) and NPH Insulin in Patients With T2D",
"officialTitle": "Short and Long Term Effects of a Dypeptidil-peptidase-4 Versus Bedtime NPH Insulin as add-on Therapy in Patients With Type 2 Diabetes",
"acronym": null,
"organization": "University of Sao Paulo General Hospital",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE4"
],
"enrollmentCount": 40,
"leadSponsor": "University of Sao Paulo General Hospital",
"sponsorClass": "OTHER",
"collaborators": [
"Fundação de Amparo à Pesquisa do Estado de São Paulo"
],
"conditions": [
"Type 2 Diabetes Mellitus"
],
"interventions": [
"DRUG: sitagliptin",
"DRUG: NPH insulin"
],
"briefSummary": "To compare the short and long term effects of inhibitor of the DPP-IV enzyme, sitagliptin , with bedtime NPH insulin in patients with T2D inadequately controlled with sulphonylurea plus biguanide: effects on beta cell function and on metabolic profile.",
"sex": "ALL",
"minimumAge": "35 Years",
"maximumAge": "70 Years",
"healthyVolunteers": false,
"startDate": "2010-01",
"completionDate": "2014-07",
"primaryCompletionDate": "2012-01",
"firstPostedDate": "2015-11-18",
"lastUpdatePostedDate": "2015-11-18",
"locations": [
{
"facility": "University of Sao Paulo General Hospital",
"city": "São Paulo",
"state": "São Paulo",
"country": "Brazil"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT02607410",
"scrapedAt": "2026-05-14T17:51:05.688Z"
},
{
"nctId": "NCT07147010",
"briefTitle": "Evaluation of Correlations Between Volatile Organic Compounds and Venous Blood Glucose in Subjects With Type 2 Diabetes",
"officialTitle": "Evaluation of Correlations Between Volatile Organic Compounds (VOCs) Spectra Measured With GC-IMS and MOx-sensors and Venous Blood Glucose in Subjects With Type 2 Diabetes",
"acronym": "Evo",
"organization": "DCB Research AG",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 20,
"leadSponsor": "DCB Research AG",
"sponsorClass": "OTHER",
"collaborators": [
"Insel Gruppe AG, University Hospital Bern",
"BOYDSENSE"
],
"conditions": [
"Type 2 Diabetes"
],
"interventions": [
"DEVICE: MIB Breath Analyzer"
],
"briefSummary": "The goal of this study is to evaluate correlations between VOCs in the breath and venous blood glucose values in various glycaemic states in people living with Type 2 Diabetes.\n\nVOCs are measured with a gold-standard GC-IMS device and a prototype of a novel breath analyzer. Participants will be exposed to different blood glucose levels at different rates of change by administering glucose solution and insulin and by a meal challenge.",
"sex": "ALL",
"minimumAge": "45 Years",
"maximumAge": "70 Years",
"healthyVolunteers": false,
"startDate": "2024-10-01",
"completionDate": "2025-11-27",
"primaryCompletionDate": "2025-03-30",
"firstPostedDate": "2025-08-28",
"lastUpdatePostedDate": "2025-12-09",
"locations": [
{
"facility": "Inselspital Bern",
"city": "Bern",
"state": null,
"country": "Switzerland"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT07147010",
"scrapedAt": "2026-05-14T17:51:05.735Z"
},
{
"nctId": "NCT05191160",
"briefTitle": "The Soy Treatment Evaluation for Metabolic Health (STEM) Trial",
"officialTitle": "Role of Soy for Metabolic Health: The Soy Treatment Evaluation for Metabolic Health (STEM) Trial",
"acronym": null,
"organization": "University of Toronto",
"overallStatus": "UNKNOWN",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 186,
"leadSponsor": "University of Toronto",
"sponsorClass": "OTHER",
"collaborators": [
"United Soybean Board"
],
"conditions": [
"Metabolic Syndrome",
"Overweight and Obesity",
"PreDiabetes",
"Diabetes",
"Healthy Obesity, Metabolically",
"Overweight",
"Obesity",
"Dysglycemia",
"Cardiovascular Diseases",
"Heart Disease Risk Factors",
"Hypertension",
"Dyslipidemias"
],
"interventions": [
"OTHER: Soy Milk",
"OTHER: Cow's Milk",
"OTHER: Sugar Sweetened Beverages"
],
"briefSummary": "Strategies to reduce sugar-sweetened beverages (SSB) have become one of the leading public health targets to address the epidemics of obesity and diabetes. National food, nutrition, and health policies and programs have positioned low-fat milk as the preferred caloric replacement strategy for SSBs. This strategy derives from evidence that replacement of SSBs with low-fat milk is associated with reductions in weight and incident diabetes in prospective cohort studies and reduces liver fat (an important early metabolic lesion linking obesity to diabetes), as well as triglycerides and blood pressure in randomized trials. Whether these benefits hold for soy milk alternatives is unclear. There is an urgent need for studies to clarify the benefits of soy milk as an alternative to cow's milk. Our overarching aim is to produce high-quality clinical evidence that informs the use of soy as a \"public health intervention\" for addressing the dual epidemics of obesity and diabetes and overall metabolic health. To achieve this aim, we propose to conduct the Soy Treatment Evaluation for Metabolic health (STEM) trial, a large, pragmatic, randomized controlled trial to assess the effect of using 2% soy milk (soy protein vehicle) versus 2% cow's milk (casein and whey vehicle matched for protein and volume) as a \"public health intervention\" to replace SSBs on liver fat and key cardiometabolic mediators/indicators in an at risk population.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": "75 Years",
"healthyVolunteers": true,
"startDate": "2021-11-02",
"completionDate": "2025-03-30",
"primaryCompletionDate": "2024-10-30",
"firstPostedDate": "2022-01-13",
"lastUpdatePostedDate": "2024-04-18",
"locations": [
{
"facility": "Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital",
"city": "Toronto",
"state": "Ontario",
"country": "Canada"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT05191160",
"scrapedAt": "2026-05-14T17:51:05.781Z"
},
{
"nctId": "NCT06145360",
"briefTitle": "Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient",
"officialTitle": "Effectivity of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes",
"acronym": null,
"organization": "SINA Health Education and Welfare Trust",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE4"
],
"enrollmentCount": 150,
"leadSponsor": "SINA Health Education and Welfare Trust",
"sponsorClass": "OTHER",
"collaborators": [
"Horizon Pharmaceutical Pvt Ltd"
],
"conditions": [
"Glucose Metabolism Disorders",
"Diabetes Mellitus, Type 2",
"Hypoglycemic Agents",
"Empagliflozin"
],
"interventions": [
"DRUG: Empagliflozin 10 MG",
"DRUG: Insulin+Metformin+DPP4 inhibitor (DPP4I)"
],
"briefSummary": "The primary aim of this study is to assess the impact of incorporating Empagliflozin, an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor, into the existing therapeutic regimen of Insulin+Metformin+Dipeptidyl peptidase 4 (DPP-4) inhibitors in poorly controlled type 2 diabetes mellitus (T2DM) patients. The study seeks to evaluate its effect on achieving glycemic goals in this patient population.",
"sex": "ALL",
"minimumAge": "20 Years",
"maximumAge": "70 Years",
"healthyVolunteers": false,
"startDate": "2023-12-01",
"completionDate": "2024-03-01",
"primaryCompletionDate": "2024-03-01",
"firstPostedDate": "2023-11-24",
"lastUpdatePostedDate": "2024-04-08",
"locations": [
{
"facility": "SINA Shireen Jinnah colony",
"city": "Karachi",
"state": null,
"country": "Pakistan"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT06145360",
"scrapedAt": "2026-05-14T17:51:05.821Z"
},
{
"nctId": "NCT02806960",
"briefTitle": "A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes",
"officialTitle": "A Single Center, Randomized, 4-Period Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Single or Repeated 3 mg Doses of Intranasally Administered Glucagon in Adults With Type 1 or Type 2 Diabetes",
"acronym": null,
"organization": "Eli Lilly and Company",
"overallStatus": "TERMINATED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE1"
],
"enrollmentCount": 12,
"leadSponsor": "Eli Lilly and Company",
"sponsorClass": "INDUSTRY",
"collaborators": [
"Locemia Solutions ULC"
],
"conditions": [
"Diabetes Mellitus, Type 1",
"Diabetes Mellitus, Type 2"
],
"interventions": [
"DRUG: Nasal Glucagon"
],
"briefSummary": "This study will investigate how the body processes nasal glucagon and the effect of nasal glucagon on the body. After an 8-hour overnight fast and 4 hours after the start of a low-carbohydrate breakfast, the study drug will be delivered into the participant's nostril(s) (intranasally) once or twice in each of four study periods. The study is open to adults with type 1 or type 2 diabetes and is expected to last about 50 days for each participant.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": "70 Years",
"healthyVolunteers": false,
"startDate": "2014-06",
"completionDate": "2014-08",
"primaryCompletionDate": "2014-06",
"firstPostedDate": "2016-06-21",
"lastUpdatePostedDate": "2019-12-13",
"locations": [
{
"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.",
"city": "Mount Royal",
"state": "Quebec",
"country": "Canada"
}
],
"hasResults": true,
"url": "https://clinicaltrials.gov/study/NCT02806960",
"scrapedAt": "2026-05-14T17:51:05.866Z"
},
{
"nctId": "NCT06273124",
"briefTitle": "Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes",
"officialTitle": "Open, Single Arm, Prospective, Multicenter Study of an Investigational Extended Wear Insulin Infusion Set During Home Use in People With Type 1 Diabetes",
"acronym": null,
"organization": "Tandem Diabetes Care, Inc.",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 260,
"leadSponsor": "Tandem Diabetes Care, Inc.",
"sponsorClass": "INDUSTRY",
"collaborators": [
"Jaeb Center for Health Research"
],
"conditions": [
"Type1diabetes"
],
"interventions": [
"DEVICE: SteadiSet Extended Wear Infusion Set"
],
"briefSummary": "The purpose of this study is to collect clinical data to support a 7-day wear of the Extended Wear Infusion Set (EWIS).\n\nParticipants will be asked to:\n\n1. Wear the EWIS for up to 7 consecutive days for 12 consecutive wear periods\n2. Perform blood glucose and ketone measurements if continuous glucose meter is ≥250mg/dL for one hour",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": "80 Years",
"healthyVolunteers": false,
"startDate": "2024-03-07",
"completionDate": "2024-12-11",
"primaryCompletionDate": "2024-12-11",
"firstPostedDate": "2024-02-22",
"lastUpdatePostedDate": "2025-09-24",
"locations": [
{
"facility": "Hoag Memorial Hospital Presbyterian",
"city": "Newport Beach",
"state": "California",
"country": "United States"
},
{
"facility": "Stanford University",
"city": "Stanford",
"state": "California",
"country": "United States"
},
{
"facility": "Barbara Davis Center",
"city": "Aurora",
"state": "Colorado",
"country": "United States"
},
{
"facility": "Endocrine Research Solutions",
"city": "Roswell",
"state": "Georgia",
"country": "United States"
},
{
"facility": "Rocky Mountain Clinical Research",
"city": "Idaho Falls",
"state": "Idaho",
"country": "United States"
},
{
"facility": "Northwestern University",
"city": "Evanston",
"state": "Illinois",
"country": "United States"
},
{
"facility": "Massachusetts General Hospital",
"city": "Boston",
"state": "Massachusetts",
"country": "United States"
},
{
"facility": "Henry Ford Health System",
"city": "Detroit",
"state": "Michigan",
"country": "United States"
},
{
"facility": "International Diabetes Center - HealthPartners Institute",
"city": "Minneapolis",
"state": "Minnesota",
"country": "United States"
},
{
"facility": "Mayo Clinic",
"city": "Rochester",
"state": "Minnesota",
"country": "United States"
},
{
"facility": "Icahn School of Medicine at Mt. Sinai",
"city": "New York",
"state": "New York",
"country": "United States"
},
{
"facility": "SUNY Upstate Medical University",
"city": "Syracuse",
"state": "New York",
"country": "United States"
},
{
"facility": "Texas Diabetes and Endocrinology",
"city": "Austin",
"state": "Texas",
"country": "United States"
},
{
"facility": "Rainier Clinical Research Center",
"city": "Renton",
"state": "Washington",
"country": "United States"
},
{
"facility": "University of Washington",
"city": "Seattle",
"state": "Washington",
"country": "United States"
}
],
"hasResults": true,
"url": "https://clinicaltrials.gov/study/NCT06273124",
"scrapedAt": "2026-05-14T17:51:05.902Z"
},
{
"nctId": "NCT07139964",
"briefTitle": "High-Dose Vitamin D3 for Diabetic Foot Ulcer Healing: Randomized Controlled Trial",
"officialTitle": "Effectiveness of High-Dose Vitamin D3 in Improving Diabetic Foot Ulcer Healing by Reducing the MMP-9 to TIMP-1 Ratio: Randomized Double-Blind Placebo-Controlled Trial",
"acronym": "DFU",
"organization": "Universitas Sriwijaya",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 24,
"leadSponsor": "Universitas Sriwijaya",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Diabetic Foot Ulcer",
"Vitamin D Deficiency",
"Wound Healing Disorder"
],
"interventions": [
"DIETARY_SUPPLEMENT: Vitamin D3",
"OTHER: Placebo"
],
"briefSummary": "This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the effectiveness of high-dose vitamin D3 supplementation in improving diabetic foot ulcer (DFU) healing. DFUs are common, serious complications of diabetes, often associated with delayed wound healing due to persistent inflammation, impaired angiogenesis, and imbalances between matrix metalloproteinase-9 (MMP-9) and its tissue inhibitor (TIMP-1). Vitamin D deficiency is prevalent among DFU patients and is linked to impaired fibroblast function, poor angiogenesis, and increased inflammation.\n\nParticipants with DFUs and serum vitamin D levels \\<30 ng/mL will be randomized to receive either 10,000 IU oral vitamin D3 daily or placebo for 28 days, in addition to standard DFU care. Primary outcomes include changes in tissue MMP-9/TIMP-1 expression ratio and wound healing progression. The study will provide evidence on whether high-dose vitamin D3 can serve as a safe, effective adjunctive therapy in DFU management.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2024-07-01",
"completionDate": "2025-07-31",
"primaryCompletionDate": "2025-01-31",
"firstPostedDate": "2025-08-24",
"lastUpdatePostedDate": "2025-08-24",
"locations": [
{
"facility": "Dr. Mohammad Hoesin General Hospital",
"city": "Palembang",
"state": "South Sumatra",
"country": "Indonesia"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT07139964",
"scrapedAt": "2026-05-14T17:51:05.981Z"
},
{
"nctId": "NCT02776098",
"briefTitle": "Muscle Accrual and Function in Cystic Fibrosis-Impact of Glucose Intolerance",
"officialTitle": "Muscle Accrual and Function in Cystic Fibrosis-Impact of Glucose Intolerance",
"acronym": null,
"organization": "Children's Hospital of Philadelphia",
"overallStatus": "COMPLETED",
"studyType": "OBSERVATIONAL",
"phases": [],
"enrollmentCount": 54,
"leadSponsor": "Children's Hospital of Philadelphia",
"sponsorClass": "OTHER",
"collaborators": [
"National Institutes of Health (NIH)",
"University of Pennsylvania",
"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"
],
"conditions": [
"Cystic Fibrosis"
],
"interventions": [],
"briefSummary": "This study will investigate the link between glucose abnormalities and elements critical to muscle function including mass, composition and energy metabolism. the primary goal of the study is to determine whether Cystic Fibrosis (CF) disease is associated with muscle dysfunction, especially in the presence of glucose intolerance. This is a longitudinal cohort study of 3 main groups: CF subjects without Cystic Fibrosis-related diabetes (CFRD), healthy matched controls and CF subjects with newly diagnosed CFRD started on insulin therapy.",
"sex": "ALL",
"minimumAge": "12 Years",
"maximumAge": null,
"healthyVolunteers": true,
"startDate": "2016-05",
"completionDate": "2024-03-04",
"primaryCompletionDate": "2024-03-04",
"firstPostedDate": "2016-05-18",
"lastUpdatePostedDate": "2024-03-07",
"locations": [
{
"facility": "Children's Hospital of Philadelphia",
"city": "Philadelphia",
"state": "Pennsylvania",
"country": "United States"
},
{
"facility": "University of Pennsylvania",
"city": "Philadelphia",
"state": "Pennsylvania",
"country": "United States"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT02776098",
"scrapedAt": "2026-05-14T17:51:06.023Z"
},
{
"nctId": "NCT02423798",
"briefTitle": "New Generation Enlite Accuracy Study",
"officialTitle": "Accuracy and Performance Evaluation of the Medtronic New Generation Enlite Glucose Sensor in Conjunction With the Medtronic 640G System Components - in Clinic and at Home",
"acronym": null,
"organization": "Medtronic MiniMed, Inc.",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 24,
"leadSponsor": "Medtronic MiniMed, Inc.",
"sponsorClass": "INDUSTRY",
"collaborators": [
"Profil Institut für Stoffwechselforschung GmbH"
],
"conditions": [
"Diabetes"
],
"interventions": [
"DEVICE: Glucose sensor (Enlite)"
],
"briefSummary": "The trial will investigate the accuracy and performance of a new sensor for continuous glucose monitoring (CGM), the (new generation) Enlite, CE-marked in 2013, in conjunction with the new Medtronic 640G system components.\n\nTo evaluate the accuracy and performance of the new generation Enlite sensor. This is a postmarket, interventional, open-label, non-randomized, single center clinical research trial.\n\nThe trial will adopt a prospective single-sample design using the Yellow Spring Instruments (YSI) plasma glucose reference sampling procedure in the clinic and self-monitoring of blood glucose (SMBG) plasma glucose reference sampling procedure at home.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": "74 Years",
"healthyVolunteers": false,
"startDate": "2015-04",
"completionDate": "2015-09",
"primaryCompletionDate": "2015-09",
"firstPostedDate": "2015-04-22",
"lastUpdatePostedDate": "2018-01-17",
"locations": [],
"hasResults": true,
"url": "https://clinicaltrials.gov/study/NCT02423798",
"scrapedAt": "2026-05-14T17:51:06.079Z"
},
{
"nctId": "NCT02589314",
"briefTitle": "Effect of Periodontal Therapy in the Systemic Status of Individuals With Chronic Periodontitis and Diabetes Type 2",
"officialTitle": "Effect of Mechanical Periodontal Therapy in the Microbiological, Immunocellular and Immunoglobulin Profiles and in the Dosage of Pro and Anti-inflammatory Cytokines From Peripheral Blood and Saliva of Subjects With Chronic Periodontitis and Diabetes Type 2",
"acronym": null,
"organization": "University of Brasilia",
"overallStatus": "TERMINATED",
"studyType": "OBSERVATIONAL",
"phases": [],
"enrollmentCount": 90,
"leadSponsor": "University of Brasilia",
"sponsorClass": "OTHER",
"collaborators": [
"Catholic University of Brasília",
"Brasilia University Hospital"
],
"conditions": [
"Chronic Periodontitis",
"Diabetes Type 2"
],
"interventions": [
"DEVICE: Mechanical periodontal therapy",
"PROCEDURE: nonsurgical periodontal therapy"
],
"briefSummary": "This study will evaluate if periodontal mechanical treatment is capable to alter immunological and genetical parameters related to systemic health in patients with chronic periodontitis ant diabetes type 2.",
"sex": "ALL",
"minimumAge": "30 Years",
"maximumAge": "65 Years",
"healthyVolunteers": true,
"startDate": "2015-11",
"completionDate": "2020-08",
"primaryCompletionDate": "2019-09",
"firstPostedDate": "2015-10-28",
"lastUpdatePostedDate": "2020-08-24",
"locations": [
{
"facility": "Priscilla Farias Naiff",
"city": "Brasília",
"state": "Federal District",
"country": "Brazil"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT02589314",
"scrapedAt": "2026-05-14T17:51:06.094Z"
},
{
"nctId": "NCT00993304",
"briefTitle": "A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 Diabetics",
"officialTitle": "A Trial to Assess the Effect of Liraglutide on Postprandial Triglyceride Levels in Subjects With Type 2 Diabetes",
"acronym": null,
"organization": "Novo Nordisk A/S",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE1"
],
"enrollmentCount": 20,
"leadSponsor": "Novo Nordisk A/S",
"sponsorClass": "INDUSTRY",
"collaborators": [],
"conditions": [
"Diabetes",
"Diabetes Mellitus, Type 2"
],
"interventions": [
"DRUG: liraglutide",
"DRUG: placebo"
],
"briefSummary": "This trial is conducted in Europe. The aim of this trial is to investigate whether a new compound, liraglutide, reduces the level of lipids (fat), including cholesterol, in the blood of type 2 diabetics, following a meal with high fat content.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2009-10",
"completionDate": "2010-12",
"primaryCompletionDate": "2010-12",
"firstPostedDate": "2009-10-12",
"lastUpdatePostedDate": "2017-01-26",
"locations": [
{
"facility": "Novo Nordisk Investigational Site",
"city": "Aarhus C",
"state": null,
"country": "Denmark"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT00993304",
"scrapedAt": "2026-05-14T17:51:06.125Z"
},
{
"nctId": "NCT00312104",
"briefTitle": "Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes",
"officialTitle": "Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes.",
"acronym": null,
"organization": "Novo Nordisk A/S",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE3"
],
"enrollmentCount": 325,
"leadSponsor": "Novo Nordisk A/S",
"sponsorClass": "INDUSTRY",
"collaborators": [],
"conditions": [
"Diabetes",
"Diabetes Mellitus, Type 1"
],
"interventions": [
"DRUG: insulin detemir",
"DRUG: insulin glargine",
"DRUG: insulin aspart"
],
"briefSummary": "The trial is conducted in Europe and Africa. The aim of the trial is to compare the use of insulin detemir twice daily combined with mealtime insulin aspart against that of insulin glargine once daily combined with mealtime insulin aspart. The trial involves patients with Type 1 Diabetes.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2002-04",
"completionDate": "2003-03",
"primaryCompletionDate": "2003-03",
"firstPostedDate": "2006-04-07",
"lastUpdatePostedDate": "2017-01-27",
"locations": [
{
"facility": "Novo Nordisk Investigational Site",
"city": "Graz",
"state": null,
"country": "Austria"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Vienna",
"state": null,
"country": "Austria"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Vienna",
"state": null,
"country": "Austria"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Vienna",
"state": null,
"country": "Austria"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Vienna",
"state": null,
"country": "Austria"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Bad Kreuznach",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Bad Mergentheim",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Bad Neuenahr-Ahrweiler",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Berlin",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Diez",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Erlangen",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Essen",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Flensburg",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Frankfurt",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Friedrichsthal",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Genthin",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Halle",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Hamburg",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Hanover",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Heidelberg",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Hennigsdorf",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Hünxe",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Jena",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Kiel",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Landau",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Ludwigshafen",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Marl",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Mönchengladbach",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Neunkirchen",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Neuss",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Northeim",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Nuremberg",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Rehlingen-Siersburg",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Rheda-Wiedenbrück",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Saarbrücken",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Saarlouis",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Schönebeck",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Schwabenheim",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Schwerin",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Völklingen",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Wiesbaden",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Würzburg",
"state": null,
"country": "Germany"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Johannesburg",
"state": "Gauteng",
"country": "South Africa"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Durban",
"state": "KwaZulu-Natal",
"country": "South Africa"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Cape Town",
"state": "Western Cape",
"country": "South Africa"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Cape Town",
"state": "Western Cape",
"country": "South Africa"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT00312104",
"scrapedAt": "2026-05-14T17:51:06.174Z"
},
{
"nctId": "NCT01075347",
"briefTitle": "Topical Autologous Serum Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries",
"officialTitle": "Clinical Study: Topical Autologous Serum Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries",
"acronym": null,
"organization": "National Taiwan University Hospital",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE1"
],
"enrollmentCount": 165,
"leadSponsor": "National Taiwan University Hospital",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Corneal Epithelial Defect",
"Diabetic Retinopathy",
"Penetrating Keratoplasty"
],
"interventions": [
"OTHER: autologous serum",
"OTHER: Non-autologous serum"
],
"briefSummary": "Ophthalmology ,cornea Autologous serum has long been known to be effective to promote corneal epithelial wound healing in a variety of ocular surface disorders. However, its effectiveness for corneal epithelial defects due to pars plana vitrectomy (PPV) for diabetic retinopathy and penetrating keratoplasty has seldom been reported. In this study, we plan to perform a prospective study to determine the effectiveness of topical autologous serum as a primary treatment for corneal epithelial defect in patients undergoing vitrectomy for diabetic retinopathy and penetrating keratoplasty. All patients enrolled in this study have received corneal epithelial debridement at the end of the ocular surgeries, namely PPV for diabetic retinopathy and penetrating keratoplasty. The patients were grouped into two treatment groups. In the control group, the patients receive conventional postoperative eye drops including topical steroid, antibiotic and mydriatics. In the experimental group, the patients receive topical autologous serum eye drops in addition to conventional postoperative eye drops. The duration for cornea surface to completely re-epithelize, the incidence of corneal complications due to delayed surface re-epithelization (e.g. infectious corneal ulcer, corneal melting, sterile corneal ulcer, corneal neovascularization), and the incidence of recurrent epithelial break down after initial epithelization will be compared between these two groups. Patients undergoing PPV for diabetic retinopathy and penetrating keratoplasty will be compared separately",
"sex": "ALL",
"minimumAge": "20 Years",
"maximumAge": "70 Years",
"healthyVolunteers": true,
"startDate": "2007-03",
"completionDate": "2008-03",
"primaryCompletionDate": "2008-03",
"firstPostedDate": "2010-02-25",
"lastUpdatePostedDate": "2010-09-14",
"locations": [
{
"facility": "National Taiwan University Hospital, department of Ophthalmology",
"city": "Taipei",
"state": "Taiwan",
"country": "Taiwan"
}
],
"hasResults": true,
"url": "https://clinicaltrials.gov/study/NCT01075347",
"scrapedAt": "2026-05-14T17:51:06.191Z"
},
{
"nctId": "NCT05874726",
"briefTitle": "Biological Sample Repository for Gastrointestinal Disorders",
"officialTitle": "Biological Sample Repository for Gastrointestinal Disorders",
"acronym": null,
"organization": "Brigham and Women's Hospital",
"overallStatus": "ACTIVE_NOT_RECRUITING",
"studyType": "OBSERVATIONAL",
"phases": [],
"enrollmentCount": 500,
"leadSponsor": "Pichamol Jirapinyo, MD, MPH",
"sponsorClass": "OTHER",
"collaborators": [
"Tufts University",
"Boston Children's Hospital",
"Mayo Clinic"
],
"conditions": [
"Obesity",
"Obesity, Morbid",
"Obesity, Primary",
"Gastro-Intestinal Disorder",
"Overweight and Obesity",
"Overweight",
"Overweight or Obesity",
"Diabetes Type 2",
"Diabetes Mellitus",
"Diabetes Mellitus, Type 2",
"Hypertension",
"Hyperlipidemias",
"Sleep Apnea",
"GERD",
"Gastroesophageal Reflux",
"Musculoskeletal Pain Disorder",
"Cancer"
],
"interventions": [
"DIAGNOSTIC_TEST: Blood Collection",
"DIAGNOSTIC_TEST: Urine Collection",
"DIAGNOSTIC_TEST: Tissue Sample Collection"
],
"briefSummary": "The goal of this observational study has the purpose of collecting biological samples from obese patients undergoing evaluation for weight loss by means of medical or endoscopic therapies; and of post bariatric surgery patients presenting with short- and long-term surgical complications. The aim is to enhance the overall understanding of the mechanisms leading to obesity, weight loss, failure to lose weight, and weight regain following treatment. Additional goals are to determine the efficacy of endoscopic and surgical procedures, to identify potential therapeutic targets and disease biomarkers that predict response to therapy.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2023-07-19",
"completionDate": "2029-04",
"primaryCompletionDate": "2028-07",
"firstPostedDate": "2023-05-25",
"lastUpdatePostedDate": "2025-12-02",
"locations": [
{
"facility": "Brigham and Women's Hospital",
"city": "Boston",
"state": "Massachusetts",
"country": "United States"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT05874726",
"scrapedAt": "2026-05-14T17:51:06.235Z"
},
{
"nctId": "NCT00741026",
"briefTitle": "A Crossover Study of the Acute Effects of Olanzapine in Healthy Volunteers",
"officialTitle": "A Double-blind, Placebo-controlled, Crossover Study Examining the Acute Effects of Olanzapine on Plasma Leptin, Glucose Tolerance and Free Fatty Acids in Healthy Volunteers",
"acronym": null,
"organization": "Milton S. Hershey Medical Center",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 15,
"leadSponsor": "Milton S. Hershey Medical Center",
"sponsorClass": "OTHER",
"collaborators": [
"American Medical Association"
],
"conditions": [
"Insulin Resistance",
"Diabetes Mellitus"
],
"interventions": [
"DRUG: Olanzapine 10 mg po qhs for 3 days",
"DRUG: Placebo"
],
"briefSummary": "The purpose of this clinical research study is to examine the acute hormonal and metabolic effects of the drug olanzapine, as well as appetite effects, in healthy volunteers. The hypotheses to be tested are that: (1) Olanzapine rapidly attenuates plasma leptin and (2) rapidly alters glucose tolerance in healthy volunteers. These questions will be answered by having volunteers undergo two glucose tolerance tests in a crossover study design.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": "30 Years",
"healthyVolunteers": true,
"startDate": "2008-08",
"completionDate": "2011-05",
"primaryCompletionDate": "2010-12",
"firstPostedDate": "2008-08-25",
"lastUpdatePostedDate": "2014-07-14",
"locations": [
{
"facility": "Penn State College of Medicine, Penn State Milton S. Hershey Medical Center",
"city": "Hershey",
"state": "Pennsylvania",
"country": "United States"
}
],
"hasResults": true,
"url": "https://clinicaltrials.gov/study/NCT00741026",
"scrapedAt": "2026-05-14T17:51:06.252Z"
},
{
"nctId": "NCT04532385",
"briefTitle": "Effect of Green Tea Extract on Lipids in Patients With Type 2 Diabetes",
"officialTitle": "Effect of a 12-week Administration of Green Tea Extract on Lipids in Patients With Type 2 Diabetes",
"acronym": "HDL",
"organization": "Centro Universitario de Ciencias de la Salud, Mexico",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 20,
"leadSponsor": "Centro Universitario de Ciencias de la Salud, Mexico",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Diabetes Mellitus, Type 2",
"Dyslipidemias",
"Arterial Stiffness"
],
"interventions": [
"DIETARY_SUPPLEMENT: Green tea extract",
"DIETARY_SUPPLEMENT: Placebo"
],
"briefSummary": "The main objectives of this study were to evaluate the effect of a 12-week supplementation with GTE (400 mg every 12 hours) on serum lipids, arterial stiffness and inflammatory cytokines in patients with T2DM.",
"sex": "ALL",
"minimumAge": "40 Years",
"maximumAge": "65 Years",
"healthyVolunteers": false,
"startDate": "2018-06-12",
"completionDate": "2019-01-14",
"primaryCompletionDate": "2019-01-14",
"firstPostedDate": "2020-08-31",
"lastUpdatePostedDate": "2020-08-31",
"locations": [
{
"facility": "Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara",
"city": "Guadalajara",
"state": "Jalisco",
"country": "Mexico"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT04532385",
"scrapedAt": "2026-05-14T17:51:06.273Z"
},
{
"nctId": "NCT00108615",
"briefTitle": "Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance",
"officialTitle": "Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance",
"acronym": null,
"organization": "VA Office of Research and Development",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE4"
],
"enrollmentCount": 48,
"leadSponsor": "US Department of Veterans Affairs",
"sponsorClass": "FED",
"collaborators": [],
"conditions": [
"Glucose Metabolism Disorders",
"Diabetes"
],
"interventions": [
"DRUG: Metformin",
"DRUG: Pioglitazone",
"DRUG: Metformin",
"DRUG: Pioglitazone",
"RADIATION: CT scans",
"PROCEDURE: Oral glucose tolerance test"
],
"briefSummary": "Subjects with impaired glucose tolerance will be randomized to receive pioglitazone or metformin for 10 weeks. Measurements of insulin sensitivity, body composition, glucose tolerance, and muscle lipid accumulation will be performed. Adipose tissue and muscle biopsies are performed. The goal of the study is to determine whether the lipotoxiciy of impaired glucose tolerance is ameliorated by pioglitazone.",
"sex": "ALL",
"minimumAge": "35 Years",
"maximumAge": "65 Years",
"healthyVolunteers": true,
"startDate": "2004-01",
"completionDate": "2007-12",
"primaryCompletionDate": "2007-04",
"firstPostedDate": "2005-04-18",
"lastUpdatePostedDate": "2008-04-25",
"locations": [
{
"facility": "Central Arkansas Veterans HCS",
"city": "Little Rock",
"state": "Arkansas",
"country": "United States"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT00108615",
"scrapedAt": "2026-05-14T17:51:06.318Z"
},
{
"nctId": "NCT05232708",
"briefTitle": "A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide",
"officialTitle": "A Study to Demonstrate Bioequivalence Between Semaglutide Formulation for the DV3396 Pen-injector and the Formulation for the PDS290 Semaglutide Pen-injector",
"acronym": null,
"organization": "Novo Nordisk A/S",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE1"
],
"enrollmentCount": 18,
"leadSponsor": "Novo Nordisk A/S",
"sponsorClass": "INDUSTRY",
"collaborators": [],
"conditions": [
"Healthy Volunteers (Diabetes Mellitus, Type 2)"
],
"interventions": [
"DRUG: Semaglutide B, 1.34 mg/mL",
"DRUG: Semaglutide D, 1.0 mg/mL",
"DRUG: Semaglutide D, 1.0 mg/mL",
"DRUG: Semaglutide B, 1.34 mg/mL"
],
"briefSummary": "In this trial, two approved solutions of the medicine semaglutide will be compared in healthy volunteers. The purpose of this trial is to see if semaglutide B and semaglutide D solutions are comparable with regards to moving into, through and out of the body when given in two separate injections. Participants will receive semaglutide B and semaglutide D in different periods of the trial (Period 1 and Period 2). Participants will receive 1 subcutaneous injection of semaglutide B (0.5 mg) and 1 subcutaneous injection of semaglutide D (0.5 mg). The trial will last for 87 to 120 days (about 3 to 4 months), depending on how long the screening period (2 to 28 days) and washout period (14 to 21 days) are. Participants will have a screening visit, followed by an in house stay (5 nights/6 days) and 9 visits for each period. Participants will have to fast for at least 6 hours overnight with only water allowed before receiving the trial medicine on the second day of in house stay (Day 1) in Period 1 and Period 2.",
"sex": "ALL",
"minimumAge": "20 Years",
"maximumAge": "55 Years",
"healthyVolunteers": true,
"startDate": "2022-01-19",
"completionDate": "2022-08-30",
"primaryCompletionDate": "2022-08-30",
"firstPostedDate": "2022-02-10",
"lastUpdatePostedDate": "2024-01-26",
"locations": [
{
"facility": "Parexel CPRU, Level 7",
"city": "Harrow",
"state": "Middlesex",
"country": "United Kingdom"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT05232708",
"scrapedAt": "2026-05-14T17:51:06.348Z"
},
{
"nctId": "NCT00641407",
"briefTitle": "Bedtime Insulins and Oral Antihyperglycemic Drugs in Type 2 Diabetes",
"officialTitle": "Bedtime Insulin Glargine or Bedtime Neutral Protamine Lispro Combined With Sulfonylurea and Metformin in Type 2 Diabetes. A Randomized, Controlled Trial",
"acronym": null,
"organization": "University of Campania Luigi Vanvitelli",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE4"
],
"enrollmentCount": 100,
"leadSponsor": "University of Campania Luigi Vanvitelli",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Type 2 Diabetes Mellitus",
"Hypoglycemia"
],
"interventions": [
"DRUG: NPL insulin",
"DRUG: Insulin glargine"
],
"briefSummary": "The maintenance of nearly normal glycemic levels reduces the risk of diabetic complications, but is difficult to achieve, despite the administration of escalating doses of oral antidiabetic drugs, such as metformin, sulfonylureas, and thiazolidinediones. Most patients eventually require insulin which usually is added when glycemic control with a regimen of oral antidiabetic agents becomes suboptimal.\n\nThe aims of the present study were: 1) To compare the clinical efficacy of insulin glargine and neutral protamine lispro (NPL) insulin when added to ongoing oral therapy in poorly controlled type 2 diabetic patients; 2) to find out the possibility to phenotype the patient who may benefit more by the single treatment.\n\nThis an open-label, randomized, parallel, 36-week comparative study was performed between January 2007 and March 2008 at a single centre.",
"sex": "ALL",
"minimumAge": "30 Years",
"maximumAge": "70 Years",
"healthyVolunteers": false,
"startDate": "2007-01",
"completionDate": "2008-03",
"primaryCompletionDate": "2007-12",
"firstPostedDate": "2008-03-24",
"lastUpdatePostedDate": "2008-03-31",
"locations": [
{
"facility": "Department of Geriatrics and Metabolic Disease",
"city": "Naples",
"state": null,
"country": "Italy"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT00641407",
"scrapedAt": "2026-05-14T17:51:06.386Z"
},
{
"nctId": "NCT04082000",
"briefTitle": "Phase 2a Study Examining the Safety and Efficacy of BOL-DP-o-04 for Treating Diabetic Neuropathy",
"officialTitle": "A Phase 2a Study Examining the Safety and Efficacy of BOL-DP-o-04 Sublingual Drops for Treating Diabetic Neuropathy",
"acronym": null,
"organization": "Breath of Life International Pharma Ltd",
"overallStatus": "TERMINATED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE1",
"PHASE2"
],
"enrollmentCount": 2,
"leadSponsor": "Breath of Life International Pharma Ltd",
"sponsorClass": "INDUSTRY",
"collaborators": [],
"conditions": [
"Diabetic Neuropathy"
],
"interventions": [
"DRUG: BOL-DP-o-04",
"DRUG: Placebo"
],
"briefSummary": "This is a randomized, double-blind, placebo-controlled Phase 2a Study Examining the Safety and Efficacy of BOL-DP-o-04 for Treating Diabetic Neuropathy",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": "80 Years",
"healthyVolunteers": false,
"startDate": "2019-04-15",
"completionDate": "2020-11-04",
"primaryCompletionDate": "2020-11-04",
"firstPostedDate": "2019-09-09",
"lastUpdatePostedDate": "2021-03-24",
"locations": [
{
"facility": "Wolfson Medical Center",
"city": "Holon",
"state": null,
"country": "Israel"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT04082000",
"scrapedAt": "2026-05-14T17:51:06.429Z"
},
{
"nctId": "NCT07515807",
"briefTitle": "Qatar Cardiometabolic Retrospective Cohort-Analysis Using Artificial Intelligence",
"officialTitle": "Qatar Cardiometabolic Retrospective Cohort-Analysis Using Artificial Intelligence",
"acronym": "QCRC-AI",
"organization": "Weill Cornell Medical College in Qatar",
"overallStatus": "NOT_YET_RECRUITING",
"studyType": "OBSERVATIONAL",
"phases": [],
"enrollmentCount": 10000,
"leadSponsor": "Weill Cornell Medical College in Qatar",
"sponsorClass": "OTHER",
"collaborators": [
"Hamad Medical Corporation"
],
"conditions": [
"Cardio Vascular Disease",
"Acute Coronary Syndromes (ACS)",
"Type 2 Diabetes",
"Pre Diabetes",
"Artifical Intelligence"
],
"interventions": [],
"briefSummary": "Cardiovascular disease is the leading cause of death worldwide, and individuals with diabetes or other cardiometabolic conditions are at increased risk of adverse cardiovascular outcomes. Although advances in prevention and treatment have reduced cardiovascular events globally, cardiometabolic disease continues to represent a significant health burden, particularly in regions with high diabetes prevalence. In Qatar and other Gulf Cooperation Council countries, the prevalence of diabetes and obesity is increasing, contributing to a high proportion of participants presenting with acute coronary syndrome who have type 2 diabetes or prediabetes. This observational study will use electronic medical record data from patients hospitalized at the Heart Hospital with acute coronary syndrome and a concomitant diagnosis of diabetes or prediabetes. The study will assess trends in cardiovascular risk factors and cardiovascular events, including readmission and mortality. An artificial intelligence component will be used to develop and validate machine learning based risk prediction models to forecast adverse cardiovascular outcomes in participants with cardiometabolic disease. These models will integrate clinical, biochemical, imaging, and other non-invasive data routinely collected during participants care to identify predictors of cardiovascular events.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2026-07-16",
"completionDate": "2030-07-16",
"primaryCompletionDate": "2030-07-16",
"firstPostedDate": "2026-04-07",
"lastUpdatePostedDate": "2026-04-21",
"locations": [
{
"facility": "Hamad Medical Corporation",
"city": "Doha",
"state": null,
"country": "Qatar"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT07515807",
"scrapedAt": "2026-05-14T17:51:06.447Z"
},
{
"nctId": "NCT01847092",
"briefTitle": "A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria",
"officialTitle": "An Exploratory Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Design Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZD1722 in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria",
"acronym": null,
"organization": "Ardelyx",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE2"
],
"enrollmentCount": 154,
"leadSponsor": "Ardelyx",
"sponsorClass": "INDUSTRY",
"collaborators": [
"AstraZeneca"
],
"conditions": [
"Chronic Kidney Disease",
"Type 2 Diabetes Mellitus"
],
"interventions": [
"DRUG: AZD1722",
"DRUG: Placebo"
],
"briefSummary": "The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing albuminuria in patients with Chronic Kidney Disease with Type 2 Diabetes.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": "80 Years",
"healthyVolunteers": false,
"startDate": "2013-05",
"completionDate": "2015-04",
"primaryCompletionDate": "2015-03",
"firstPostedDate": "2013-05-06",
"lastUpdatePostedDate": "2020-05-27",
"locations": [
{
"facility": "Creekside Endocrine Associates PC",
"city": "Denver",
"state": "Colorado",
"country": "United States"
}
],
"hasResults": true,
"url": "https://clinicaltrials.gov/study/NCT01847092",
"scrapedAt": "2026-05-14T17:51:06.482Z"
},
{
"nctId": "NCT00958711",
"briefTitle": "The Mechanism of Action of the Unite Biomatrix in Diabetic Foot Ulcer",
"officialTitle": "The Mechanism of Action of the Unite Biomatrix in Diabetic Foot Ulcer",
"acronym": null,
"organization": "Baxter Healthcare Corporation",
"overallStatus": "TERMINATED",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 90,
"leadSponsor": "Baxter Healthcare Corporation",
"sponsorClass": "INDUSTRY",
"collaborators": [
"Synovis Surgical Innovations"
],
"conditions": [
"Diabetic Foot Ulcers"
],
"interventions": [
"DEVICE: Unite Biomatrix",
"OTHER: Saline and Gauze"
],
"briefSummary": "The purpose of this study is to assess the mechanism of action of the Unite Biomatrix and compare its performance with the standard of care, saline moistened gauze, for the treatment of diabetic foot ulcers.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2009-01",
"completionDate": "2012-05",
"primaryCompletionDate": "2012-05",
"firstPostedDate": "2009-08-13",
"lastUpdatePostedDate": "2019-12-18",
"locations": [
{
"facility": "University of California - San Diego",
"city": "San Diego",
"state": "California",
"country": "United States"
},
{
"facility": "University of Miami, Miller School of Medicine",
"city": "Miami",
"state": "Florida",
"country": "United States"
},
{
"facility": "Aiyan Diabetes Center",
"city": "Evans",
"state": "Georgia",
"country": "United States"
},
{
"facility": "Foot & Ankle Associates of Central Illinois, LLC",
"city": "Springfield",
"state": "Illinois",
"country": "United States"
},
{
"facility": "Eastern Carolina Foot and Ankle",
"city": "Greenville",
"state": "North Carolina",
"country": "United States"
},
{
"facility": "Foot and Ankle East",
"city": "Greenville",
"state": "North Carolina",
"country": "United States"
},
{
"facility": "Carolina East Family Medicine",
"city": "Greenville",
"state": "North Carolina",
"country": "United States"
},
{
"facility": "Family Foot & Ankle Physicians",
"city": "Greenville",
"state": "North Carolina",
"country": "United States"
},
{
"facility": "Comprehensive Wound Care Thoracic & Vascular Associates of Kinston P.A.",
"city": "Kinston",
"state": "North Carolina",
"country": "United States"
},
{
"facility": "The Foot & Ankle Associates of North Carolina, PLLC",
"city": "Rocky Mount",
"state": "North Carolina",
"country": "United States"
},
{
"facility": "Martin Foot and Ankle",
"city": "York",
"state": "Pennsylvania",
"country": "United States"
}
],
"hasResults": true,
"url": "https://clinicaltrials.gov/study/NCT00958711",
"scrapedAt": "2026-05-14T17:51:06.515Z"
},
{
"nctId": "NCT00198471",
"briefTitle": "Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment",
"officialTitle": "An Open-label Assessment of Intravitreous Injections of Vitrase (Hyaluronidase for Injection) for Inducing Posterior Vitreous Detachment in Subjects With Moderate to Severe Non-proliferative Diabetic Retinopathy",
"acronym": null,
"organization": "Bausch & Lomb Incorporated",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE2"
],
"enrollmentCount": 10,
"leadSponsor": "Bausch & Lomb Incorporated",
"sponsorClass": "INDUSTRY",
"collaborators": [],
"conditions": [
"Vitreous Detachment",
"Diabetic Retinopathy"
],
"interventions": [
"DRUG: Vitrase"
],
"briefSummary": "The purpose of this study is to assess the efficacy of intravitreous injections of Vitrase to induce posterior vitreous detachment(PVD) in subjects with moderate to severe non-proliferative diabetic retinopathy.",
"sex": "ALL",
"minimumAge": "50 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2005-07",
"completionDate": "2006-11",
"primaryCompletionDate": "2006-11",
"firstPostedDate": "2005-09-20",
"lastUpdatePostedDate": "2013-03-15",
"locations": [
{
"facility": "Edgar L. Thomas, MD",
"city": "Beverly Hills",
"state": "California",
"country": "United States"
},
{
"facility": "Ronni Lieberman, MD",
"city": "New York",
"state": "New York",
"country": "United States"
},
{
"facility": "Valley Retina Institute, PA",
"city": "McAllen",
"state": "Texas",
"country": "United States"
},
{
"facility": "The Virginia Retina Center",
"city": "Leesburg",
"state": "Virginia",
"country": "United States"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT00198471",
"scrapedAt": "2026-05-14T17:51:06.551Z"
},
{
"nctId": "NCT03248271",
"briefTitle": "Effects of Insulin on Hypotension and Sarcopenia",
"officialTitle": "Effects of Insulin on Hypotension and Sarcopenia",
"acronym": null,
"organization": "University of British Columbia",
"overallStatus": "WITHDRAWN",
"studyType": "OBSERVATIONAL",
"phases": [],
"enrollmentCount": 0,
"leadSponsor": "Kenneth Madden",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Diabetes",
"Sarcopenia",
"Hypotension, Orthostatic"
],
"interventions": [
"DRUG: Insulin Lispro"
],
"briefSummary": "In this study investigator's aim to determine the impact of insulin therapy on hypotension and sarcopenia",
"sex": "ALL",
"minimumAge": "65 Years",
"maximumAge": null,
"healthyVolunteers": null,
"startDate": "2017-10-01",
"completionDate": "2023-01-10",
"primaryCompletionDate": "2023-01-10",
"firstPostedDate": "2017-08-14",
"lastUpdatePostedDate": "2023-01-12",
"locations": [
{
"facility": "University of British Columbia - Gerontology Research Lab",
"city": "Vancouver",
"state": "British Columbia",
"country": "Canada"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT03248271",
"scrapedAt": "2026-05-14T17:51:06.623Z"
},
{
"nctId": "NCT01705899",
"briefTitle": "Islet Allotransplantation in Type 1 Diabetes",
"officialTitle": "Islet Allotransplantation in Type 1 Diabetes",
"acronym": null,
"organization": "Ohio State University",
"overallStatus": "SUSPENDED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE1"
],
"enrollmentCount": 20,
"leadSponsor": "Ohio State University",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Type 1 Diabetes"
],
"interventions": [
"DRUG: Human Pancreatic Islets"
],
"briefSummary": "Islet transplantation can provide physiologic insulin replacement to patients with type 1 diabetes without the complications associated with whole pancreas transplantation. The purpose of this study is to achieve insulin-independence in patients with type 1 diabetes, thereby eliminating the need for exogenous insulin injections to maintain normal glucose levels, ameliorating severe hypoglycemia and potentially decreasing the development of diabetes-related complications. This study will investigate islet transplantation in subjects who have preserved renal function and subjects who have undergone cadaveric renal transplantation, since the latter subjects are already on immunosuppression.\n\nThis is a single center, prospective trial of islet transplantation in subjects receiving islets alone or islets after kidney transplant. This is a phase I study investigating the use of islet transplantation for the treatment of type 1 diabetes. Subjects will be eligible for an islet transplant if they meet all of the inclusion criteria and none of the exclusion criteria outlined in the protocol. In brief, the aims of this study are to establish an islet transplant program at the Ohio State University, determine the safety of islet transplantation in islet alone and kidney transplant recipients, determine whether islet transplantation will reduce the frequency of severe hypoglycemic events, determine whether a novel steroid-free immunosuppressive protocol will prevent rejection in islet transplants and to achieve insulin independence at one year after the final islet transplant.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": "65 Years",
"healthyVolunteers": false,
"startDate": "2006-11",
"completionDate": "2033-10",
"primaryCompletionDate": "2033-10",
"firstPostedDate": "2012-10-12",
"lastUpdatePostedDate": "2025-01-16",
"locations": [
{
"facility": "The Ohio State University Medical Center",
"city": "Columbus",
"state": "Ohio",
"country": "United States"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT01705899",
"scrapedAt": "2026-05-14T17:51:06.662Z"
},
{
"nctId": "NCT06103799",
"briefTitle": "Application of Information-Motivation-Behavioral Model-based Continuity of Care on the Peri-implantitis Recovery in Diabetic Implant Overdenture Patients",
"officialTitle": "Application of Information-Motivation-Behavioral Model-based Continuity of Care on the Peri-implantitis Recovery in Diabetic Implant Overdenture Patients: A Randomised Controlled Trial",
"acronym": null,
"organization": "The Dental Hospital of Zhejiang University School of Medicine",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 32,
"leadSponsor": "The Dental Hospital of Zhejiang University School of Medicine",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Bone Resorption",
"Diabetes"
],
"interventions": [
"BEHAVIORAL: IMB model-based continuity of care"
],
"briefSummary": "The investigators recruited 32 diabetic IOD patients with a total of 110 problematic implants who had completed the treatment for peri-implantitis between January 2021 and March 2023 as research subjects. The patients were randomly assigned to the control group or the experimental group using the random number table. The control group received routine postoperative medical advice, whereas the experimental group was given an IMB model-based continuity of care.",
"sex": "ALL",
"minimumAge": null,
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2023-01-01",
"completionDate": "2023-09-30",
"primaryCompletionDate": "2023-09-20",
"firstPostedDate": "2023-10-27",
"lastUpdatePostedDate": "2023-10-27",
"locations": [
{
"facility": "The Stomatologic Hospital, School of Medicine, Zhejiang University",
"city": "Hangzhou",
"state": "Zhejiang",
"country": "China"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT06103799",
"scrapedAt": "2026-05-14T17:51:06.702Z"
},
{
"nctId": "NCT06474598",
"briefTitle": "An Adaptive Design Study of MTX228",
"officialTitle": "A Open Label, Parallel Group Phase IIA, Adaptive Design Study of MTX228 in Adult Subjects With Type 1 Diabetes and Preserved β-Cell Function",
"acronym": null,
"organization": "University of Alberta",
"overallStatus": "RECRUITING",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE2"
],
"enrollmentCount": 24,
"leadSponsor": "University of Alberta",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Type 1 Diabetes Mellitus"
],
"interventions": [
"DRUG: MTX228",
"DEVICE: DEXCOM G6"
],
"briefSummary": "MTX228 has been identified as a medication that might allow the re-growth of insulin producing beta cells in people with Type 1 Diabetes. Promoting the re-growth of lost beta cells would be beneficial to people with Type 1 Diabetes because it would allow them to take less insulin by injection and would improve their overall blood sugar control while reducing the risk and rate of low blood sugars. This open-label dose selection study aims to determine the optimal dose ofMTX228 for use in a future phase IIb study.\n\nThe purpose is to investigate the relative effectiveness of different doses of MTX228 and to select the most effective dose for further investigation in a phase 2b study.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": "65 Years",
"healthyVolunteers": false,
"startDate": "2024-11-14",
"completionDate": "2027-12",
"primaryCompletionDate": "2026-10",
"firstPostedDate": "2024-06-25",
"lastUpdatePostedDate": "2026-04-13",
"locations": [
{
"facility": "University of Alberta",
"city": "Edmonton",
"state": "Alberta",
"country": "Canada"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT06474598",
"scrapedAt": "2026-05-14T17:51:06.885Z"
},
{
"nctId": "NCT05316298",
"briefTitle": "Diabetic Foot Osteomyelitis Treatment Using Gentamicin-loaded Calcium Sulfate-hydroxyapatite Biocomposite",
"officialTitle": "Gentamicin-loaded Calcium Sulfate-hydroxyaPatite Biocomposite to tREat Diabetic Foot Ulcers Complicated by oSteomyElitis: a pRospectiVE Cohort Study",
"acronym": "PRESERVE",
"organization": "University Medical Center Groningen",
"overallStatus": "UNKNOWN",
"studyType": "OBSERVATIONAL",
"phases": [],
"enrollmentCount": 182,
"leadSponsor": "University Medical Center Groningen",
"sponsorClass": "OTHER",
"collaborators": [
"Ziekenhuisgroep Twente",
"Slingeland Hospital",
"Franciscus Gasthuis",
"UMC Utrecht",
"Rijnstate Hospital",
"Jeroen Bosch Ziekenhuis",
"Reinier de Graaf Groep",
"St. Antonius Hospital",
"St Jansdal Hospital",
"Maasstad Hospital"
],
"conditions": [
"Diabetic Foot Ulcer",
"Osteomyelitis",
"Diabetes Mellitus"
],
"interventions": [],
"briefSummary": "The amputation risk is high when diabetic foot ulcers, complicated by osteomyelitis, fail to heal after non-surgical standard-of-care treatment. A new treatment regimen has been developed recently and has been proven feasible. This treatment regimen consists of surgical debridement, followed by bone void filling with gentamicin-loaded calcium sulfate-hydroxyapatite biocomposite and closure of soft tissues and skin, in combination with antibiotic therapy and offloading. This treatment regimen has not been investigated prospectively.\n\nTherefore, this multicenter prospective cohort study was designed, with the primary objective of investigating postoperative wound healing. Patients with diabetic forefoot ulcers, complicated by osteomyelitis, will be included. The most relevant exclusion criteria are: Severe diabetic foot infection, severe limb ischemia, and foot deformity causing high pressure and friction on the diabetic foot ulcer. After inclusion, subjects will undergo study phase 1, which is observation of the standard-of-care non-surgical treatment. When standard-of-care non-surgical treatment is unsuccessful, subjects will be included in study phase 2, which consists of treatment by surgical debridement of the diabetic foot ulcer and underlying osteomyelitis, followed by bone void filling with gentamicin-loaded calcium sulfate-hydroxyapatite biocomposite and closure of soft tissues and skin, followed by a postoperatieve treatment regimen which involves wound care, 10 days of antibiotic therapy and offloading.\n\nThe primary outcome measure of this study is the proportion of subjects with post-operative wound healing, which will be investigated clinically and will be objectified by a review panel of blinded, independent experts based on digital photographs. Follow-up will be performed until wound healing or for a maximum of 20 weeks. The primary outcome measure is the proportion of subjects with postoperative wound healing during 20 weeks of follow-up. Secondary outcome measures are: days until postoperative wound healing, proportion of subjects with persistent osteomyelitis post-operatively, proportion of subjects undergoing amputations during follow-up, foot function index scores at inclusion and after 20 weeks follow-up.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2022-12-01",
"completionDate": "2025-01-01",
"primaryCompletionDate": "2025-01-01",
"firstPostedDate": "2022-04-07",
"lastUpdatePostedDate": "2022-11-16",
"locations": [
{
"facility": "Jeroen Bosch Hospital",
"city": "'s-Hertogenbosch",
"state": null,
"country": "Netherlands"
},
{
"facility": "Hospitalgroup Twente",
"city": "Almelo",
"state": null,
"country": "Netherlands"
},
{
"facility": "Rijnstate Hospital",
"city": "Arnhem",
"state": null,
"country": "Netherlands"
},
{
"facility": "Reinier de Graaf Hospital",
"city": "Delft",
"state": null,
"country": "Netherlands"
},
{
"facility": "Slingeland Hospital",
"city": "Doetinchem",
"state": null,
"country": "Netherlands"
},
{
"facility": "St. Jansdal Hospital",
"city": "Harderwijk",
"state": null,
"country": "Netherlands"
},
{
"facility": "St. Antonius Hospital",
"city": "Nieuwegein",
"state": null,
"country": "Netherlands"
},
{
"facility": "Franciscus Gasthuis & Vlietland",
"city": "Rotterdam",
"state": null,
"country": "Netherlands"
},
{
"facility": "Maasstad Hospital",
"city": "Rotterdam",
"state": null,
"country": "Netherlands"
},
{
"facility": "University Medical Center Utrecht",
"city": "Utrecht",
"state": null,
"country": "Netherlands"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT05316298",
"scrapedAt": "2026-05-14T17:51:06.927Z"
},
{
"nctId": "NCT07387393",
"briefTitle": "To Test the Effectiveness and Implementation Approach of a 3-month PILI Pasifika Program Lifestyle Program With Components of Social Determinants of Health Activities in Real-world Settings (Clinical and Non-clinical Settings) Across 3 Years",
"officialTitle": "Peau o le Vasa: Accelerating the Currents of Health Advances for Pasifika People",
"acronym": null,
"organization": "University of Hawaii",
"overallStatus": "NOT_YET_RECRUITING",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 400,
"leadSponsor": "University of Hawaii",
"sponsorClass": "OTHER",
"collaborators": [
"National Association of Pasifika Organizations",
"Papa Ola Lōkahi",
"National Heart, Lung, and Blood Institute (NHLBI)"
],
"conditions": [
"Cardiometabolic Conditions",
"Hypertension (HTN)",
"Dyslipidemia",
"Pre-diabetes",
"Type 2 Diabetes Mellitus (T2DM)",
"Overweight (BMI > 25)",
"Weight Loss Trial"
],
"interventions": [
"BEHAVIORAL: PILI (Partnership for Improving Lifestyle Intervention) Pasifika Program"
],
"briefSummary": "In this study, the investigators are conducting a Type 3 hybrid effectiveness-implementation trial to evaluate the implementation of the Community Health Workers (CHW)-delivered PILI Pasifika Program (PPP) across 3 regions, the U.S. Affiliated Pacific Islands (USAPI), the continental U.S., and Hawai'i, among 400 Native Hawaiian and Pacific Islander (NHPI) participants in two settings, (clinical and non-clinical) over a 3-year period. The PPP is a 3-month lifestyle intervention that includes a Social Determinants of Health (SDOH) component and was NHPI-adapted from the Diabetes Prevention Program's Lifestyle Program, renamed to the PILI Lifestyle Program (PLP), which demonstrated effectiveness in improving weight, blood pressure, physical activity, and diet among NHPIs. The PPP consists of 8 lifestyle lessons and 4 SDOH activities delivered over a 3-month period.\n\nThe aims of this study are threefold:\n\n1. To evaluate the implementation of the PPP across multiple community sites using a Type 3 hybrid effectiveness-implementation design guided by established frameworks such as RE-AIM and PRISM.\n2. To examine participant-level outcomes associated with PPP implementation, including changes in cardiometabolic risk factors, health behaviors, and SDOH factors from baseline to 3 and 9-month follow-up.\n3. To evaluate the cost and cost-effectiveness of implementing the PPP across community settings.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2026-05-01",
"completionDate": "2028-10-31",
"primaryCompletionDate": "2028-09-15",
"firstPostedDate": "2026-02-04",
"lastUpdatePostedDate": "2026-04-22",
"locations": [
{
"facility": "National Association of Pasifika Organizations",
"city": "Fayetteville",
"state": "Arkansas",
"country": "United States"
},
{
"facility": "Papa Ola Lokahi",
"city": "Honolulu",
"state": "Hawaii",
"country": "United States"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT07387393",
"scrapedAt": "2026-05-14T17:51:06.994Z"
},
{
"nctId": "NCT00408993",
"briefTitle": "Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China",
"officialTitle": "Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China",
"acronym": null,
"organization": "Eli Lilly and Company",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE3"
],
"enrollmentCount": 215,
"leadSponsor": "Eli Lilly and Company",
"sponsorClass": "INDUSTRY",
"collaborators": [
"Boehringer Ingelheim"
],
"conditions": [
"Diabetic Neuropathies"
],
"interventions": [
"DRUG: Duloxetine Hydrochloride",
"DRUG: Placebo"
],
"briefSummary": "To determine if duloxetine 60mg up to 120mg daily can work in treating pain from Diabetic Neuropathy.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2006-12",
"completionDate": "2008-02",
"primaryCompletionDate": "2008-02",
"firstPostedDate": "2006-12-08",
"lastUpdatePostedDate": "2011-07-26",
"locations": [
{
"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.",
"city": "Beijing",
"state": null,
"country": "China"
},
{
"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.",
"city": "Changsha",
"state": null,
"country": "China"
},
{
"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.",
"city": "Harbin",
"state": null,
"country": "China"
},
{
"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.",
"city": "Nanjin",
"state": null,
"country": "China"
},
{
"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.",
"city": "Nanjing",
"state": null,
"country": "China"
},
{
"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.",
"city": "Shanghai",
"state": null,
"country": "China"
},
{
"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.",
"city": "Wuhan",
"state": null,
"country": "China"
}
],
"hasResults": true,
"url": "https://clinicaltrials.gov/study/NCT00408993",
"scrapedAt": "2026-05-14T17:51:07.038Z"
},
{
"nctId": "NCT01002521",
"briefTitle": "Wound Healing In Diabetes (WHy) Study",
"officialTitle": "Molecular and Genetic Analysis of Disturbed Wound Healing in Barbadians With Diabetic Foot Ulcers",
"acronym": "WHy",
"organization": "The University of The West Indies",
"overallStatus": "UNKNOWN",
"studyType": "OBSERVATIONAL",
"phases": [],
"enrollmentCount": 605,
"leadSponsor": "The University of The West Indies",
"sponsorClass": "OTHER",
"collaborators": [
"Chronic Disease Research Centre",
"Barbados Diabetes Foundation"
],
"conditions": [
"Impaired Wound Healing",
"Diabetes Mellitus"
],
"interventions": [],
"briefSummary": "This observational study aims to identify risk factors and molecular mechanisms of impaired wound healing, to guide better foot care in the diabetic population.",
"sex": "ALL",
"minimumAge": null,
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2009-12",
"completionDate": "2012-06",
"primaryCompletionDate": "2011-06",
"firstPostedDate": "2009-10-27",
"lastUpdatePostedDate": "2009-10-27",
"locations": [
{
"facility": "Chronic Disease Research Centre",
"city": "Bridgetown",
"state": "Saint Michael",
"country": "Barbados"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT01002521",
"scrapedAt": "2026-05-14T17:51:07.083Z"
},
{
"nctId": "NCT00001733",
"briefTitle": "Screening for Studies on Retinovascular Diseases",
"officialTitle": "Screening Study for the Evaluation and Diagnosis of Potential Research Subjects With Retinovascular Diseases",
"acronym": null,
"organization": "National Institutes of Health Clinical Center (CC)",
"overallStatus": "COMPLETED",
"studyType": "OBSERVATIONAL",
"phases": [],
"enrollmentCount": 2000,
"leadSponsor": "National Eye Institute (NEI)",
"sponsorClass": "NIH",
"collaborators": [],
"conditions": [
"Diabetic Retinopathy",
"Macular Degeneration",
"Pathologic Neovascularization",
"Retinal Disease"
],
"interventions": [],
"briefSummary": "This screening protocol is designed to help recruit patients for National Eye Institute (NEI) studies of the retina, such as diabetic retinopathy and macular degeneration. Patients must meet the specific criteria of a research study, and this protocol serves as a first step for admitting patients to a retinal disease study.\n\nCandidates will undergo a medical history and comprehensive eye examination. The eye examination includes dilation of the pupils to fully examine the retina. In some studies, photographs of the eye are required. This is done using fluorescein angiography. In this procedure, a dye called sodium fluorescein is injected into the blood stream through a vein. After the dye reaches the blood vessels of the eye, photographs are taken of the retina. Other diagnostic procedures may include physical examination, questionnaires, routine laboratory tests and other standard or specialized tests, as needed.\n\nWhen the screening is completed, patients will be informed of their options to participate in a study. Patients who are ineligible for a current study will be informed of alternative treatments or options. No treatment is offered under this protocol.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": true,
"startDate": "1998-03-06",
"completionDate": "2008-07-02",
"primaryCompletionDate": null,
"firstPostedDate": "1999-11-04",
"lastUpdatePostedDate": "2017-07-02",
"locations": [
{
"facility": "National Institutes of Health Clinical Center, 9000 Rockville Pike",
"city": "Bethesda",
"state": "Maryland",
"country": "United States"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT00001733",
"scrapedAt": "2026-05-14T17:51:07.102Z"
},
{
"nctId": "NCT07075133",
"briefTitle": "Chrono-restricted Diet and Physical Activity as a New Preventive Strategy for Sarcopenia in Postmenopausal Women With Obesity and Type 2 Diabetes",
"officialTitle": "Chrono-restricted Diet and Physical Activity as a New Preventive Strategy for Sarcopenia in Postmenopausal Women With Obesity and Type 2 Diabetes",
"acronym": "TIMEDIAB",
"organization": "University Hospital, Toulouse",
"overallStatus": "NOT_YET_RECRUITING",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 45,
"leadSponsor": "University Hospital, Toulouse",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Obesity",
"Sarcopenia",
"Post Menopause",
"Type 2 Diabetes",
"Circadian Clock"
],
"interventions": [
"OTHER: Antidiabetic diet (control)",
"OTHER: eTRE diet",
"OTHER: Physical activity in the morning",
"OTHER: Physical activity in the afternoon"
],
"briefSummary": "The aim of TIMEDIAB is to demonstrate that early TRE (eTRE) combined to late (afternoon) exercise will outperform eTRE combined to morning exercise on muscle function as primary endpoint, and glucose homeostasis as secondary endpoint",
"sex": "ALL",
"minimumAge": "45 Years",
"maximumAge": "70 Years",
"healthyVolunteers": true,
"startDate": "2025-07-15",
"completionDate": "2029-07-15",
"primaryCompletionDate": "2029-07-15",
"firstPostedDate": "2025-07-20",
"lastUpdatePostedDate": "2025-07-20",
"locations": [
{
"facility": "Rangueil Hospital",
"city": "Toulouse",
"state": "France",
"country": "France"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT07075133",
"scrapedAt": "2026-05-14T17:51:07.140Z"
},
{
"nctId": "NCT04213547",
"briefTitle": "Sleep and Glycemic Control in Type 2 Diabetes Adolescents",
"officialTitle": "Sleep Duration and Glycemic Control in Adolescents With Type 2 Diabetes Mellitus",
"acronym": null,
"organization": "Children's Hospital of Philadelphia",
"overallStatus": "RECRUITING",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 90,
"leadSponsor": "Children's Hospital of Philadelphia",
"sponsorClass": "OTHER",
"collaborators": [
"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"
],
"conditions": [
"Type 2 Diabetes"
],
"interventions": [
"BEHAVIORAL: Loss frame sleep extension intervention"
],
"briefSummary": "The primary objective is to determine the cross-sectional relationship between sleep duration (as measured by 14 days of actigraphy) and glycemic control in an adolescent Type 2 Diabetes (T2DM) cohort (age 12-20y, n=67). A secondary objective is to determine if a loss-framed incentive for achieving sleep goals can increase sleep duration in 15 adolescent patients diagnosed with T2DM with insufficient sleep. Another secondary objective is to test if increasing sleep duration leads to improved glycemic control in 15 adolescents with T2DM identified in Aim 1 as having \\<8 hr sleep/evening. A focus group will be conducted prior to this intervention with patients ineligible for the intervention in order to determine appropriate text messaging.",
"sex": "ALL",
"minimumAge": "12 Years",
"maximumAge": "20 Years",
"healthyVolunteers": false,
"startDate": "2020-09-16",
"completionDate": "2026-06-01",
"primaryCompletionDate": "2026-06-01",
"firstPostedDate": "2019-12-30",
"lastUpdatePostedDate": "2026-04-03",
"locations": [
{
"facility": "Children's Hospital of Philadelphia",
"city": "Philadelphia",
"state": "Pennsylvania",
"country": "United States"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT04213547",
"scrapedAt": "2026-05-14T17:51:07.166Z"
},
{
"nctId": "NCT00534547",
"briefTitle": "Duodenal Exclusion for the Treatment of Type 2 Diabetes",
"officialTitle": "Phase IV Study of Duodenal Exclusion for the Treatment of Type 2 Diabetes (T2DM)",
"acronym": null,
"organization": "Medtronic - MITG",
"overallStatus": "WITHDRAWN",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 0,
"leadSponsor": "Medtronic - MITG",
"sponsorClass": "INDUSTRY",
"collaborators": [],
"conditions": [
"Diabetes"
],
"interventions": [
"PROCEDURE: Duodenal Exclusion"
],
"briefSummary": "The purpose of this study is to investigate the role of an experimental surgery that may offer better short and long-term control of T2DM in select patients who have not achieved adequate blood sugar control with regular means.",
"sex": "ALL",
"minimumAge": "20 Years",
"maximumAge": "50 Years",
"healthyVolunteers": false,
"startDate": null,
"completionDate": null,
"primaryCompletionDate": null,
"firstPostedDate": "2007-09-26",
"lastUpdatePostedDate": "2015-07-27",
"locations": [],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT00534547",
"scrapedAt": "2026-05-14T17:51:07.241Z"
},
{
"nctId": "NCT07385547",
"briefTitle": "Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency",
"officialTitle": "A Phase 1 Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of GL0034",
"acronym": null,
"organization": "Sun Pharmaceutical Industries Limited",
"overallStatus": "RECRUITING",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE1"
],
"enrollmentCount": 40,
"leadSponsor": "Sun Pharmaceutical Industries Limited",
"sponsorClass": "INDUSTRY",
"collaborators": [],
"conditions": [
"Type II Diabetes Mellitus"
],
"interventions": [
"DRUG: GL0034"
],
"briefSummary": "This is an open-label, single-dose, Phase 1 clinical study designed to evaluate the effect of renal impairment on the pharmacokinetics (PK) of GL0034, a long-acting GLP-1 receptor agonist. Approximately 40 adult participants will be enrolled across four groups: normal renal function, moderate renal impairment, severe renal impairment without dialysis, and severe renal impairment with dialysis. Each participant will receive a single subcutaneous dose of GL0034. Blood samples will be collected for PK analysis. Secondary objectives include assessing safety and tolerability. The study will help determine whether renal impairment affects GL0034 exposure and inform dosing recommendations for patients with compromised renal function.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": "80 Years",
"healthyVolunteers": true,
"startDate": "2026-02-25",
"completionDate": "2026-09-27",
"primaryCompletionDate": "2026-09",
"firstPostedDate": "2026-02-04",
"lastUpdatePostedDate": "2026-03-13",
"locations": [
{
"facility": "Syneos Miami",
"city": "Miami",
"state": "Florida",
"country": "United States"
},
{
"facility": "Panax Clinical Research",
"city": "Miami Lakes",
"state": "Florida",
"country": "United States"
},
{
"facility": "Orlando Clinical Research Center (OCRC)",
"city": "Orlando",
"state": "Florida",
"country": "United States"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT07385547",
"scrapedAt": "2026-05-14T17:51:07.279Z"
},
{
"nctId": "NCT00806858",
"briefTitle": "Observational Study of NovoPen® 4 on Treatment Satisfaction of Insulin Therapy in Type 1 or Type 2 Subjects With Diabetes Mellitus",
"officialTitle": "NovoPen®4 Clinical Experience Programme: A Multicentre, Observational Study of NovoPen®4 on Treatment Satisfaction of Insulin Therapy in Type 1 or Type 2 Subjects With Diabetes Mellitus",
"acronym": null,
"organization": "Novo Nordisk A/S",
"overallStatus": "COMPLETED",
"studyType": "OBSERVATIONAL",
"phases": [],
"enrollmentCount": 526,
"leadSponsor": "Novo Nordisk A/S",
"sponsorClass": "INDUSTRY",
"collaborators": [],
"conditions": [
"Diabetes",
"Diabetes Mellitus, Type 1",
"Diabetes Mellitus, Type 2",
"Delivery Systems"
],
"interventions": [
"DEVICE: NovoPen® 4"
],
"briefSummary": "This study is conducted in Asia. The aim of this observational study is to evaluate subjects' treatment satisfaction and to evaluate subjects' preference of pen device and the incidence of clinical technical complains while using NovoPen® 4 under normal clinical practice conditions.",
"sex": "ALL",
"minimumAge": null,
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2008-11",
"completionDate": "2009-07",
"primaryCompletionDate": "2009-07",
"firstPostedDate": "2008-12-11",
"lastUpdatePostedDate": "2016-11-23",
"locations": [
{
"facility": "Novo Nordisk Investigational Site",
"city": "Beijing",
"state": "Beijing Municipality",
"country": "China"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT00806858",
"scrapedAt": "2026-05-14T17:51:07.298Z"
},
{
"nctId": "NCT01943357",
"briefTitle": "Improving Self Management Skills of Older Adults With Diabetes",
"officialTitle": "Improving the Self Management Skills of Older Adults With Diabetes",
"acronym": null,
"organization": "Stanford University",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 1000,
"leadSponsor": "Stanford University",
"sponsorClass": "OTHER",
"collaborators": [
"HealthCore, Inc."
],
"conditions": [
"Type 2 Diabetes",
"Diabetes"
],
"interventions": [
"BEHAVIORAL: Diabetes Self Management Program"
],
"briefSummary": "The study will help determine if the Better Choices Better Health Diabetes program (community-based or online, also known as the Diabetes Self-Management Program) improves the hbA1C of people with Type-II diabetes. The investigators will also examine 1) symptoms (fatigue, sleep, low blood sugar symptoms, depression, shortness of breath), 2) healthy behaviors (blood sugar monitoring; taking medications as prescribed; getting eye, foot, kidney and cholesterol exams; and activity), 3) the use of health care services. This project is a translational study to demonstrate the effectiveness of the intervention in the context of a major insurer.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2013-09",
"completionDate": "2017-02",
"primaryCompletionDate": "2016-03",
"firstPostedDate": "2013-09-16",
"lastUpdatePostedDate": "2017-04-25",
"locations": [
{
"facility": "Stanford University School of Medicine",
"city": "Stanford",
"state": "California",
"country": "United States"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT01943357",
"scrapedAt": "2026-05-14T17:51:07.318Z"
},
{
"nctId": "NCT00278057",
"briefTitle": "STUDY OF GLUCOSE IN DIALYSIS WATER WITH REGARD TO BLOOD PRESSURE AND QUALITY OF LIFE",
"officialTitle": "PHASE 4 STUDY OT THE EFFECT OF GLUCOSE ADDED TO THE DIALYSIS FLUID ON BLOOD PRESSURE, BLOOD GLUCOSE AND QUALITY OF LIFE IN HEMODIALYSIS PATIENTS.",
"acronym": null,
"organization": "Regional Hospital Holstebro",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE4"
],
"enrollmentCount": 55,
"leadSponsor": "Regional Hospital Holstebro",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Hemodialysis"
],
"interventions": [
"DRUG: dialysisis with and without glucose in the dialysis"
],
"briefSummary": "We wanted to test the hypotheses that blood pressure level was lower, that the variability of blood pressure and blood glucose was reduced, and that quality of life was improved when glucose was added to the dialysis fluid.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2003-05",
"completionDate": "2003-05",
"primaryCompletionDate": null,
"firstPostedDate": "2006-01-18",
"lastUpdatePostedDate": "2006-01-18",
"locations": [
{
"facility": "Department of Medicine, Holstebro Hospital",
"city": "Holstebro",
"state": null,
"country": "Denmark"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT00278057",
"scrapedAt": "2026-05-14T17:51:07.334Z"
},
{
"nctId": "NCT02356757",
"briefTitle": "Preventing Amputations by Tailored Risk-based Intervention to Optimize Therapy",
"officialTitle": "Preventing Amputations by Tailored Risk-based Intervention to Optimize Therapy",
"acronym": "PATRIOT",
"organization": "VA Office of Research and Development",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 406,
"leadSponsor": "VA Office of Research and Development",
"sponsorClass": "FED",
"collaborators": [],
"conditions": [
"Diabetes",
"Foot Ulcer"
],
"interventions": [
"BEHAVIORAL: Personalized Behavioral Intervention",
"BEHAVIORAL: Current Best Practice"
],
"briefSummary": "The PATRIOT study will evaluate a risk-based personalized behavioral intervention to improve foot self-care, self-monitoring, and modifiable risks for amputation such as blood glucose, blood pressure and cholesterol in order to prevent diabetic foot ulcers in patients at higher than normal risk for amputation. This novel intervention aims to improve self-care and early detection of foot abnormalities in at-risk patients with diabetes and poor foot self-care using advanced behavioral approaches to target adherence to multiple health behaviors, including foot self-care, self-monitoring, medication adherence, dietary adherence, and physical activity simultaneously. If this promising behavioral theory-driven approach delivered using common technology (phone) to the patient at home can work in a setting where improvements in foot care are so urgent, it will be an important scientific contribution.",
"sex": "ALL",
"minimumAge": "21 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2015-08-24",
"completionDate": "2021-09-30",
"primaryCompletionDate": "2021-06-30",
"firstPostedDate": "2015-02-05",
"lastUpdatePostedDate": "2021-10-22",
"locations": [
{
"facility": "Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY",
"city": "New York",
"state": "New York",
"country": "United States"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT02356757",
"scrapedAt": "2026-05-14T17:51:07.367Z"
},
{
"nctId": "NCT01194830",
"briefTitle": "Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study",
"officialTitle": "A Phase IIIb, 24-week, Randomised, Placebo-controlled, Double-blinded, Efficacy and Safety Study of Linagliptin (BI 1356) in Black/African American Patients With Type 2 Diabetes With a MTT Sub-study",
"acronym": null,
"organization": "Boehringer Ingelheim",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE3"
],
"enrollmentCount": 234,
"leadSponsor": "Boehringer Ingelheim",
"sponsorClass": "INDUSTRY",
"collaborators": [
"Eli Lilly and Company"
],
"conditions": [
"Diabetes Mellitus, Type 2"
],
"interventions": [
"DRUG: Linagliptin",
"DRUG: Placebo"
],
"briefSummary": "Study of linagliptin vs. placebo in Black/African American patients with T2DM with a MTT sub-study",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": "80 Years",
"healthyVolunteers": false,
"startDate": "2010-09",
"completionDate": "2011-10",
"primaryCompletionDate": "2011-10",
"firstPostedDate": "2010-09-03",
"lastUpdatePostedDate": "2014-01-29",
"locations": [
{
"facility": "1218.75.059 Boehringer Ingelheim Investigational Site",
"city": "Birmingham",
"state": "Alabama",
"country": "United States"
},
{
"facility": "1218.75.054 Boehringer Ingelheim Investigational Site",
"city": "Huntsville",
"state": "Alabama",
"country": "United States"
},
{
"facility": "1218.75.035 Boehringer Ingelheim Investigational Site",
"city": "Mobile",
"state": "Alabama",
"country": "United States"
},
{
"facility": "1218.75.101 Boehringer Ingelheim Investigational Site",
"city": "Toney",
"state": "Alabama",
"country": "United States"
},
{
"facility": "1218.75.066 Boehringer Ingelheim Investigational Site",
"city": "Little Rock",
"state": "Alaska",
"country": "United States"
},
{
"facility": "1218.75.008 Boehringer Ingelheim Investigational Site",
"city": "Pell City",
"state": "Alaska",
"country": "United States"
},
{
"facility": "1218.75.071 Boehringer Ingelheim Investigational Site",
"city": "Anaheim",
"state": "California",
"country": "United States"
},
{
"facility": "1218.75.018 Boehringer Ingelheim Investigational Site",
"city": "Chino",
"state": "California",
"country": "United States"
},
{
"facility": "1218.75.081 Boehringer Ingelheim Investigational Site",
"city": "Garden Grove",
"state": "California",
"country": "United States"
},
{
"facility": "1218.75.109 Boehringer Ingelheim Investigational Site",
"city": "Los Angeles",
"state": "California",
"country": "United States"
},
{
"facility": "1218.75.040 Boehringer Ingelheim Investigational Site",
"city": "Colorado Springs",
"state": "Colorado",
"country": "United States"
},
{
"facility": "1218.75.047 Boehringer Ingelheim Investigational Site",
"city": "Denver",
"state": "Colorado",
"country": "United States"
},
{
"facility": "1218.75.106 Boehringer Ingelheim Investigational Site",
"city": "Bartow",
"state": "Florida",
"country": "United States"
},
{
"facility": "1218.75.098 Boehringer Ingelheim Investigational Site",
"city": "Bradenton",
"state": "Florida",
"country": "United States"
},
{
"facility": "1218.75.036 Boehringer Ingelheim Investigational Site",
"city": "Chiefland",
"state": "Florida",
"country": "United States"
},
{
"facility": "1218.75.105 Boehringer Ingelheim Investigational Site",
"city": "Fort Lauderdale",
"state": "Florida",
"country": "United States"
},
{
"facility": "1218.75.083 Boehringer Ingelheim Investigational Site",
"city": "Fort Myers",
"state": "Florida",
"country": "United States"
},
{
"facility": "1218.75.002 Boehringer Ingelheim Investigational Site",
"city": "Hialeah",
"state": "Florida",
"country": "United States"
},
{
"facility": "1218.75.080 Boehringer Ingelheim Investigational Site",
"city": "Jacksonville",
"state": "Florida",
"country": "United States"
},
{
"facility": "1218.75.065 Boehringer Ingelheim Investigational Site",
"city": "Jupiter",
"state": "Florida",
"country": "United States"
},
{
"facility": "1218.75.007 Boehringer Ingelheim Investigational Site",
"city": "Miami",
"state": "Florida",
"country": "United States"
},
{
"facility": "1218.75.029 Boehringer Ingelheim Investigational Site",
"city": "Miami",
"state": "Florida",
"country": "United States"
},
{
"facility": "1218.75.045 Boehringer Ingelheim Investigational Site",
"city": "Miami",
"state": "Florida",
"country": "United States"
},
{
"facility": "1218.75.084 Boehringer Ingelheim Investigational Site",
"city": "Miami",
"state": "Florida",
"country": "United States"
},
{
"facility": "1218.75.017 Boehringer Ingelheim Investigational Site",
"city": "Ocala",
"state": "Florida",
"country": "United States"
},
{
"facility": "1218.75.012 Boehringer Ingelheim Investigational Site",
"city": "Pinellas Park",
"state": "Florida",
"country": "United States"
},
{
"facility": "1218.75.074 Boehringer Ingelheim Investigational Site",
"city": "Port Orange",
"state": "Florida",
"country": "United States"
},
{
"facility": "1218.75.076 Boehringer Ingelheim Investigational Site",
"city": "South Miami",
"state": "Florida",
"country": "United States"
},
{
"facility": "1218.75.003 Boehringer Ingelheim Investigational Site",
"city": "St. Petersburg",
"state": "Florida",
"country": "United States"
},
{
"facility": "1218.75.039 Boehringer Ingelheim Investigational Site",
"city": "St. Petersburg",
"state": "Florida",
"country": "United States"
},
{
"facility": "1218.75.075 Boehringer Ingelheim Investigational Site",
"city": "Tallahassee",
"state": "Florida",
"country": "United States"
},
{
"facility": "1218.75.100 Boehringer Ingelheim Investigational Site",
"city": "Tamarac",
"state": "Florida",
"country": "United States"
},
{
"facility": "1218.75.015 Boehringer Ingelheim Investigational Site",
"city": "Tampa",
"state": "Florida",
"country": "United States"
},
{
"facility": "1218.75.103 Boehringer Ingelheim Investigational Site",
"city": "West Palm Beach",
"state": "Florida",
"country": "United States"
},
{
"facility": "1218.75.049 Boehringer Ingelheim Investigational Site",
"city": "Atlanta",
"state": "Georgia",
"country": "United States"
},
{
"facility": "1218.75.067 Boehringer Ingelheim Investigational Site",
"city": "Calhoun",
"state": "Georgia",
"country": "United States"
},
{
"facility": "1218.75.016 Boehringer Ingelheim Investigational Site",
"city": "Dunwoody",
"state": "Georgia",
"country": "United States"
},
{
"facility": "1218.75.063 Boehringer Ingelheim Investigational Site",
"city": "Lawrenceville",
"state": "Georgia",
"country": "United States"
},
{
"facility": "1218.75.056 Boehringer Ingelheim Investigational Site",
"city": "Marietta",
"state": "Georgia",
"country": "United States"
},
{
"facility": "1218.75.026 Boehringer Ingelheim Investigational Site",
"city": "Rosswell",
"state": "Georgia",
"country": "United States"
},
{
"facility": "1218.75.079 Boehringer Ingelheim Investigational Site",
"city": "Sandy Springs",
"state": "Georgia",
"country": "United States"
},
{
"facility": "1218.75.034 Boehringer Ingelheim Investigational Site",
"city": "Snellville",
"state": "Georgia",
"country": "United States"
},
{
"facility": "1218.75.001 Boehringer Ingelheim Investigational Site",
"city": "Chicago",
"state": "Illinois",
"country": "United States"
},
{
"facility": "1218.75.055 Boehringer Ingelheim Investigational Site",
"city": "Chicago",
"state": "Illinois",
"country": "United States"
},
{
"facility": "1218.75.069 Boehringer Ingelheim Investigational Site",
"city": "Owensboro",
"state": "Kentucky",
"country": "United States"
},
{
"facility": "1218.75.044 Boehringer Ingelheim Investigational Site",
"city": "Baton Rouge",
"state": "Louisiana",
"country": "United States"
},
{
"facility": "1218.75.108 Boehringer Ingelheim Investigational Site",
"city": "Essex",
"state": "Maryland",
"country": "United States"
},
{
"facility": "1218.75.086 Boehringer Ingelheim Investigational Site",
"city": "Brockton",
"state": "Massachusetts",
"country": "United States"
},
{
"facility": "1218.75.087 Boehringer Ingelheim Investigational Site",
"city": "Watertown",
"state": "Massachusetts",
"country": "United States"
},
{
"facility": "1218.75.051 Boehringer Ingelheim Investigational Site",
"city": "Detroit",
"state": "Michigan",
"country": "United States"
},
{
"facility": "1218.75.088 Boehringer Ingelheim Investigational Site",
"city": "Flint",
"state": "Michigan",
"country": "United States"
},
{
"facility": "1218.75.099 Boehringer Ingelheim Investigational Site",
"city": "Biloxi",
"state": "Mississippi",
"country": "United States"
},
{
"facility": "1218.75.006 Boehringer Ingelheim Investigational Site",
"city": "Atco",
"state": "New Jersey",
"country": "United States"
},
{
"facility": "1218.75.004 Boehringer Ingelheim Investigational Site",
"city": "Camden",
"state": "New Jersey",
"country": "United States"
},
{
"facility": "1218.75.031 Boehringer Ingelheim Investigational Site",
"city": "Brooklyn",
"state": "New York",
"country": "United States"
},
{
"facility": "1218.75.095 Boehringer Ingelheim Investigational Site",
"city": "Brooklyn",
"state": "New York",
"country": "United States"
},
{
"facility": "1218.75.038 Boehringer Ingelheim Investigational Site",
"city": "Asheboro",
"state": "North Carolina",
"country": "United States"
},
{
"facility": "1218.75.009 Boehringer Ingelheim Investigational Site",
"city": "Charlotte",
"state": "North Carolina",
"country": "United States"
},
{
"facility": "1218.75.023 Boehringer Ingelheim Investigational Site",
"city": "Charlotte",
"state": "North Carolina",
"country": "United States"
},
{
"facility": "1218.75.060 Boehringer Ingelheim Investigational Site",
"city": "Charlotte",
"state": "North Carolina",
"country": "United States"
},
{
"facility": "1218.75.005 Boehringer Ingelheim Investigational Site",
"city": "Greensboro",
"state": "North Carolina",
"country": "United States"
},
{
"facility": "1218.75.107 Boehringer Ingelheim Investigational Site",
"city": "High Point",
"state": "North Carolina",
"country": "United States"
},
{
"facility": "1218.75.020 Boehringer Ingelheim Investigational Site",
"city": "Jacksonville",
"state": "North Carolina",
"country": "United States"
},
{
"facility": "1218.75.027 Boehringer Ingelheim Investigational Site",
"city": "Winston-Salem",
"state": "North Carolina",
"country": "United States"
},
{
"facility": "1218.75.096 Boehringer Ingelheim Investigational Site",
"city": "Akron",
"state": "Ohio",
"country": "United States"
},
{
"facility": "1218.75.090 Boehringer Ingelheim Investigational Site",
"city": "Columbus",
"state": "Ohio",
"country": "United States"
},
{
"facility": "1218.75.078 Boehringer Ingelheim Investigational Site",
"city": "Dayton",
"state": "Ohio",
"country": "United States"
},
{
"facility": "1218.75.037 Boehringer Ingelheim Investigational Site",
"city": "Philadelphia",
"state": "Pennsylvania",
"country": "United States"
},
{
"facility": "1218.75.082 Boehringer Ingelheim Investigational Site",
"city": "Philadelphia",
"state": "Pennsylvania",
"country": "United States"
},
{
"facility": "1218.75.010 Boehringer Ingelheim Investigational Site",
"city": "Uniontown",
"state": "Pennsylvania",
"country": "United States"
},
{
"facility": "1218.75.028 Boehringer Ingelheim Investigational Site",
"city": "Uniontown",
"state": "Pennsylvania",
"country": "United States"
},
{
"facility": "1218.75.091 Boehringer Ingelheim Investigational Site",
"city": "Anderson",
"state": "South Carolina",
"country": "United States"
},
{
"facility": "1218.75.072 Boehringer Ingelheim Investigational Site",
"city": "Columbia",
"state": "South Carolina",
"country": "United States"
},
{
"facility": "1218.75.068 Boehringer Ingelheim Investigational Site",
"city": "Greenwood",
"state": "South Carolina",
"country": "United States"
},
{
"facility": "1218.75.097 Boehringer Ingelheim Investigational Site",
"city": "Greer",
"state": "South Carolina",
"country": "United States"
},
{
"facility": "1218.75.024 Boehringer Ingelheim Investigational Site",
"city": "Brentwood",
"state": "Tennessee",
"country": "United States"
},
{
"facility": "1218.75.025 Boehringer Ingelheim Investigational Site",
"city": "Collierville",
"state": "Tennessee",
"country": "United States"
},
{
"facility": "1218.75.011 Boehringer Ingelheim Investigational Site",
"city": "Germantown",
"state": "Tennessee",
"country": "United States"
},
{
"facility": "1218.75.042 Boehringer Ingelheim Investigational Site",
"city": "Humboldt",
"state": "Tennessee",
"country": "United States"
},
{
"facility": "1218.75.030 Boehringer Ingelheim Investigational Site",
"city": "Memphis",
"state": "Tennessee",
"country": "United States"
},
{
"facility": "1218.75.050 Boehringer Ingelheim Investigational Site",
"city": "Memphis",
"state": "Tennessee",
"country": "United States"
},
{
"facility": "1218.75.053 Boehringer Ingelheim Investigational Site",
"city": "Dallas",
"state": "Texas",
"country": "United States"
},
{
"facility": "1218.75.057 Boehringer Ingelheim Investigational Site",
"city": "Houston",
"state": "Texas",
"country": "United States"
},
{
"facility": "1218.75.064 Boehringer Ingelheim Investigational Site",
"city": "Houston",
"state": "Texas",
"country": "United States"
},
{
"facility": "1218.75.104 Boehringer Ingelheim Investigational Site",
"city": "Houston",
"state": "Texas",
"country": "United States"
},
{
"facility": "1218.75.043 Boehringer Ingelheim Investigational Site",
"city": "Houton",
"state": "Texas",
"country": "United States"
},
{
"facility": "1218.75.022 Boehringer Ingelheim Investigational Site",
"city": "San Antonio",
"state": "Texas",
"country": "United States"
},
{
"facility": "1218.75.058 Boehringer Ingelheim Investigational Site",
"city": "Sugar Land",
"state": "Texas",
"country": "United States"
},
{
"facility": "1218.75.033 Boehringer Ingelheim Investigational Site",
"city": "Tomball",
"state": "Texas",
"country": "United States"
},
{
"facility": "1218.75.102 Boehringer Ingelheim Investigational Site",
"city": "Tomball",
"state": "Texas",
"country": "United States"
},
{
"facility": "1218.75.094 Boehringer Ingelheim Investigational Site",
"city": "Waco",
"state": "Texas",
"country": "United States"
},
{
"facility": "1218.75.092 Boehringer Ingelheim Investigational Site",
"city": "Whitney",
"state": "Texas",
"country": "United States"
},
{
"facility": "1218.75.019 Boehringer Ingelheim Investigational Site",
"city": "Virgnia Beach",
"state": "Virginia",
"country": "United States"
}
],
"hasResults": true,
"url": "https://clinicaltrials.gov/study/NCT01194830",
"scrapedAt": "2026-05-14T17:51:07.385Z"
},
{
"nctId": "NCT05205928",
"briefTitle": "Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care",
"officialTitle": "Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care: a Double-blind, Cross-over, Randomized Controlled Trial",
"acronym": "SEMA-AP",
"organization": "McGill University Health Centre/Research Institute of the McGill University Health Centre",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE2",
"PHASE3"
],
"enrollmentCount": 28,
"leadSponsor": "McGill University Health Centre/Research Institute of the McGill University Health Centre",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Type 1 Diabetes",
"Diabetes Mellitus, Type 1"
],
"interventions": [
"DRUG: Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy"
],
"briefSummary": "A closed-loop insulin system, also referred to as the \"artificial pancreas\" (AP), is made up of an insulin pump, a continuous glucose monitor, and an application communicating between the two to adjust insulin administration based on glucose control. This is meant for the treatment of type 1 diabetes. The McGill Artificial Pancreas (MAP) has been used previously in type 1 diabetes with significant benefits. Though prior studies have shown significant benefit with this system, some challenges still exist.\n\nSemaglutide is used in type 2 diabetes and obesity; it is a once-weekly injectable medication that increases levels of a gut hormone called Glucagon-Like Peptide-1, which modifies gastric emptying, suppresses glucagon, and suppresses appetite. Though its use is not approved in type 1 diabetes in North America, it (along with similar drugs) has been used in studies as adjunctive therapy with insulin with benefits on blood sugar control. Similar medications have been used in type 1 diabetes (such as liraglutide and exenatide), but are not as strong in glucose effect even in type 2 diabetes as compared with semaglutide.\n\nThe purpose of our study is to see if semaglutide administered weekly at the maximum tolerated dose in those with type 1 diabetes will have improved glucose control (as per time in target range from continuous glucose monitoring data) compared to placebo, while using a closed-loop insulin system.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2022-10-02",
"completionDate": "2024-06-30",
"primaryCompletionDate": "2024-04-15",
"firstPostedDate": "2022-01-25",
"lastUpdatePostedDate": "2025-01-22",
"locations": [
{
"facility": "Research Institute of the McGill University Health Centre",
"city": "Montreal",
"state": "Quebec",
"country": "Canada"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT05205928",
"scrapedAt": "2026-05-14T17:51:07.411Z"
},
{
"nctId": "NCT07560800",
"briefTitle": "Effect of Beetroot Juice on Cardiovascular and Autonomic Responses to Exercise in Adults With Type 2 Diabetes",
"officialTitle": "Effect of Beetroot Juice on Cardiovascular and Autonomic Responses During and After Exercise in Adults With Type 2 Diabetes",
"acronym": "DiaBEET",
"organization": "Oxford Brookes University",
"overallStatus": "NOT_YET_RECRUITING",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 20,
"leadSponsor": "Oxford Brookes University",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Type 2 Diabetes Mellitus",
"Hypertension",
"Autonomic Nervous System Diseases"
],
"interventions": [
"DIETARY_SUPPLEMENT: Beetroot juice",
"DIETARY_SUPPLEMENT: Nitrate-depleted Beetroot Juice Placebo"
],
"briefSummary": "This study will investigate whether a single dose of beetroot juice can improve cardiovascular responses and recovery after exercise in adults with Type 2 Diabetes.\n\nType 2 Diabetes is associated with higher blood pressure, impaired blood vessel function, and reduced autonomic control of the heart, all of which increase cardiovascular risk and may affect how the body responds to and recovers from physical activity. Beetroot juice is naturally rich in dietary nitrate, which is converted in the body into nitric oxide, a molecule that helps blood vessels relax and improve blood flow. While these effects have been demonstrated in healthy individuals, less is known about their impact in people with Type 2 Diabetes.\n\nIn this study, approximately 16 to 20 adults aged 40 to 65 years with Type 2 Diabetes will take part. After an online screening and consent process, eligible participants will attend two laboratory visits at Oxford Brookes University. In a randomised, double-blind, placebo-controlled crossover design, participants will receive beetroot juice during one visit and a nitrate-depleted placebo during the other visit.\n\nDuring each visit, participants will undergo physiological measurements, including blood pressure, heart rate, oxygen saturation, and capillary blood glucose. Participants will then complete a short session of supervised, light-to-moderate cycling exercise. Measurements will continue during the recovery period to assess how quickly the cardiovascular system returns to resting levels.\n\nThe main outcomes are systolic blood pressure and heart rate variability during recovery, which reflect cardiovascular regulation and autonomic function. Secondary outcomes include diastolic blood pressure, heart rate, blood glucose, and markers related to nitric oxide availability.\n\nThis study may help determine whether a simple, dietary-based intervention such as beetroot juice can support cardiovascular function and improve recovery after exercise in people living with Type 2 Diabetes.",
"sex": "ALL",
"minimumAge": "40 Years",
"maximumAge": "65 Years",
"healthyVolunteers": false,
"startDate": "2026-04-02",
"completionDate": "2026-07-31",
"primaryCompletionDate": "2026-07-31",
"firstPostedDate": "2026-05-01",
"lastUpdatePostedDate": "2026-05-01",
"locations": [
{
"facility": "Clinical Physiology Laboratory, Oxford Brookes University",
"city": "Oxford",
"state": "Oxfordshire",
"country": "United Kingdom"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT07560800",
"scrapedAt": "2026-05-14T17:51:07.438Z"
},
{
"nctId": "NCT05683392",
"briefTitle": "Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers With Type 1 Diabetes",
"officialTitle": "Control-IQ 2.0 Feasibility Study #2: Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers With Type 1 Diabetes",
"acronym": null,
"organization": "Tandem Diabetes Care, Inc.",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 72,
"leadSponsor": "Tandem Diabetes Care, Inc.",
"sponsorClass": "INDUSTRY",
"collaborators": [],
"conditions": [
"Type 1 Diabetes"
],
"interventions": [
"DEVICE: t:slim X2 insulin pump with Control-IQ technology 2.0"
],
"briefSummary": "The goal of this clinical trial is to assess safety of and explore glycemic outcomes with Control-IQ technology 2.0 in adults, children and preschoolers with type 1 diabetes.",
"sex": "ALL",
"minimumAge": "2 Years",
"maximumAge": "80 Years",
"healthyVolunteers": false,
"startDate": "2023-02-01",
"completionDate": "2023-12-13",
"primaryCompletionDate": "2023-12-13",
"firstPostedDate": "2023-01-13",
"lastUpdatePostedDate": "2024-12-20",
"locations": [
{
"facility": "Barbara Davis Center (Pediatric Clinic)",
"city": "Aurora",
"state": "Colorado",
"country": "United States"
},
{
"facility": "Barbara Davis Center",
"city": "Aurora",
"state": "Colorado",
"country": "United States"
},
{
"facility": "Joslin Diabetes Center",
"city": "Boston",
"state": "Massachusetts",
"country": "United States"
},
{
"facility": "University of Virginia",
"city": "Charlottesville",
"state": "Virginia",
"country": "United States"
}
],
"hasResults": true,
"url": "https://clinicaltrials.gov/study/NCT05683392",
"scrapedAt": "2026-05-14T17:51:07.494Z"
},
{
"nctId": "NCT04860336",
"briefTitle": "Glycemic Observation and Metabolic Outcomes in Mothers and Offspring",
"officialTitle": "Glycemic Observation and Metabolic Outcomes in Mothers and Offspring / Glycemic Profile of Pregnancy Consortium",
"acronym": "GO MOMs",
"organization": "Northwestern University",
"overallStatus": "COMPLETED",
"studyType": "OBSERVATIONAL",
"phases": [],
"enrollmentCount": 2179,
"leadSponsor": "Northwestern University",
"sponsorClass": "OTHER",
"collaborators": [
"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
"Yale University",
"Women and Infants Hospital of Rhode Island",
"University of Pittsburgh",
"Massachusetts General Hospital",
"Tufts Medical Center",
"Columbia University",
"Kaiser Permanente"
],
"conditions": [
"Gestational Diabetes",
"Pregnancy Related"
],
"interventions": [
"OTHER: Observational"
],
"briefSummary": "The overarching goal of Glycemic Observation and Metabolic Outcomes in Mothers and Offspring (GO MOMs) is to perform a comprehensive, longitudinal description of maternal glycemia over the course of pregnancy and to evaluate how glucose levels throughout pregnancy relate to traditional third trimester gestational diabetes mellitus (GDM) screening and perinatal outcomes.",
"sex": "FEMALE",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2021-04-01",
"completionDate": "2025-07-18",
"primaryCompletionDate": "2025-06-09",
"firstPostedDate": "2021-04-26",
"lastUpdatePostedDate": "2026-04-16",
"locations": [
{
"facility": "Yale University",
"city": "New Haven",
"state": "Connecticut",
"country": "United States"
},
{
"facility": "Kaiser Permanente - Hawaii",
"city": "Honolulu",
"state": "Hawaii",
"country": "United States"
},
{
"facility": "Northwestern University",
"city": "Chicago",
"state": "Illinois",
"country": "United States"
},
{
"facility": "Tufts Medical Center",
"city": "Boston",
"state": "Massachusetts",
"country": "United States"
},
{
"facility": "Massachusetts General Hospital",
"city": "Boston",
"state": "Massachusetts",
"country": "United States"
},
{
"facility": "Columbia University",
"city": "New York",
"state": "New York",
"country": "United States"
},
{
"facility": "Kaiser Permanente - Northwest",
"city": "Portland",
"state": "Oregon",
"country": "United States"
},
{
"facility": "Magee Womens Research Institute & Foundation",
"city": "Pittsburgh",
"state": "Pennsylvania",
"country": "United States"
},
{
"facility": "Women and Infants Hospital of Rhode Island",
"city": "Providence",
"state": "Rhode Island",
"country": "United States"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT04860336",
"scrapedAt": "2026-05-14T17:51:07.524Z"
},
{
"nctId": "NCT01880736",
"briefTitle": "A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes",
"officialTitle": "A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes",
"acronym": null,
"organization": "Novo Nordisk A/S",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE3"
],
"enrollmentCount": 458,
"leadSponsor": "Novo Nordisk A/S",
"sponsorClass": "INDUSTRY",
"collaborators": [],
"conditions": [
"Diabetes",
"Diabetes Mellitus, Type 2"
],
"interventions": [
"DRUG: insulin degludec",
"DRUG: insulin degludec",
"DRUG: insulin degludec"
],
"briefSummary": "This trial is conducted in Asia. The aim of the trial is to investigate the efficacy and safety of flexible versus fixed dosing and simple versus stepwise titration with OD insulin degludec in inadequately treated subjects with type 2 diabetes.",
"sex": "ALL",
"minimumAge": "20 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2013-06",
"completionDate": "2014-04",
"primaryCompletionDate": "2014-04",
"firstPostedDate": "2013-06-19",
"lastUpdatePostedDate": "2017-02-10",
"locations": [
{
"facility": "Novo Nordisk Investigational Site",
"city": "Chuo-ku, Tokyo",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Chuo-ku, Tokyo",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Fukui-shi, Fukui",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Fukuoka",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Gifu-shi, Gifu",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Izumisano",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Kagoshima-shi, Kagoshima",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Kamakura-shi",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Kashiwara-shi, Osaka",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Katsushika-ku, Tokyo",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Kawasaki-shi, Kanagawa",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Kitakyushu-shi, Fukuoka",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Kitakyushu-shi, Fukuoka",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Kitakyusyu-shi, Fukuoka",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Koriyama-shi, Fukushima",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Kumamoto-shi,Kumamoto",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Mito-shi, Ibaraki",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Miyazaki",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Naka-shi, Ibaraki",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Niigata-shi, Niigata",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Nishinomiya-shi, Hyogo",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Okawa-shi, Fukuoka",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Osaka-shi, Osaka",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Oyama-shi, Tochigi",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Ōita",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Sakaide-shi, Kagawa",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Sapporo-shi, Hokkaido",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Sapporo-shi, Hokkaido",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Sapporo-shi, Hokkaido",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Sendai",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Shimotsuke-shi, Tochigi",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Suita-shi, Osaka",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Takatsuki-shi, Osaka",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Tokyo",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Tokyo",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Tokyo",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Tokyo",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Tokyo",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Tokyo",
"state": null,
"country": "Japan"
},
{
"facility": "Novo Nordisk Investigational Site",
"city": "Yokkaichi-shi, Mie",
"state": null,
"country": "Japan"
}
],
"hasResults": true,
"url": "https://clinicaltrials.gov/study/NCT01880736",
"scrapedAt": "2026-05-14T17:51:07.542Z"
},
{
"nctId": "NCT03942471",
"briefTitle": "Mindfulness for Adolescents With Type 1 Diabetes",
"officialTitle": "The Effects of Learning Mindfulness Based Stress Reduction on Psychosocial Variables and HbA1c in Adolescents With Type 1 Diabetes",
"acronym": null,
"organization": "Duquesne University",
"overallStatus": "COMPLETED",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 65,
"leadSponsor": "Duquesne University",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Type 1 Diabetes Mellitus"
],
"interventions": [
"BEHAVIORAL: Mindfulness Based Stress Reduction"
],
"briefSummary": "Adolescents with Type 1 Diabetes will be invited to the Mindfulness study. They will be randomly assigned to a Control or Active Group. The Active Group will learn Mindfulness Based Stress Reduction (MBSR) through an online website designed to teach the basic principles of MBSR in six week-long modules. They will be measured in three main areas: before learning the intervention, directly after learning it and 3 months after learning it to determine any changes in their Mindful attention awareness, Diabetes Quality of Life and HbA1c. The Control Group will also take the questionnaires at the beginning of the study, 6 weeks after it begins and then 3 months from the beginning to obtain data for all three time points when they have not received access to the modules/intervention.",
"sex": "ALL",
"minimumAge": "12 Years",
"maximumAge": "19 Years",
"healthyVolunteers": false,
"startDate": "2015-10-14",
"completionDate": "2019-01-05",
"primaryCompletionDate": "2018-10-01",
"firstPostedDate": "2019-05-08",
"lastUpdatePostedDate": "2019-05-08",
"locations": [],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT03942471",
"scrapedAt": "2026-05-14T17:51:07.596Z"
},
{
"nctId": "NCT04917471",
"briefTitle": "Effect of Nitrate on Red Blood Cell Function in Type 2 Diabetes",
"officialTitle": "The Effect of Dietary Nitrate Supplementation on Red Blood Cell Function in Patients with Type 2 Diabetes",
"acronym": null,
"organization": "Karolinska Institutet",
"overallStatus": "RECRUITING",
"studyType": "INTERVENTIONAL",
"phases": [
"NA"
],
"enrollmentCount": 20,
"leadSponsor": "Karolinska Institutet",
"sponsorClass": "OTHER",
"collaborators": [],
"conditions": [
"Type 2 Diabetes"
],
"interventions": [
"DIETARY_SUPPLEMENT: Beet root juice",
"DIETARY_SUPPLEMENT: Placebo juice"
],
"briefSummary": "To investigate the effect of nitrate supplementation on red blood cell function in patients with type 2 diabetes.",
"sex": "ALL",
"minimumAge": "18 Years",
"maximumAge": null,
"healthyVolunteers": false,
"startDate": "2021-06-01",
"completionDate": "2025-12-31",
"primaryCompletionDate": "2025-12-30",
"firstPostedDate": "2021-06-08",
"lastUpdatePostedDate": "2024-10-09",
"locations": [
{
"facility": "Karolinska Institutet, Karolinska University Hospital",
"city": "Stockholm",
"state": null,
"country": "Sweden"
}
],
"hasResults": false,
"url": "https://clinicaltrials.gov/study/NCT04917471",
"scrapedAt": "2026-05-14T17:51:07.616Z"
}
] |